

Wednesday, 3 November 2021

(10.00 am)

Presentation by Counsel to the Inquiry relating to knowledge of and response to risk by pharmaceutical companies involved in blood products

SIR BRIAN LANGSTAFF: Yes.

MR HILL: Sir, we continue from August 1983, with a document that we were discussing last night. It comes from a Congressional hearing that took place on 1 and 2 August, before a subcommittee of the House of Representatives Committee on Government Operations. The hearing was about the AIDS epidemic as a whole, and focused on the Federal Government's response to it. The document to which I would like to take you is a written statement that was submitted to the hearing by Dr Edward Brandt, who was the Assistant Secretary for Health at the Department of Health and Human Services. Soumik, it's JREE0000006, and it's electronic page 306.

In his statement, Dr Brandt said this:

"1. How is AIDS transmitted?

"Based on the best available information, we believe AIDS is transmitted sexually, particularly among homosexual partners; less frequently, through transfusion of blood or blood products; or by the

1

misuse of needles. We have no evidence that the disease is spread through air, food, water, or 'casual' contact. To the contrary, AIDS is a difficult disease to contract.

"2. What is the risk after acquiring AIDS through a blood transfusion?

"At present, the risk of acquiring AIDS through blood transfusion appears to be extremely small. Although as many as 10 million Americans received transfusions during the 3 years of the AIDS epidemic, CDC is investigating approximately two dozen AIDS cases in which transfusions may be a risk factor. We believe that the PHS recommendations issued in March 1983, which suggested that members of the groups at increased risk not donate blood, will decrease the current risk."

Those are the Public Health Service recommendations that were subsequently replaced by the FDA recommendations.

"3. What is the cause of AIDS?

"Although we do not yet know the cause of AIDS, the evidence is strong that we are dealing with an infectious agent with a long incubation period. Public Health Service laboratory scientists are using the most sophisticated methods available in the search

2

for this putative agent. The most plausible agents are viruses. The absence of illness in animals already inoculated with specimens may be a reflection of the long incubation period or may indicate that the 'AIDS agent' affects only humans. Unfortunately, it is not possible to predict when the cause of AIDS will be found."

Then if we could go forward in the statement, please, to electronic page 325. If we could highlight the paragraph beginning "At its July 19 meeting". By this point in his statement, Dr Brandt has moved on to discuss some of the debates that have been taking place within the American scientific community:

"At its July 19 meeting, FDA's Blood Products Advisory Committee discussed the safety of plasma derivatives. This is of concern because haemophiliac patients require treatment with a product, antihemophiliac factor ... derived from plasma ..."

SIR BRIAN LANGSTAFF: I think it ought to be "antihemophilic factor", after all the factor is not supposed to be anti-haemophiliac, is it?

MR HILL: No, it's not supposed to be, it should be "antihemophilic factor":

"... derived from plasma which is pooled from thousands of donors. However, I would emphasize that

3

the risk of transmitting AIDS to an individual hemophiliac from a special lot of AHF is very small, if it exists at all. The Committee recommended that no regulatory requirements regarding the recall or destruction of lots of AHF, which may contain plasma from an AIDS donor, be developed but that any cases that are identified be examined individually. In reaching such a conclusion, a number of variables must be considered, such as: the degree of specificity of the diagnosis, the time of onset of symptoms in relation to the time of donation, the potential effect upon the immediate supply of AHF and the long-term productions of this essential plasma derivative. Let me emphasize that the health of the individual hemophiliac patient will be a continuing concern for the [Public Health Service]."

I pause there to note that that is the reason that we were looking at yesterday and the summary that is contained in Dr Brandt's statement to Congress draws seemingly from Dr Donohue's memorandum that we looked at yesterday.

Going back to the statement, Dr Brandt continues:

"Additionally, through these collaborative efforts, progress in developing new procedures for

4

1 increasing the safety of clotting factor concentrates
2 have been accelerated. One such product is currently
3 available and others are at a late stage of
4 development. This ongoing cooperative effort will
5 continue to monitor the nation's blood supply in
6 attempts to insure maximum safety and at the same time
7 maintain adequate supplies of blood and blood
8 products."

9 I take the reference, sir, to the new procedures
10 to be references to heat treatment.

11 There was, of course, much other testimony heard
12 at the Congressional hearing, I won't take you through
13 it. The purpose of bringing up Dr Brandt's -- or
14 parts of Dr Brandt's statement is that it contains
15 a summation of what the Federal Government's position
16 was at the time and, as we mentioned yesterday, we
17 know that the hearing was reported back to the DHSS in
18 the UK.

19 **SIR BRIAN LANGSTAFF:** Could you just go down to the bottom
20 of the page that's in front of us at the moment, the
21 last paragraph, "The National Institute of Mental
22 Health"?

23 **MR HILL:** If I read out that paragraph, sir:

24 "The National Institute of Mental Health (NIMH)
25 held a research planning workshop on August 1, 1983 to

5

1 address the mental health aspects of AIDS. Research
2 will be encouraged in several areas: (1) the effects
3 of stress on the immune system; (2) the psychological
4 effects of AIDS on high risk groups; (3) how to meet
5 the psychological and emotional needs of AIDS
6 patients; (4) anxiety in health care workers; and (5)
7 the role of community and family in providing
8 emotional support. A workshop to address the
9 emotional concerns and support needs of AIDS patients,
10 relatives and health care providers will be held on
11 August 3, 1983."

12 **SIR BRIAN LANGSTAFF:** I appreciate this is dealing with
13 AIDS victims generally, not specifically those who had
14 contracted the AIDS through taking a blood product,
15 but it looks as though, in America, at any rate, there
16 was almost immediately concern for the mental health,
17 psychological consequences, of infection.

18 **MR HILL:** Yes, sir. A document that I didn't take you to
19 yesterday, but, is referred to in the written
20 statement, comes from the Alpha pack of documents that
21 was sent out in December 1982. We looked at the
22 document which was given to the donor in order to
23 educate the donor, and the donor was asked whether or
24 not they were in any of the high-risk groups. There
25 was a further document that was provided in

6

1 December 1982 to any deferred donor, offering that
2 donor a short piece of advice about the steps that
3 that donor may wish to take in light of the fact that
4 they had been deferred because of the ongoing element
5 of -- or the ongoing risk of AIDS. That is another
6 example, perhaps, of how such considerations were in
7 the minds of at least some of those involved in this
8 area in the United States at an early stage.

9 **SIR BRIAN LANGSTAFF:** To what extent was there anything
10 comparable in this country? I don't think the Inquiry
11 has heard, has it, of any similar concentrated effort
12 to address the psychological consequences this early.

13 **MR HILL:** I certainly can't bring one to mind.

14 **SIR BRIAN LANGSTAFF:** Well, if there is anything which
15 comes to mind let me know about it in due course.

16 **MR HILL:** We will look into that, sir. Thank you.

17 Thank you, Soumik, we can take that down now.

18 Moving to the autumn of 1983, according to
19 Dr Evatt in his Tragic History, by the end of
20 August 1983, 26 patients with haemophilia and
21 26 patients who had received transfusions had been
22 diagnosed with AIDS in the United States. You will
23 have seen the reference to a couple of dozen of
24 transfusion patients in the evidence of Dr Brandt.

25 The following month, so September 1983,

7

1 Dr Luc Montagnier attended a conference in New York
2 where he presented his team's findings that suggested
3 that the virus he had isolated, LAV, was responsible
4 for AIDS. This began a period of cooperation between
5 Dr Montagnier and the CDC, which led to the CDC
6 developing assays that would be used in testing viral
7 inactivation, particularly in heat-treated products.
8 I just flag that now, the discussion we will have
9 later about those products.

10 **SIR BRIAN LANGSTAFF:** I mean, he had already reported his
11 results in May, had he not?

12 **MR HILL:** Yes, he had.

13 **SIR BRIAN LANGSTAFF:** So that hadn't been picked up until
14 now, it seems.

15 **MR HILL:** I wouldn't like to say that it hadn't been
16 picked up. I'm not sure of the extent to which
17 the CDC had been aware of those findings. But it
18 seems to have been from September that there is
19 personal contact between Dr Montagnier and the CDC,
20 which leads to the development of their cooperative
21 work together.

22 **SIR BRIAN LANGSTAFF:** Okay.

23 **MR HILL:** In the same month, September 1983, Hyland and
24 the American Red Cross withdrew some fractionated
25 blood products because of a perceived AIDS risk.

8

1 Cutter did the same in November 1983. So these were
 2 the second and third product withdrawals from
 3 US companies. We have an internal memorandum from
 4 Armour, commenting on the Cutter withdrawal, and if we
 5 could have that on screen, please, it's ARMO0000302.
 6 The memorandum is dated 7 November 1983, and
 7 it's to Mr Bishop, from whom you'll be hearing
 8 tomorrow. He's part of the UK subsidiary of Armour.
 9 What the memorandum says is this:
 10 "Cutter recalled 16 AHF lots (6,400 vials,
 11 2.2 MIO [I think that's 2.2 million international] AHF
 12 units) distributed to 33 countries, including Japan.
 13 Several other lots are on hold. One of Cutter's
 14 plasma donors recently died because of AIDS. The man
 15 donated about 5 liters of plasma over the time, but
 16 apparently failed to indicate any information about
 17 his disease during that time. We will probably have
 18 to expect very detailed questions regarding donor
 19 screening/selection of donors during the BGA hearing
 20 at ..."
 21 Unfortunately, this is obscured, and I'm not
 22 quite sure what that next word is.
 23 **COURT:** It's not Berlin, is it?
 24 **MR HILL:** It could well be Berlin, sir, yes. The BGA was
 25 the German regulator so, yes, Berlin fits:

9

1 Factor VIII HT is the heat-treated product.
 2 On 22 October 1983, after these products had
 3 been -- or at least after the Hyland and American Red
 4 Cross recall but before the Cutter recall, on
 5 22 October 1983, the National Hemophilia Foundation
 6 issued a recommendation in effect restating its formal
 7 position from the July 1983 meeting, namely automatic
 8 recall of products manufactured from plasma donated by
 9 a person who was later identified as having AIDS or
 10 characteristics strongly suggestive of AIDS.
 11 You will recall, sir, that that proposition was
 12 put at the July meeting, but was somewhat undermined
 13 by Dr Aledort immediately saying that he personally
 14 didn't agree with it. The NHF, however, restated it
 15 in October of 1983.
 16 It did not lead to any change in regulatory
 17 policy at that time, so that continued on a
 18 case-by-case basis.
 19 In the same month, this is October 1983, Hyland
 20 took a policy decision to cease using plasma from
 21 prisons in the manufacture of coagulation factors. We
 22 can look at a document which we've seen before but
 23 I think is worth looking at again in the context of
 24 the wide debate of what should be done.
 25 It's CGRA0000291.

11

1 "I am also concerned about suggestions that paid
 2 donors are less likely to be truthful when asked
 3 questions which would disqualify them as donors.
 4 Under the circumstances I suggest that we have
 5 a meeting at 1:00 MP [I think that should be PM],
 6 Sunday, the 13th, prior to the BPI meeting at 3 PM, at
 7 the Hotel Kempinski. The Cutter incident is under
 8 investigation now and Dr Rodell will be have detailed
 9 information available for our meeting.
 10 "We regret the unfortunate circumstances of the
 11 Cutter incident. However, a possibility of something
 12 like that happening to any plasma manufacturer cannot
 13 be excluded. It should be to our advantage to
 14 [remind] our customers in an appropriate form, that
 15 Armour processes plasma from our wholly owned and
 16 fully [controlled] plasmapheresis centres. Plasma
 17 Alliances has a worldwide reputation for excellent
 18 quality and highest standards. Although it is obvious
 19 but is it actually not known how to avoid transmission
 20 of AIDS, it should also be emphasized that we have
 21 recently introduced factorate HT to improve the safety
 22 of our project.
 23 "We will keep you informed on this matter and
 24 would appreciate any feedback. Regards ..."
 25 And it's from an I Regier.

10

1 It is from Dr Srigley to D Castaldi dated
 2 20 October 1983, so an internal Hyland document.
 3 It refers to a telecon with Dr Donohue of the FDA.
 4 What the document says is this:
 5 "Attached is the text which I used to define for
 6 Dr Donohue Travenol's policy with regard to the use of
 7 plasma from prison centers.
 8 "He expressed his satisfaction with the policy
 9 and appreciation that we responded promptly to him.
 10 He asked that we not send it to him in writing at this
 11 time."
 12 Then he says:
 13 "If you have any additional questions ..."
 14 Let him know. If we could turn over, please, to
 15 the next page, you can see this is the text that was
 16 used, it's marked as "Proposed Text" but we know from
 17 the memorandum that it was used with Dr Donohue. What
 18 it says is this, and I quote:
 19 "We had previously made the decision to
 20 discontinue the purchase of plasma from licensed
 21 centers in prisons. To that end we have chosen not to
 22 renew any pre-existing contracts with such centers
 23 after this year. Following my conversation with you
 24 yesterday, we have decided that we will promptly
 25 discontinue the use of such plasma for the manufacture

12

of coagulation factors. We have pools in process this week which contain plasma drawn in prison centers. As of the end of this week, we will not make any coagulation factors from any of the prison plasma which remains in our possession or which we are contractually bound to purchase through the remainder of the year; no further plasma pools used for coagulation factors will contain prison plasma. Any intermediate fractions manufactured from plasma pooled this week, or in previous weeks, would be processed to final product."

Then there is an offer to put that policy in writing, which we know Dr Donohue did not take up.

We discussed this document before, sir. It is clear from the statement that Hyland Travenol had previously manufactured coagulation factors from plasma taken from prisoners, and that they were continuing to do so up until that very week. This is October 1983.

The document doesn't specify whether or not that plasma was used in any particular set of products or whether it was sent to any particular markets. There is nothing in the document to say that it was treated any differently from the plasma that was used generally by the company.

13

SIR BRIAN LANGSTAFF: Well, I think it does indicate, doesn't it, that the pools were used for coagulation factors?

MR HILL: Yes.

SIR BRIAN LANGSTAFF: So --

MR HILL: It was certainly used for the creation of factor products --

SIR BRIAN LANGSTAFF: Yes.

MR HILL: -- and there is nothing to say that those factor products were treated in any way differently to any other factor products that the company made.

SIR BRIAN LANGSTAFF: Yes.

MR HILL: Just to break sequence slightly, on 7 January 1983, so nine months before, 16 cases of AIDS in prison inmates had been reported to the MMWR.

If we could have on screen, please, JREE0000019, page 76. This is taken from the Institute of Medicine report, and they've helpfully set out a table which shows the number of cases reported in different risk groups from across the United States.

We can see, 7 January 1983, risk groups 16 prison inmates, and there is a snippet of the report, which says:

"Since male homosexuals and IV drug abusers are known to be at increased risk for AIDS, the occurrence

14

of AIDS among imprisoned members of these groups might have been anticipated."

That comes from January 1983. Thank you, Soumik, we can take that down. I'm sorry, just at bottom there.

Moving on to December 1983, there is discussion of the issue of surrogate testing. A joint meeting was convened on 15 December 1983 by the National Heart, Lung, and Blood Institute, and the Office of Biologics. It took place to consider work that had been done by that time on surrogate testing, the trials had been running in different parts of the country. In particular, it considered anti-hepatitis B core antigen testing, so the antibodies for hepatitis B core antigen.

The Krever Report summarised the meeting in a helpful way, which I will now take us to, it's KREV0000001, electronic page 770, please. From the top of that page, this is what Mr Justice Krever said about that meeting:

"In December 1983, the Food and Drug Administration's blood products advisory committee reviewed the research on various surrogate tests, including several pilot tests performed at blood banks in high-risk areas. Four studies had been done on

15

anti-core testing, two on Beta-2-microglobulins, and single studies had been made of cytomegalovirus, EBV [which is Epstein-Barr Virus], immune complexes, Neopterin, T-cell ratio measurement, Thymosinal, and Alpha interferon."

So these are all different surrogate tests have been considered in various studies:

"Most of the discussion focused on the usefulness of anti-core testing. Dr Johanna Pindyck, for example, summarized the results of anti-core testing done at the Greater New York Blood Program. She reported that 5.5 per cent of male donors under thirty-five years of age were core antibody positive, as were 7.7 per cent of those over thirty-five years. The estimated cost of the test was three dollars, but the cost of discarding the units as well as recruiting efforts to replace the donor required further evaluation. Data from testing 8,049 donors at Irwin Memorial Blood Bank were also discussed. They demonstrated that donors living in an area of homosexually active men were likely to be positive for anti-HBc and that the test could identify 89 per cent of those most at risk of contracting AIDS. The committee members asked whether these data constituted 'sufficient evidence to substantiate testing for

16

(4) Pages 13 - 16

1 anti-HBc,' and expressed concern about the potential
 2 cost of such testing."
 3 If we can go to the next paragraph, please:
 4 "Although Dr Donohue, the director of the Food
 5 and Drug Administration's division of blood and blood
 6 products, had recommended to the committee that
 7 anti-core testing be implemented, Dr Michael Rodell,
 8 a representative of Armour, suggested that a task
 9 force be struck to consider the potential application
 10 of the anti-HBc test as an additional risk-reduction
 11 measure and to report within three months. This
 12 suggestion met with universal approval from the
 13 committee members; many representatives of blood
 14 products manufacturers had met the previous evening
 15 and agreed that the task force would 'provide
 16 a delaying tactic for the implementation of further
 17 testing', which they expected would become
 18 a requirement later that year."
 19 We're going to look at a different source from
 20 the same meeting in a second but, before I do, I flag
 21 the point that Dr Donohue of the FDA had, at the start
 22 of 1983, expressed some reservations about hepatitis B
 23 core testing. From the summary that we see of that
 24 meeting, and indeed from other sources, we can see
 25 that, by this stage, December 1983, Dr Donohue's

17

1 "The advisory committee agreed with this
 2 recommendation, with the dissension of the Acting
 3 Chairman, Bill Miller of the St Louis Red Cross.
 4 Dr Miller stated that he believed that any testing
 5 required for plasma should also be required for whole
 6 blood. The committee is aware of a scheduled January
 7 publication in the New England Journal by the CDC
 8 indicating AIDS transmission in more than
 9 30 transfusions. Several members of the audience
 10 objected to the proposal for one reason or another,
 11 but Mike Rodell of Armour proposed a Task Force to
 12 deliberate the details of the recommendation and
 13 provide further in 3 months."
 14 Go over to the next page, please:
 15 "This proposal was one that had been agreed upon
 16 by all of the fractionators the previous evening. The
 17 general thrust of the task force is to provide
 18 a delaying tactic for the implementation of further
 19 testing. It was generally agreed that core testing
 20 would eventually become a requirement.
 21 "The addition of core testing is expected to
 22 eliminate approximately 15% of plasma donors, and 6-7%
 23 of whole blood donors if used by blood banks. Some
 24 blood bankers mentioned that public pressures would
 25 certainly be a motivating factor for core testing at

19

1 position had changed and he was recommending that such
 2 testing be introduced.
 3 The reference to the meeting of the
 4 fractionators appears to be drawn from a note of the
 5 meeting prepared by Dr Ojala of Cutter, we've seen
 6 many of his memorandums in the last day or so. The
 7 reference is UCSF0000034. The memorandum is dated 19
 8 December, it's sent to a number of people within
 9 Cutter, and it is a report on the meeting that took
 10 place on 15 and 16 December, the meeting that we have
 11 just been discussing.
 12 If I could pick it up from the third paragraph,
 13 starting "Donohue recommended", this is Dr Ojala's
 14 account of the meeting:
 15 "Donohue recommended that Anti-core Hepatitis B
 16 testing be incorporated for routine plasma screening
 17 (in addition to current requirements) since it would
 18 identify 90% of all potentially infectious (or high
 19 risk) donors. The Anti-core testing would add
 20 a further measure of confidence in product safety at
 21 a relatively low cost for the products involved. He
 22 reviewed the AHF market withdrawals that had been
 23 conducted and indicated that core testing and heat
 24 treatment could eliminate this potential for the
 25 future.

18

1 their facilities.
 2 "The fractionators met with Donohue following
 3 the meeting and, although Donohue was not completely
 4 satisfied with the task force approach, he agreed to
 5 it. He stated that we should also take on the
 6 responsibility for all testing of recovered plasma.
 7 Rodell was named chairman of the Task Force and
 8 a meeting would be scheduled in January."
 9 If you go on, please:
 10 "John Hink [who, as we heard yesterday, is
 11 a fellow Cutter employee], in a prescient move, has
 12 already begun core testing at Cutter centers. We
 13 recommend that the implementation of core testing be
 14 accelerated to the maximum degree possible to obtain
 15 a competitive advantage in the marketplace. The
 16 approval of our heat-treat submission, in conjunction
 17 with core-screened plasma could present us with
 18 a potent marketing advantage. We made no mention of
 19 our plans to the others.
 20 "In summary, the conclusion of this meeting was
 21 that the time had come for Hepatitis core anti-body
 22 testing for plasma. Implementation will probably be
 23 achieved during 1984 for the industry."
 24 We will come back to Cutter's approach to
 25 hepatitis B core testing in due course.

20

(5) Pages 17 - 20

1 We have reached the end of 1983 and, in summary,
2 the year saw the introduction by all fractionators of
3 enhanced donor screening processes. Following the
4 publication of the FDA recommendations in March 1983,
5 blood banks also introduced further steps, but they
6 continued to be less robust with the ones that were
7 put in place at the plasmapheresis centres.

8 The five firms that supplied the United Kingdom
9 gave undertakings to the DHSS that, going forward,
10 they would only supply products that had been
11 manufactured from plasma after the introduction of
12 their new enhanced screening processes. That
13 commitment was prospective. Products that had already
14 been produced were not affected and were not
15 withdrawn, nor did the DHSS or the American
16 authorities insist upon such products being recalled
17 or withheld from distribution.

18 One firm, Hyland, continued to fractionate from
19 prison blood until October 1983.

20 The wider issue of when product should be
21 recalled had been discussed at length but no consensus
22 had emerged. The fractionators had argued that a
23 policy of automatic recall would jeopardise supply,
24 and even the continuing existence of some firms.
25 Their arguments were effective in that the FDA was not

21

1 advised to, and did not, take formal regulatory steps
2 in this period; instead, recall was considered on
3 a case-by-case basis. There were three such recalls
4 in 1983.

5 In July of 1983, the NHF had formally called for
6 a policy of automatic recall, but, as we have seen, it
7 was somewhat undermined by Dr Aledort's personal
8 views. His approach, as expressed at the meeting
9 in July, was similar to that of the fractionators;
10 however, the NHF restated its official position in
11 October 1983.

12 On surrogate testing, the fractionators had
13 successfully argued for further consideration through
14 a task force, something that Dr Ojala has referred to
15 as a "delaying tactic". His company, Cutter, had
16 unilaterally begun to test plasma for
17 anti-hepatitis B core antigen, something that he
18 thought would steal a march on his rivals.

19 1983 also saw the first heat-treated product
20 being licensed. That was Hyland's Hemofil-T. Armour,
21 Cutter and Alpha had all applied for licences
22 during 1983, and, as we will see, they were granted
23 early in 1984.

24 Meanwhile, products continued to be recalled,
25 the number of cases of AIDS among people with

22

1 haemophilia and people having blood transfusions
2 continued to grow.

3 Turning then to the first six months of 1984.
4 January saw the publication in the New England Journal
5 of Medicine of a study of 18 AIDS cases where the only
6 risk factor identified was exposure to blood
7 components within five years of the onset of
8 the illness. The lead author was Dr Curran of
9 the CDC.

10 Mr Justice Krever placed some weight on this
11 application, and he quoted the evidence of
12 Dr Thomas Zuck, of the FDA, who said that the article,
13 and I quote:

14 "... put the whole medical community and perhaps
15 the world on notice that AIDS is transmitted by blood
16 transfusions ... the debate [was] over."

17 That was Dr Zuck's view in his evidence to the
18 Krever inquiry.

19 The same month, January 1984, saw Alpha recall
20 factor concentrates as a result of the donor later
21 developing AIDS, so this was the fourth such
22 withdrawal. Hyland, in May 1983, Hyland and the Red
23 Cross in September 1983, Cutter in November 1983, and
24 now Alpha in January 1984.

25 Cutter and Armour products received FDA licences

23

1 for heat-treated products in January. Those are the
2 pasteurised form of Koate HT and Armour's dry-heated
3 Factor VIII HT. In the following month,
4 February 1984, licences were granted by the FDA to
5 a different heat treatment method from Cutter, that's
6 Koate HT dry-heated and Alpha's Profilate HT. We will
7 come back to those products in the heat treatment
8 processes in due course.

9 On 9 February 1984, a meeting was held at the
10 UK's National Institute for Biological Standards and
11 Control, NIBSC. It was a meeting that was entitled
12 "Meeting on the Infectious Hazards of Blood Products",
13 and it was attended by a number of US and
14 UK fractionators and officials. Among those present
15 on the UK side were Joseph Smith of the Committee on
16 the Safety of Medicines, he seems to have taken
17 a convening role at the meeting, Duncan Thomas of the
18 NIBSC, and as we saw yesterday Dr Thomas had been
19 present at the some of the meetings in the
20 United States that had taken place the previous year.

21 Also present from the UK: Dr Craske,
22 Dr Richard Tedder, Dr Richard Lane, the director of
23 the Blood Products Laboratory, Dr Terry Snape, his
24 colleague at BPL, Dr Brian McClelland and Dr John Cash
25 of the Scottish National Blood Transfusion Service.

24

(6) Pages 21 - 24

1 US attendees included Dr Petricciani, and
 2 representatives of Cutter (Dr Ashworth), Armour
 3 (Dr Rodell) and Alpha (Dr Carr).
 4 A European representative of Hyland Travenol
 5 attended, Mr J Van Kalster, as did Dr Eibl of Immuno.
 6 I'm going to ask Soumik to bring up the minutes
 7 of the meeting that were prepared by Dr Thomas. They
 8 are at PRSE0003071.
 9 We've looked at parts of these minutes before.
 10 Although they're noted to be draft minutes, we know
 11 from other documents, which are set out paragraph 173
 12 of the written presentation, that Dr Thomas circulated
 13 these minutes, and there are one or two corrections to
 14 specific points of detail but generally they were
 15 agreed.
 16 I'm not going to take you through all of the
 17 document. At paragraph 184 of the written
 18 presentation there is a summary of the issues that
 19 were discussed.
 20 Dr Smith opened the meeting by speaking about
 21 how the benefits of factor concentrates were assessed
 22 against what he called the "well recognised
 23 side-effect" of hepatitis, and against the emerging
 24 knowledge of AIDS.
 25 The meeting recorded that 21 people with

25

1 deficiency of both cellular and humoral immune
 2 systems. One possible explanation is that the
 3 occurrence of AIDS in recipients of blood and blood
 4 products is due to a filterable agent, presumably
 5 a virus. Another possible explanation is an
 6 overwhelming of the immune system by repeated infusion
 7 of foreign and possibly altered proteins. He
 8 suggested that the true explanation may lie between
 9 the two extremes, namely that there may be
 10 a transmissible agent which only becomes infective
 11 when certain conditions are met in the host."
 12 Then there is a discussion of possible viruses
 13 that may be the cause.
 14 Dr Tedder was presenting a paper which he had
 15 prepared for the meeting.
 16 If we then move on to the next page, this is
 17 dealing with Dr Petricciani's paper, and his
 18 presentation to the meeting. If we go down to the
 19 paragraph starting "Dr [Petricciani] (FDA ...)":
 20 "Dr [Petricciani] (FDA, Bethesda, [Maryland])
 21 outlined the current strategies adopted by the FDA for
 22 the identification and exclusion of high-risk donors.
 23 Four strategies have been considered: 1) voluntary
 24 limitation by high-risk groups; 2) exclusion of
 25 high-risk donors; 3) laboratory testing ..."

27

1 haemophilia in the US, 11 in Europe, including two in
 2 the UK, had contracted AIDS. There were 21 in the
 3 United States, 11 in Europe, which included the two in
 4 the United Kingdom.
 5 **SIR BRIAN LANGSTAFF:** Did you say to me just earlier that
 6 there had been 26 identified?
 7 **MR HILL:** Yes. That was Dr Evatt's figure.
 8 **SIR BRIAN LANGSTAFF:** 26 of transfusion and 26 from --
 9 **MR HILL:** 26 from.
 10 **SIR BRIAN LANGSTAFF:** -- haemophiliacs.
 11 **MR HILL:** That's Dr Evatt's figure by the end
 12 of August 1983. I'm afraid I can't explain the
 13 difference between that figure of 26 and the figure
 14 of 21 that was given in the minutes of this meeting.
 15 The discussion included an examination of
 16 pool sizes that were used in fractionation, and we
 17 looked at that during September, the point being made
 18 that pool sizes could range anywhere from 1,000 to
 19 20,000 litres of plasma.
 20 If we could go to page 3 of the minutes, please.
 21 To the final paragraph of that section. This is
 22 recording a comment made by Dr Tedder:
 23 "In considering current views on the aetiology
 24 of AIDS, Dr Tedder (Middlesex Hospital, London)
 25 pointed out that AIDS is manifested as a profound

26

1 I take that to be a reference to surrogate
 2 testing. And:
 3 "... 4) a combination of the above. Currently,
 4 there are no specific laboratory tests that are able
 5 to identify a possible AIDS carrier. Although
 6 anti-hepatitis B core antibody is positive in more
 7 than 90 per cent of AIDS cases, it is also positive in
 8 approximately five per cent of normal individuals.
 9 The approach adopted by the Office of Biologics since
 10 March, 1983, was for plasma connect centres to give
 11 information to each donor on AIDS, to encourage
 12 self-exclusion, and to examine donors for
 13 lymphadenopathy. The New York Blood Center had
 14 introduced an additional option, allowing donors to
 15 indicate privately that their blood should be used
 16 only for research purposes."
 17 There is a longer paper that the Inquiry has,
 18 which is at BAYP0005158. I won't bring it up, sir,
 19 but it's the full text of the presentation that
 20 Dr Petricciani made. It describes many of the matters
 21 that we went through yesterday, summarising the
 22 US debate on them, and the position reached as of
 23 February 1984. I flag it merely as a helpful resource
 24 in understanding what information UK officials had
 25 received as of that time from the US, their

28

(7) Pages 25 - 28

1 US counterparts. The minute there is a summary of
2 that paper.
3 If we could now turn to page 5, please, of the
4 document, right, at the bottom Dr Ashworth:
5 "Dr Ashworth (Cutter ...) described collection
6 procedures at plasmapheresis centres used by the four
7 main US companies."
8 Go to the next page, please:
9 "There are some 340 plasmapheresis stations in
10 42 states, employing 6,000 people. Approximately
11 a third of these centres are owned by the companies,
12 and the rest supply plasma under contract. All
13 plasmapheresis stations in the United States are
14 licensed by the FDA, as is the centre in Belize.
15 Dr Ashworth described the donor records in detail,
16 including questions intended to identify and exclude
17 AIDS carriers. The detailed system exist which allows
18 easy identification of product batches that contain
19 material from a particular donor. Some companies are
20 now avoiding taking plasma from centres in high-risk
21 areas of the United States, although he pointed out
22 that not all donors who contracted AIDS lived in these
23 areas. For example, both Cutter and Alpha
24 Therapeutics have each had one donor who was later
25 shown to have developed AIDS; in both cases, the

29

1 **MR HILL:** Yes. The FDA's conversation with Hyland was
2 about the use of prison plasma specifically in factor
3 concentrates. It is possible that plasma from prisons
4 might have been used in other blood products which
5 were thought or known not to pass on infectious
6 diseases. So that may be an economic reason why those
7 centres could continue. But certainly the FDA would
8 have been aware of those centres, and would have been
9 regulating them.
10 **SIR BRIAN LANGSTAFF:** Yes. Yes.
11 **MR HILL:** Going back to the document, the following
12 paragraph -- sorry, just before we do move to the next
13 paragraph, I just flag up the reference there to
14 a donor from Texas that had led to recalls -- or
15 donors from Texas that had led to recalls of product
16 by Cutter and Alpha.
17 You will recall that yesterday, I showed you
18 a document from February 1983 from the Alpha company,
19 a committee of Alpha, which discussed a Dallas donor
20 who had, and I quote, "some AIDS symptoms". That was
21 February 1983. We know that the Alpha withdrawal of
22 product was in January 1984, and in the following
23 month, February 1984, there is reference to a donor
24 from Texas being responsible for that recall, what we
25 don't know is whether or not that Texas donor is the

31

1 donors were from Texas, which is considered a low risk
2 area."
3 **SIR BRIAN LANGSTAFF:** Just as a point of detail on that
4 account, you showed me earlier the memo when Hyland
5 decided to stop taking plasma from prisons. It showed
6 that Hyland had a contract with the donor centre at
7 the prison --
8 **MR HILL:** Yes.
9 **SIR BRIAN LANGSTAFF:** -- and the contract would persist,
10 and therefore they'd have to pay, even though they
11 were not going to use the plasma which they then
12 received until the contract expired. It would follow
13 that the centre, or some of the centres concerned at
14 any rate, were not directly owned by Hyland.
15 **MR HILL:** Yes.
16 **SIR BRIAN LANGSTAFF:** And it would also follow that they
17 were going on operating. But it was the FDA that was
18 asking Hyland to stop taking plasma from prisons, and
19 yet, if this is right, it looks as though, in the
20 absence of further information, there were
21 plasmapheresis stations in the United States operating
22 in prisons, collecting plasma, which remained licensed
23 by the FDA despite the knowledge or belief that
24 those in prison would disproportionately be affected
25 by hepatitis and by AIDS.

30

1 same as the Dallas donor who was being discussed
2 a year earlier.
3 Going on to the next paragraph:
4 "In discussion, Dr Cash commented that paid
5 donors are perhaps less likely to be truthful about
6 their activities than volunteer donors. Dr Rodell
7 disputed this, and pointed out that in three of the
8 four instances of blood donors contracting AIDS,
9 leading to subsequent withdrawal of product, the
10 donors were in fact non-paid volunteers. Furthermore,
11 the payment to plasmapheresis donors probably sufficed
12 only to cover their expenses."
13 If we -- yes, I think we can go to pages 9 and
14 10 now of the document. There was a discussion from
15 Dr Lane and Dr Snape about fractionation, and there
16 were also discussions about hepatitis B testing.
17 I'd like to turn now to the bottom of page 9,
18 and the section of the minutes that deal with an open
19 discussion that took place after the formal
20 presentations had occurred. It says that the
21 discussion focused on four main issues, and I quote:
22 "1. What should be done about blood products
23 made from plasma pools when one of the donors to that
24 pool subsequently developed AIDS? This has already
25 happened to US manufacturers, leading to withdrawal of

32

(8) Pages 29 - 32

the affected batches. Dr Thomas asked Dr Petricciani whether the FDA had specifically requested the manufacturer to withdraw batches that had been made from an affected pool. Dr Petricciani replied that no formal instruction had been issued by the FDA, but the withdrawal had taken place as a result of informal discussion and agreement. The general feeling of the meeting was that if the diagnosis of AIDS in a donor is definite, then products prepared from pools to which the donor had contributed should be withdrawn. If a donor is found to have symptoms and signs, such as lymphadenopathy, which were associated with incipient AIDS, but were neither diagnostic nor specific for the condition, the recall of material to which the subject had previously contributed plasma was not justified. It was recognised that the scientific rationale for this course of action left much to be desired, but that no other action could be taken which would not imperil the supply of Factor VIII.

"2. As far as laboratory tests for screening for AIDS are concerned, it was generally agreed that, on present evidence, only the test for hepatitis B core antibody was thought likely to be of value. However, there was no general agreement that such

33

testing for core antibody should be part of the routine screening carried out on all donors.

"3. There was much discussion about the optimal size of plasma pools, but no agreement that reduction of pool size would either a practicable or a successful way to reduce the transmission of either hepatitis or AIDS."

I will leave that document there, sir, and instead turn to the other source that we have for what was said at that meeting, which was a memorandum prepared by Dr Carr of Alpha. That gives a slightly different perspective on some of the passages that we have just read.

If we could have on screen, please CGRA0000610. This is dealing with the same section-- sorry, page 6. You can see from that first page that it's an internal Cutter memorandum -- sorry, an internal Alpha memorandum.

We're looking now at Dr Carr's summary of the general discussion and suggested recommendations. This is the same part of the meeting that we've just been looking at. What Dr Carr wrote is this:

"a. Identification and exclusion of high-risk donors:

"Dr Smith [that's Dr Joseph Smith] stated that

34

he was very reassured by the clear policies in the US and the UK. He expressed concern over what is done when the donor is identified as an AIDS donor and additionally as a suspect AIDS donor. Dr Petricciani stated that we were still struggling with the question as to what should be done. The four US market withdrawals were discussed and we explained that we were all still making decisions on a case-by-case basis. The decisions were not being made based on scientific information, but simply because of emotional and political considerations. During this discussion it was very emphatically noted that three out of the four market withdrawals involved volunteer donors not paid donors.

"b. Fractionation and processing methods:

"There were some concerns expressed over the safety of heat-treated products. Dr Bloom as a consultant to NIBSC stated that he was not sure that there was enough data on the potential immunogenicity of the heat-treated products. A brief explanation of the types of animal immunogenicity data collected was described.

"There followed a very lengthy discussion on the value of small pool size versus the use of large pools. We were finally able to show them that even

35

with a small pool size because of the fact that they are collecting individual donations the exposure of the hemophiliac to numerous donors would still be there. Dr Smith summed up this discussion by stating that they should encourage the development of fractionation and procession controls for lowered infectivity, ie physical and chemical inactivation."

Go to the next page, please:

"Dr Smith asked Dr Bloom whether or not dosage guidelines should be developed. Dr Bloom stated he did not see how they could develop them when they do not have enough NTS [I think that should probably be NHS] material and hemophiliacs must either go untreated or they must use foreign material. Dr Petricciani noted that AHF was not considered overused in the United States and this was not an issue. Rather there was some concern that it was being underused.

"c. Laboratory test procedures. Dr Smith summed up this item with practically no discussion at all stating for the attendees that no laboratory test procedures can be recommended at this time."

If we go to the bottom, the last couple of sentences. There is a discussion about the safety of hepatitis B immune globulin, then this:

36

"Finally, it seemed apparent to me that the British will watch very closely what is done in the US and in this case seem to be tending to follow our lead. In talking privately with Dr Thomas before the meeting he told me he wasn't sure that we should have withdrawn our product but postulated probably our lawyers would advise us that we had to. From his [point of view] he did not think we should have."

That's Dr Carr's record of the final stages of that meeting in February 1984.

Moving back to the United States. The task force, or what's sometimes referred to as a study group, on anti-hepatitis B core testing that had been established in the December 1983 meeting -- that's the body that was seen by Dr Ojala as a delaying tactic -- met on 6 March 1984, Dr Rodell was in the chair. A full report from the committee, or the task force, wasn't presented until July 1984 but, following the 6 March meeting, the group provided an interim report and recommendations. If we could have a look at those, please, they're at MHRA0000076_010.

You can see that this is entitled "Interim Summary Statement of Hepatitis B Core Antibody Testing Study Group, by Michael B Rodell, Chairman". What the interim statement says is this:

37

indicated that they would likely be compelled to follow suit if any of the organizations represented initiated Anti-HBc testing programmes. The report to be prepared will contain position papers summarizing the majority and minority opinions on this issue.

"It was clearly recognized by the Study Group that a positive finding of Anti-HBc in an individual was not necessarily indicative of AIDS or the future development of the disease state; rather, it was viewed as a possible mechanism of identifying high risk group members, a number of whom are positive for this serologic marker. It without the prevailing opinion of the Study Group that if testing programs for Anti-HBc are employed, they should not be confined to the plasma donor population, but should extend to whole blood donors as well.

"There was unanimity on two additional issues that the Study Group addressed. First, the Study Group recommended the initiation of a pilot study in at least two metropolitan areas to ascertain the effectiveness of allowing plasma donors to privately provide a written indication as to whether their plasma should be used in the manufacture of products used in haemophilia treatment, analogous to the system currently utilized by the New York Blood Center in

39

"On March 6, 1984, the Study Group, formed subsequent to the December, 1983 meeting of the FDA Blood Products Advisory Committee, met to discuss the issue of testing potential blood and/or plasma donors for core antibody and to hepatitis B ... Membership of the Study Group consisted of representatives of the commercial and noncommercial fractionation industry, the plasmapheresis community, nonprofit blood collection and processing organisations, and the Food and Drug Administration.

"The purpose of the meeting was to review all aspects and ramifications of the use of testing for Anti-HBc as an additional means of determining whether potential donors were members of high risk groups associated with Acquired Immuno Deficiency Syndrome. Although a full report of the Study Group's deliberations and exclusion will be furnished to the Food and Drug Administration in the near future, it was felt that an interim statement should be made available at this time."

The Study Group was divided in its position on testing for Anti-HBc as a means of identifying AIDS high risk group members, with the majority believing that such testing was not appropriate for that purpose. However, members of a majority group

38

whole blood collections. Secondly, the Study Group recommended that pilot studies involving testing for [Beta-2-microglobulin] levels be designed, since the presence of this analyte appears to offer a higher degree of correlation with prodromal or active AIDS."

Thank you, that can be taken down.

That is the formal record as prepared by Dr Rodell, the chair of the group. We also have an account of the meeting from an internal Cutter memorandum prepared by Dr Hink. That is at CGRA0000319, please. This is dated 13 March 1984, it refers back to that meeting held on 6 March. The first thing note, the people who are on that working group: it's Marietta Carr from Alpha, whose memorandum we just looked at; Dr Donohue from the FDA; Dr Marilyn Horowitz from the New York Blood Center; Dr Peter Page of the American Red Cross; Dr Robert Gerety, again of the Bureau of Biologics, we mentioned him yesterday; Dr Hink himself from Cutter; Dr Johanna Pindyck, of the New York Blood Center; Dr Bob Reilly of the American Blood Resources Association; Dr Toby Simon, the American Association of Blood Banks, so a blood banking industry body; Dr Rick Strigley of Hyland; Dr Mike Rodell of Armour, who was the chair.

We begin with this summary. Paragraph 1, what

40

(10) Pages 37 - 40

1 Dr Hink wrote is this:
 2 "On the question of beginning Hepatitis B Core
 3 Antibody (anti-HBc) testing of Source Plasma Donors:
 4 following 5 hours of discussion, a vote was taken.
 5 Donohue, Srigley and Hink voted in favor. All others
 6 (with the exception of Gerety who I believe abstained)
 7 were not in favor."
 8 I pause there to note, sir, that Dr Donohue of
 9 the FDA is therefore in favour of the testing, as are
 10 the representatives of Hyland, Dr Srigley, and Cutter,
 11 Dr Hink. Dr Gerety is believed to have abstained.
 12 Everybody else, being the representatives of Alpha and
 13 of Armour, voted against. The summary goes on to
 14 mention the position papers that will be prepared and
 15 the pilot studies and investigations that the working
 16 group had recommended. If we go to point 5, please:
 17 "Immediately prior to the conclusion of our
 18 meeting it was recommended that the Industry should
 19 refrain from starting anti-HBc testing. Carr was
 20 adamant that Alpha would not begin, Rodell said Armour
 21 would not use the test unless a competitor was using
 22 it to competitive advantage. Srigley indicated he
 23 could not speak for his company management, and
 24 I parroted his comment."
 25 I pause there note to, sir, that we know from

41

1 candidate. When questioned about certain current AIDS
 2 investigations at Hyland he thought, but could not be
 3 certain, that of 7 cases only 3 or 4 were anti-HBc
 4 positive."
 5 Dr Pindyck is quoted or cited next, she was from
 6 the New York Blood Center. I quote -- I won't go
 7 through everything which she said, but I quote:
 8 "Anti-HBc has low selectivity, not worthwhile
 9 for volunteer segment."
 10 I take that to be a reference to voluntary blood
 11 donor blood banks:
 12 "Suggests there may be better tests being
 13 developed."
 14 So that was her view.
 15 Gerety, this is Robert Gerety of the FDA's
 16 hepatitis branch, and you may recall, sir, that we
 17 looked yesterday at the scepticism that Dr Gerety had
 18 expressed about anti-hepatitis B testing in the
 19 January 1983 meeting but, rather like Dr Donohue, we
 20 see that he had, by this time --
 21 **SIR BRIAN LANGSTAFF:** I think we may need to move on to
 22 the next screen.
 23 **MR HILL:** Sorry, it's electronic page 3, so Gerety there.
 24 If we pick up from the top of that:
 25 "... AIDS cases remain with high risk groups.

43

1 the memorandum that, by this stage, Cutter had already
 2 commenced some form of anti-HBc testing.
 3 If we go over to the next page, please, page 2,
 4 electronically. If we can pick up some of the
 5 contributions that were made to the test -- sorry, to
 6 the debate. It began with Dr Donohue setting out his
 7 concerns. I won't go through that. If we can pick up
 8 from Dr Hink, and I quote:
 9 "... additional screening is necessary to reduce
 10 the risk of coagulation product withdrawal/recall.
 11 Recalls are not only costly but could create
 12 a shortage of material available to hemophiliacs.
 13 Anti-HBc testing can be carried out in high volume by
 14 the Industry and by the volunteer segments, if
 15 desirable. CDC reports that over 75% of the high risk
 16 AIDS groups are positive and as a marker for hepatitis
 17 it is reported that the exclusion of positive units
 18 has reduced the incidence of non-A non-B hepatitis
 19 from blood transfusion. If the test is implemented
 20 for SP(H) it should be agreed that the coagulation
 21 products manufactured from core antibody negative
 22 plasma would not be subject to AIDS related recall."
 23 Dr Srigley said, and I quote:
 24 "Srigley -- agrees that additional plasma
 25 screening is necessary and anti-HBc is a likely

42

1 Concerned about anti-HBs level in plasma pools if
 2 anti-HBc positives excluded."
 3 So that's the concern that we discussed
 4 previously, that the inadvertent effect of this might
 5 be to reduce the protection against hepatitis B:
 6 "However, only small amount necessary to provide
 7 antigen 'complex' safety. Feels elimination of
 8 anti-HBc positives would improve HBV [hepatitis B
 9 virus], non-A non-B hepatitis virus and AIDS safety of
 10 coagulation products. Questions mechanics/validity of
 11 test with 50% cut off. Suggests a 75% cut off ... It
 12 would reduce the 15% positive rate now experienced."
 13 I pause there note to that this now seems to be
 14 a suggestion that, instead of excluding any donation
 15 which tested positive, a certain level would be
 16 imposed, and if it was above that level then that
 17 plasma would be excluded, which would reduce the
 18 amount of plasma that would have to be discarded --
 19 that's the 15 per cent positive rate -- that there is
 20 then a discussion that goes on about whether or not
 21 that is a good idea.
 22 Looking at some of the other contributions --
 23 **SIR BRIAN LANGSTAFF:** Just go on, I think.
 24 **MR HILL:** "(... It would reduce the 15% positive rate now
 25 experienced).

44

(11) Pages 41 - 44

1 This is still Dr Gerety, yes, sorry:
 2 "High percentage (up to 90%) of haemophiliacs
 3 now dying of liver disease. If anti-HBc testing
 4 implemented, antibody positive plasma should be used
 5 in manufacture of gamma globulins."
 6 Presumably that was on the basis that those
 7 products wouldn't pass on infectious diseases and it
 8 would avoid the waste of plasma that would otherwise
 9 take place.
 10 I note there, sir, that Dr Gerety was thought by
 11 Dr Hink to have abstained during the subsequent vote.
 12 It was certainly a softening of his position compared
 13 to where he was in January 1983.
 14 The next contribution is from Dr Peter Page of
 15 the American Red Cross, and I quote:
 16 "... doesn't think we should start with low
 17 specificity anti-HBc test now. If begun we could be
 18 stuck with it even if better test developed."
 19 Dr Gerety appears to have intervened at this
 20 point. The record says:
 21 "(Gerety sees no reason anti-HBc should be
 22 continued if better test implemented at later date.)"
 23 Dr Carr of Alpha, and I quote:
 24 "... sees problem with volunteer plasma if
 25 anti-HBc test conducted with SP(H) only. Suggests

45

1 positivity in donors is echoed by the exact same
 2 percentage in those who suffer from the disease. It's
 3 the point I raised with you yesterday.
 4 **MR HILL:** Yes. But the figures that Dr Simon cites there
 5 are not consistent with Dr Evatt's figures from that
 6 table.
 7 **SIR BRIAN LANGSTAFF:** What does he say in the table for
 8 those who were --
 9 **MR HILL:** If we could bring up, please -- can we do
 10 a split screen, please, Soumik, and have CVHB0000042,
 11 page 5. If we put that on one side and then the
 12 document that we've just been looking at on the other.
 13 Sorry, I'm throwing this one at you at the last
 14 minute. CVHB0000042. And it's electronic page 5 of
 15 that document.
 16 **SIR BRIAN LANGSTAFF:** We can come back to it later. At
 17 the moment we're just getting each page in turn -- we
 18 can see enough, I think, from that, if we just enlarge
 19 the table at the bottom.
 20 **MR HILL:** I have the figures from Dr Simon in front of me,
 21 so I can remind you of those in a second, sir.
 22 **SIR BRIAN LANGSTAFF:** Thank you.
 23 So let's just enlarge the table at the bottom and
 24 see what he was saying.
 25 **MR HILL:** This is from 1982, and the first cohort of

47

1 plasma shortage if test implemented."
 2 Then it says that:
 3 "Alpha is currently conducting 8,000 HBsAg
 4 tests/day ..."
 5 The next contribution is from Toby Simon of the
 6 American Association of Blood Banks, and I quote:
 7 "... whatever test is imposed on Industry would
 8 impact (be required) for volunteer segment. Earlier
 9 pilot study with anti-HBc identified only 38% of known
 10 gays as positive. Evatt of CDC told him only 50% of
 11 key blood donors (suspected of transmitting AIDS) were
 12 found anti-HBc positive."
 13 So Dr Simon casting some doubt on the figures
 14 that had been elsewhere cited of 90 per cent.
 15 Rodell made a contribution --
 16 **SIR BRIAN LANGSTAFF:** This may go back to link what you
 17 showed me yesterday as the expanded table which Evatt
 18 produced, where he showed the greater prevalence of
 19 hepatitis B core antigen in certain risk groups and
 20 showed the high-risk groups were significantly higher
 21 in their prevalence rates than was the so-called
 22 "normal" donor.
 23 **MR HILL:** Yes.
 24 **SIR BRIAN LANGSTAFF:** And it must follow -- sorry, it
 25 doesn't necessarily follow that the percentage of

46

1 population is labelled "AIDS cases", so presumably
 2 people who have been identified as having AIDS.
 3 It's the left-hand column we're interested in:
 4 "Anti-HBc% positive".
 5 **SIR BRIAN LANGSTAFF:** Yes.
 6 **MR HILL:** 88 per cent of people who had AIDS and who were
 7 homosexual or bisexual; 100 per cent of people who had
 8 AIDS and were drug users intravenously; 86 per cent of
 9 people who had AIDS and were Haitians; and the
 10 "Others" group, we don't know what that specifies.
 11 One can perhaps surmise that this is probably people
 12 who have developed AIDS through person-to-person
 13 contact, or possibly through blood transfusion and the
 14 use of blood products. The "Others" group is
 15 42.9 per cent.
 16 **SIR BRIAN LANGSTAFF:** I mean, the issue is knowing
 17 for those who made donations, as opposed to those who
 18 actually were AIDS cases, so the group, the risk
 19 group, the Haitians are 36 per cent, so they're seven
 20 times more likely to have hepatitis B than --
 21 hepatitis or to be anti-HBc positive than are normal
 22 controls, homosexuals are 80 per cent roughly.
 23 **MR HILL:** Yes.
 24 **SIR BRIAN LANGSTAFF:** Four out of every five are likely to
 25 be. It doesn't take an overall figure across the risk

48

(12) Pages 45 - 48

1 groups, does it?

2 **MR HILL:** No, it doesn't, but the figure that is given by

3 Dr Simon was that Dr Evatt of CDC told him only

4 50 per cent of key blood donors suspected of

5 transmitting AIDS.

6 **SIR BRIAN LANGSTAFF:** Yes, it's a very difficult

7 description to mine, to understand precisely what is

8 being said.

9 **MR HILL:** Yes. And also the other point to make about it

10 is that Dr Simon was saying that in March 1984. This

11 table comes from 1982.

12 **SIR BRIAN LANGSTAFF:** And the person who is saying it has

13 a particularly vested interest in not wanting to do

14 the test.

15 **MR HILL:** Yes. And voted against it.

16 **SIR BRIAN LANGSTAFF:** Yes.

17 **MR HILL:** We do have some later figures that I will come

18 to about anti-hepatitis B core testing, but that is,

19 I think, as far as we can take it from that document.

20 **SIR BRIAN LANGSTAFF:** But it shows that my initial

21 suggestion that it refers back to that table, it

22 doesn't necessarily.

23 **MR HILL:** No. No.

24 Dr Simon also refers to a pilot study. We don't

25 know which pilot study that was, but that was said to

49

1 a copy of his summary report to Dr Thomas of NIBSC in

2 March 1984, following up on the meeting that had taken

3 place on 9 February.

4 I'm about to move on to a related but distinct

5 topic of Cutter's approach to hepatitis B core

6 testing, and I note the time, sir.

7 **SIR BRIAN LANGSTAFF:** Well, shall we have a morning break

8 then until 11.55. 11.55.

9 (11.23 am)

10 (A short break)

11 (11.55 am)

12 **MR HILL:** Sir, you will recall from the memorandum of

13 Dr Hink that I read before the break that there

14 appears to have been some discussion at the end of the

15 meeting about the industry as a whole not introducing

16 anti-HBc testing, and Dr Carr from Alpha saying that

17 they wouldn't begin, Dr Rodell from Armour saying they

18 wouldn't begin unless they were forced by a competitor

19 doing so. You will also recall that Dr Srigley from

20 Hyland said he couldn't speak for his company

21 management and Dr Hink gratefully parroted that line.

22 We know that a few weeks later, on 2 April 1984,

23 Cutter publicly announced that it would commence

24 testing all donated plasma for anti-hepatitis B core

25 antigen. The company declared that:

51

1 have identified only 38 per cent of "known gays" as

2 positive. What is meant by "known gays" is not

3 explained in this document.

4 Just to finish off the meeting from 13 March,

5 Dr Rodell, and I quote:

6 "Rodell - questions if anti-HBc test is

7 sufficiently specific to be effective. It would

8 exclude only 50% of donors with AIDS [prodrome].

9 Provided figures show anti-HBc testing and rejection

10 of positive donors should cost several million \$ per

11 year."

12 So that's -- Dr Rodell provided those figures:

13 "14 to 15 Plasma Alliance centers collecting

14 about 850,000 liters per year. Armour currently

15 derives all plasma from Plasma Alliance, no contract

16 centers."

17 What isn't clear from that note is whether the

18 cost of several million dollars per year is intended

19 to refer just to Armour's costs, or to the costs

20 across the industry. But what is perhaps notable is

21 that the figures of \$100 million and \$150 million per

22 year, which we saw yesterday, aren't repeated at this

23 meeting, at least according to the records that we

24 have of it.

25 Finally on that meeting, Dr Rodell provided

50

1 "Until a specific test for any AIDS agent has been

2 discovered ... Cutter intends to take these

3 precautionary measures to protect those with

4 haemophilia who depend upon our products."

5 The reference is at paragraph 198 of the written

6 presentation.

7 A document from May 1984 shows the debate that

8 took place within Cutter that month, when the policy

9 was reviewed, it's a helpful document, because it

10 literally sets out the arguments for and against

11 hepatitis B testing, and it does so in the context of

12 an internal company document, so it's something not

13 for public consumption, but for the company itself to

14 cogitate upon before deciding whether or not to

15 continue the policy that it had announced of anti-HBc

16 testing.

17 If we could have on screen, please, CGRA0000362.

18 We can see that the memorandum is dated 25 May 1984,

19 and it comes from John Hink, and it is sent to the

20 members of a committee within Cutter, which was

21 responsible for making decisions on matters such as

22 these. It refers to the materials that have been

23 provided ahead of the meeting on 31 May.

24 If we turn over to the second page, please. We

25 can see a document headed "Arguments Advocating

52

(13) Pages 49 - 52

Continued Hepatitis B core Antibody Testing". Not to give anything away but, on the following page, there is a heading "Arguments for Discontinuing Hepatitis B Core Antibody Testing", so the pros and the cons being set out. I'll read through this document from the top:

"Arguments Advocating Continued Hepatitis B core Antibody Testing of Cutter Plasma

"1. Exclusion of [HB core antibody] positive plasma from use in the manufacture of coagulation products will reduce the risk of further product withdrawals.

"a. National Hemophilia Foundation and FDA agree that coagulation products 'contaminated' with plasma collected from a donor subsequently diagnosed with AIDS must be withdrawn and/or withheld from market. Until proof that the AIDS agent is inactivated by heat treatment or other means, it is unlikely that this position will be changed.

"b. Donor populations at greatest risk for AIDS are homosexuals/bisexuals and IV drug users.

"c. Screening my interviews and lymphadenopathy have been effective only partially in eliminating 'high risk' donors.

"d. CDC reports 88% of homosexuals/bisexuals

53

gain back market share.

"b. If HTLV-III screening test is available at years end '84, Cutter will have 8 months production from core screened plasma available before any HTLV-III screened products are available.

"c. If HTLV-III screen test is delayed Cutter will have even more advantages over competition."

On the next page:

"d. Core screening is just one advantage we can offer with Koate that competition cannot.

"4. Separation of HBcAb positive plasma provides the opportunity to more efficiently identify plasma donors with high levels of other hepatitis 'marker' antibodies, ie [cytomegalovirus] and HB [surface antigen]."

Sorry, I think that might be HB surface antibody rather than antigen.

"5. It may be possible to fractionate core positive plasma to concentrate. If later development in AIDS screening (for example HTLV-III) can be used to test the concentrate, much of it can be salvaged.

"6. Startup costs are already sunk and testing costs are not financially significant -- the exclusion of a plasma allocation of \$13.25 per liter is the real expense.

55

and 96% of IV drug users with AIDS are [HB core antibody] positive. 78% of individuals with AIDS prodrome are positive. A high percent of populations considered 'at risk' for AIDS have been shown to be [HB surface antibody] positive."

We'll come back to those figures later, sir:

"2. Cutter has an obligation to use all reasonable means to provide safe effective products.

"a. [Hepatitis B core antibody] is a 'marker' for hepatitis and in indication for exposure to multiple infectious diseases. [Hepatitis B core antibody] positive plasma may be expected to have greater virus contamination than untested plasma.

"b. Retrospective studies show 25% to 50% of [hepatitis B core antibody] positive blood can cause post [transmission] *[sic]* non-A non-B hepatitis. Coagulation products derived from [hepatitis B core antibody] negative plasma should transmit less non-A non-B than those produced from conventional plasma.

"3. [Hepatitis B core antigen] positive plasma exclusion from coagulation products should result in high customer acceptance with increased sales at appropriate prices.

"a. Cutter ([without] chimp data) needs to differentiate itself from the other manufacturers to

54

"7. We may be able to make stronger claims concerning Non A non B Hepatitis risk from core screened products."

So those, sir, are the seven reasons in favour of continuing the testing. Arguments for discontinuing were then set out, and I quote those now:

"1. Cost.

"a. Implementation of HBcAb testing has cost somewhat more than [US] \$100,000. Continuation of this testing will add approximately \$0.03 to all liters procured.

"b. 15% of plasma tested has been HBcAb positive. Exclusion of this plasma from coagulation products and quarantine of HBsAb positive AHF concentrates will have significant but indeterminate costs.

"2. HBcAb is a marker for hepatitis B and a potential indicator of population groups at risk for AIDS. It is not an AIDS specific test and will not identify all potential AIDS victims. Even with continued HBcAb testing we are at risk for product withdrawal due to AIDS 'contamination'.

"3. More specific AIDS screening tests will be available in the future. HTLV-III is assumed to be

56

(14) Pages 53 - 56

the causative agent for AIDS. Press announcements indicate that an HTLV-III antibody test will be available by Oct 1984."

I pause there to say, sir, that we will be looking at the screening tests shortly:

"It is contentious whether this target will be met for commercial availability in quantities approaching/plasma screening requirements (ie 1.5 million per month). Coagulation product derived from HTLV-III tested plasma could be commercially available 8 to 11 months following implementation of testing.

"4. The Cutter dry heat treat method may demonstrate inactivation of HTLV-III. Use of HBcAb negative plasma plus [heat treatment] of coagulation products would then be considered a 'belt and suspenders' redundancy.

"5. Exclusion of [hepatitis B core antibody] positive plasma from coagulation products should reduce the already low level of HBcAb, thereby potentially increasing the risk for transmission of hepatitis B virus.

"6. Flexibility of Plasma Procurement operation is considerably reduced by the requirement for HBcAb testing. Many suppliers to our industry are unable to

57

comply (or will not comply) with procedures necessary for separation and control of tested plasma.

"7. Identification, separation and isolation of HBcAb tested plasma has placed a large burden on Cutter employees and staff. Blending of [hepatitis B surface antibody] positive and [hepatitis B surface antibody] negative Fraction II to assure normal ISG will increase this burden."

So those are the pros and cons set out. I will come back to the figures that are contained in a second. I would just note that the company agreed to the continuation of the testing programme in a meeting on 25 June 1984, a reference to that is at paragraph 202 of the written presentation.

SIR BRIAN LANGSTAFF: The document that you're showing me, I think it was anticipating a meeting which took place on 31 May.

MR HILL: It is. I don't know why it was that the decision was delayed until 25 June 1984. We can trace that through if necessary. But the overall point is that Cutter continued that programme.

SIR BRIAN LANGSTAFF: I mean, just to fit in what had happened between the starting of testing for anti-HBc by Cutter on 2 April, and this document which is at 25 May '84, is that on 21 April there was a press --

58

or Gallo announced his discovery that the HTLV-III was, he claimed, the cause of AIDS, and two days later there was a press conference with the Secretary of State for Health to announce it --

MR HILL: Yes.

SIR BRIAN LANGSTAFF: -- and to announce that tests would be forthcoming.

MR HILL: Yes. The somewhat optimistic statement on 23 April 1984, by Secretary Margaret Heckler was that the tests would be available within six months, and that is why I think there is a reference in the document that we've just looked at to the tests being available in October.

Scepticism is expressed -- justified scepticism it turns out -- about whether or not that target could be met if what Secretary Heckler meant was that these tests would be available across the country at the level that the industry required. That, in fact, didn't take place until the early and mid part of the following year, 1985, and we'll come on to that in due course.

The decision then by Cutter is to continue the testing. The meeting on 25 June 1984 also contains an interesting detail, that an insurance claim had been made for a sum for the -- to cover the costs of the

59

withdrawal of 16 lots of Koate and Konyne the previous year, that's the product withdrawal that we mentioned earlier. The insurance claim was for \$4.9 million. That was for 16 lots of the product.

If we could just go back, Soumik, to the second page of the document that we were just looking at, CGRA0000362. If we could go to 1.d.

Now, this is the Cutter rendering of the CDC position as of the time of this document, which is May 1984. There, it is saying that:

"CDC reports 88% of homosexuals/bisexuals and 96% of [intravenous] drug users with AIDS are HBcAb positive."

That contrasts with the figures given by Dr Evatt in 1982, which were -- and I'll just read them to you rather than putting them up on the screen. The figure for homosexuals and bisexuals with AIDS in 1982 was 88.2 per cent, so a very similar figure to the one that is contained in that document.

The figure for intravenous drug users with AIDS in 1982 was 100 per cent, so all 21 such cases. That has fallen slightly, but it is still very high: 96 per cent as of May 1984.

The figure given in 1982 for probable AIDS -- and the test then was lymphadenopathy, so swollen

60

(15) Pages 57 - 60

1 lymph nodes -- was 81.3 per cent; a very slight
 2 decrease by 1984 of 78 per cent of individuals with
 3 AIDS prodrome are positive.
 4 That might not be comparing precisely like with
 5 like, but the figures, you may feel, sir, are
 6 strikingly similar.
 7 **SIR BRIAN LANGSTAFF:** Yes. I mean, for no numbers you'd
 8 speculate that they would be bound to be within the
 9 same confidence interval, speaking statistically.
 10 **MR HILL:** I wouldn't disagree with that at all.
 11 Those figures are notably different from the ones
 12 that were cited at the meeting that we have just
 13 looked at. I won't take you back over those.
 14 What I would add here is that according to the
 15 Krever Report, and it's electronic page 772 of that
 16 report, I won't take you to it, but Mr Justice Krever
 17 said that in early 1985 the CDC published a study that
 18 demonstrated that 62 per cent of donors to whom CDC
 19 had traced a transfusion-related AIDS case had tested
 20 anti-HBc positive. So that figure of 62 per cent
 21 seems to relate to all AIDS cases. And as we saw
 22 earlier, the correlation between anti-HBc positivity
 23 and the Haitian community was lower than that --
 24 **SIR BRIAN LANGSTAFF:** Well, it's looking at something
 25 a bit different there, isn't it, because that's

61

1 prepared by the CDC, using the first generation of LAV
 2 tests, so the tests that they have developed with
 3 Dr Montagnier. That showed that 18 of 25 asymptomatic
 4 people with haemophilia tested positive for LAV, as
 5 did two-thirds of a larger sample size, the references
 6 for those are at paragraph 205 of the written
 7 presentation.
 8 On 16 July, the study group that had been
 9 chaired by Dr Rodell on anti-HBc testing presented its
 10 final report. The majority continued to oppose the
 11 introduction of the test, they cited the lack of
 12 specificity, the 6 to 20 per cent rejection rate for
 13 plasma, an increased risk of hepatitis B transmission,
 14 plasma shortages and price increases. The minority
 15 argued that the tests would have identified 60 to
 16 80 per cent of homosexual men, but they accepted that
 17 it would no longer be worth implementing
 18 anti-hepatitis B core testing in light of the
 19 identification of HTLV-III and the prospect of
 20 a screening test that was specific for AIDS.
 21 Later that month, July 1984, there was some
 22 discussion of an industry-wide public relations
 23 campaign. You've seen the documents in respect of
 24 that, sir. We don't know how far that campaign went,
 25 but the references are at paragraph 207 of the written

63

1 looking at donors, whereas I think what you've just
 2 been showing me has been looking at cases.
 3 **MR HILL:** Yes. That's correct, yes.
 4 **SIR BRIAN LANGSTAFF:** So they're two different
 5 communities.
 6 **MR HILL:** Two different -- those are donors to whom AIDS
 7 cases had been traced.
 8 **SIR BRIAN LANGSTAFF:** Yes.
 9 **MR HILL:** But, yes, they are a different community, and it
 10 would include donors who might fall outside the groups
 11 of intravenous drug users and homosexuals.
 12 But I stress that study had not been reported
 13 publicly at the time of this meeting.
 14 You may also feel, sir, that it is unlikely that
 15 the CDC would have made figures, their figures,
 16 available only to Cutter. There would have been no
 17 purpose in them doing so.
 18 Moving on from that meeting, and this is --
 19 you've said, sir -- between those two meetings you
 20 have the announcement from Dr Gallo and then
 21 Secretary Heckler about the isolation of HTLV-III.
 22 By June 1984, 49 cases of AIDS in people with
 23 haemophilia had been identified in the United States.
 24 The following month, on 13 July 1984, there was
 25 a publication in MMWR, which was a preliminary report

62

1 presentation, if people wish to pick them up.
 2 So that takes us to the end of July 1984, which
 3 is where we're going to break with the strict
 4 narrative, chronological narrative, that we've had so
 5 far, to summarise the position at that point: the
 6 debate about the safety of blood products in the first
 7 half of 1984 had predominantly been about
 8 anti-hepatitis B core testing.
 9 The coalition of two of the fractionation
 10 companies, Armour and Alpha, and a number of blood
 11 banking organisations had successfully resisted calls
 12 from the FDA to introduce such testing, and had done
 13 so until a point in time when even advocates of
 14 testing were resigned to waiting for the emergence of
 15 a specific test for HTLV-III. However, two companies,
 16 Hyland and Cutter, had taken a contrary view. The
 17 latter had unilaterally introduced anti-HBc screening
 18 tests, despite pressure not to do so.
 19 Product withdrawals had continued in the first
 20 six months of 1984, as had the increased number of
 21 AIDS cases identified among people with haemophilia.
 22 Initial results on patient testing had also provided
 23 evidence of devastating rates of infection within that
 24 community in the United States.
 25 **SIR BRIAN LANGSTAFF:** Do we actually know how many

64

(16) Pages 61 - 64

1 withdrawals there were in this part?

2 **MR HILL:** Up until this point, four.

3 **SIR BRIAN LANGSTAFF:** In 1984?

4 **MR HILL:** Yes.

5 **SIR BRIAN LANGSTAFF:** They're the four you mentioned

6 earlier.

7 **MR HILL:** The four that we mentioned earlier, yes.

8 **SIR BRIAN LANGSTAFF:** So when you say product withdrawals

9 had continued --

10 **MR HILL:** They had continued -- the last two of those

11 withdrawals had been in the early months of 1984.

12 **SIR BRIAN LANGSTAFF:** Thank you.

13 **MR HILL:** The year had, however, seen the announcement of

14 the isolation of the HTLV-III virus, and the granting

15 of licences for heat-treated products, all four

16 companies had a licence for heat-treated products, and

17 it's to heat treatment that we will now turn.

18 In the written presentation I set out why it is

19 that no effort is made today to try to provide

20 a comprehensive presentation on the development of the

21 heat treatment, it is a very complicated and dense

22 story. The main narrative events are the ones that

23 I will seek to highlight today.

24 There is an abundance of evidence, you may feel,

25 sir, that during the 1970s, Factor VIII and Factor IX

65

1 Factor VIII inhibitors:

2 "2. [Antihaemophilic] Hepatitis Risk Removal

3 "A. Heat Inactivation/Radiation

4 "B. Ultrafiltration/Glycine."

5 So two different methods of viral inactivation

6 which are the second item on Hyland's division

7 priority list as of September 1979. Other documents

8 are referred into the written presentation as well.

9 Behringwerke obtained a German licence for its

10 product in early 1981. That product was pasteurised,

11 so that's heated in a solution, at 60°C for 10 hours.

12 It's important throughout this section to keep in mind

13 the different methods of heat treatment, as well as

14 the different temperatures used. Behringwerke's was

15 a true pasteurisation technique which means that the

16 product was heated in a solution.

17 That product was not, at that time, licensed or

18 marketed in the US and the UK, and there were various

19 drawbacks to it, including the fact that there was

20 very low yield. At about the same time, early 1981,

21 Hyland were proceeding to clinical trials in humans of

22 Hemofil-T. We heard a little about that from the

23 evidence of Dr Kingdon that we looked at in September

24 and October.

25 Other companies had also commenced work on

67

1 were considered to be highly heat labile proteins,

2 such that they would not survive the sort of heat

3 treatment that was used as a method of viral

4 inactivation on, for example, albumin, and you'll

5 recall the evidence of Sarah Middleton. However, in

6 1977, the German company, Behringwerke commenced work

7 on heat treatment studies with a view to providing

8 factor concentrates with lower risk of hepatitis

9 transmission. So that's 1977 that we have a date for

10 Behringwerke beginning these studies.

11 By the following year, 1978, Hyland had begun

12 some form of research on heat treatment of Hemofil.

13 There is a memorandum dated 26 April 1978, stating

14 that that work required additional funding and

15 manpower if it was going to be progressed. Hyland's

16 parent company, Travenol, appears to have obtained

17 information from its German subsidiary about the

18 Behringwerke process, but encouraged further efforts

19 in that field.

20 If we could have on screen, please, CGRA0000222.

21 This is an internal Hyland document marked

22 "Confidential Division Priority List September 1979."

23 The division, I take to be Hyland division of

24 Travenol. 1, top of the priority list is Autoplex,

25 which was the product intended for patients with

66

1 heat-treated products by this time. There is a Cutter

2 budgeting document from 1983, I won't bring up the

3 document but I will just summarise what we have taken

4 from it, and it's at paragraph 215 of the written

5 presentation. That document suggests that in 1981,

6 the total amount spent on research and development by

7 the drug research and development division was

8 \$4.2 million, or \$4.27 million. Of that, \$293,000,

9 6.9 per cent of the budget, was spent on

10 hepatitis-free product development.

11 In 1982, an estimated \$558,000 of the same

12 budget was forecast to be spent on that project, which

13 was 9.2 per cent of the total. In addition, an

14 estimated \$102,000 was estimated to be spent from the

15 technical operations division on the project, which

16 was 5.1 per cent of that budget. The notes to the

17 budget describe the project as being, and I quote:

18 "... a defensive move necessary to maintain AHF

19 market share."

20 The 1983 budget included a projected \$632,000

21 under the international division budget, which was

22 36 per cent of that total budget, which seemed to be

23 earmarked for applications for a Japanese licence and

24 for testing in the first quarter of 1983. Now, we

25 don't suggest, sir, that these numbers are the sole

68

(17) Pages 65 - 68

1 figures for what was spent by that company at that
2 time, they're what we can discern from the document
3 that we have.

4 If we could have on screen, please, Soumik,
5 JREE --

6 **SIR BRIAN LANGSTAFF:** Just before you do that, this is
7 looking at Factor VIII?

8 **MR HILL:** The project is referred to as hepatitis free
9 product development.

10 **SIR BRIAN LANGSTAFF:** Because in -- I have a note to
11 myself that -- the reference is BAYP0003708 -- that
12 the Cutter's "Biochemical Research Department
13 Quarterly Progress Report for April to June 1972", so
14 10 years earlier, more or less, showed that
15 experiments had been conducted to see if the virus
16 with which Factor IX had been spiked could be
17 inactivated without the Factor IX losing its activity,
18 and suggested that the activity was indeed maintained
19 if certain salts were used; in other words, the
20 Factor IX could be stabilised and I think the virus in
21 that experiment remained active.

22 But it may indicate that there were certainly
23 moves in the early '70s to look at whether heat and
24 stabilisers might be an answer, so far as Cutter was
25 concerned.

69

1 about this that you're aware of, so far as pharma are
2 concerned?

3 **MR HILL:** There are many thousands of documents that we
4 have and there will be some references to -- or there
5 are -- certainly from Cutter, there are a large number
6 of documents in which do refer to research products.

7 **SIR BRIAN LANGSTAFF:** Because, in due course, I will be
8 quite interested in the progress of research into
9 inactivation of virus in products during the 1970s.

10 **MR HILL:** That is something that we can look into, sir, as
11 I say, it's a fairly significant.

12 **SIR BRIAN LANGSTAFF:** This is now, I think, not the time
13 to deal with it.

14 **MR HILL:** No, I certainly won't be able to do it on an
15 *ex tempore* basis.

16 If we could have JREE0000019 on the screen,
17 please, page 106.

18 This is taken from the Institute of Medicine
19 report, and it's a helpful table which sets out when
20 licences were applied for and when they were granted.

21 I've mentioned these as we went through, but
22 it's perhaps helpful just to look at this now.

23 Baxter, which is the parent company of Hyland,
24 the application for a licence was made in June 1982,
25 and it was granted in March 1983, a period of

71

1 **MR HILL:** Yes. I think it's fair to say that the heat
2 development techniques that were developed in the
3 early 1980s were generally applied to both Factor VIII
4 and Factor IX, but there were additional difficulties
5 with Factor IX, particularly in establishing that the
6 resulting product didn't cause blood clots. You heard
7 a little about that from Dr Middleton. There was
8 a considerable concern amongst the clinicians about
9 thrombogenicity.

10 **SIR BRIAN LANGSTAFF:** Yes.

11 **MR HILL:** But the way -- when we looked at the licensing
12 of these products, we would often see that the same
13 heat treatment regime was applied both to Factor VIII
14 and Factor IX, and so I have taken it that the work in
15 the early '80s was being done generally on factor
16 concentrates, and then the licences would be applied
17 for specifically the Factor VIII and Factor IX --

18 **SIR BRIAN LANGSTAFF:** I think my question was directed
19 towards activity on the research front anyway, during
20 the 1970s, given that there had been some evidence of
21 some in 1972.

22 **MR HILL:** Yes. As I understand it, the concern in the
23 1970s, and it's often in the papers presented as
24 a received wisdom --

25 **SIR BRIAN LANGSTAFF:** Do we actually have any documents

70

1 nine months.

2 We then have Miles, which is -- perhaps --
3 I think it might be more helpful actually to take it
4 chronologically. So:

5 Baxter, June 1982, granted March 1983.

6 Armour, this is Factor VIII, December 1982,
7 granted January 1984, so 13 months.

8 Alpha, which is -- I should have mentioned the
9 Factor VIII is dry heated. The Hyland product was dry
10 heated. There was a different -- both were heated at
11 the same temperature, 60 degrees. Hemofil was heated
12 for 72 to 74 hours. And Factor VIII was heated for
13 30 hours. That may be of some significance later.

14 Alpha applied for its licence for Profilate in
15 December 1982, and it was granted in February 1984.
16 It's referred to as "wet heat" there.

17 As we've discussed before, sir, it was heated in
18 suspension, so not a true pasteurisation, but
19 a suspension. But 60°C for 20 hours.

20 Then we have Cutter. They applied for and
21 received two licences. The first was for
22 a pasteurised product, heated at 60 degrees C for
23 10 hours, so similar to the Behringwerke product.
24 That's applied for in August 1983, and approved in
25 January 1984. And then a dry-heated product, 68°C for

72

(18) Pages 69 - 72

1 72 hours, applied for in November 1983 and granted in
2 February 1984. So the speed at which these licences
3 are granted increases in late 1983.

4 I also point out there that the Miles dry heat
5 treatment was heated at a higher temperature,
6 68 degrees, than both the Hyland and the Armour
7 product, and it was heated for 72 hours, which was
8 longer than the Armour product, and about the same
9 time as the Hyland product.

10 Immuno don't appear to have sought an FDA
11 licence for their heat-treated Kryobulin. Their
12 UK application was made in December 1984, and it was
13 approved in February 1985. So a short period. And
14 you will recall, sir, from the licensing section, that
15 the DHSS were encouraging the pharmaceutical firms in
16 the autumn of 1984 to put in applications for their
17 heat-treated products.

18 **SIR BRIAN LANGSTAFF:** When the meeting at Heathrow Airport
19 took place on 24 January 1983, Immuno were presenting
20 on a method of chemical inactivation.

21 **MR HILL:** Yes, they were.

22 **SIR BRIAN LANGSTAFF:** Do we know anything more about that?
23 Did anything come of it?

24 **MR HILL:** There are a couple of documents from later in
25 that year, where the ...

73

1 later picked up by some of the companies and taken
2 forward.

3 That led to a second generation of products
4 which were safer in respect of non-A, non-B hepatitis
5 in particular.

6 It's clear from the documents, and indeed from
7 the chronology, that the initial work that was
8 undertaken on heat treatment was for the purpose of
9 inactivating hepatitis, and not AIDS, it pre-dated the
10 knowledge of AIDS. We've seen the meeting that took
11 place on 9 September 1982, where fractionators met
12 with officials from the US federal government and the
13 discussion there was on hepatitis and AIDS wasn't even
14 mentioned in the record of the meeting.

15 I won't go back to that meeting, but at
16 paragraph 219 of the written presentation there is
17 a summary of some of the topics that were discussed
18 and some of the difficulties that the companies were
19 having as of 9 September 1982 in heat treating their
20 products: difficulties in plasma protein denaturation,
21 the protein being heat labile; difficulties with
22 chimpanzee experiments, which were described as being
23 slow and fraught, with inherent problems; whether to
24 change inactivation processes known to inactivate
25 hepatitis B virus in order to seek to inactivate

75

1 **SIR BRIAN LANGSTAFF:** Just take a moment.

2 **(Pause)**

3 **SIR BRIAN LANGSTAFF:** Yes?

4 **MR HILL:** There were a couple of documents from later in
5 that year which indicated that Immuno had given some
6 presentations at conferences, hinting at this process
7 and the work that they were doing on it. What appears
8 to have happened, or may have happened, is that
9 the heat-treated products were seen as a more likely
10 avenue of success from later in 1983, and therefore
11 Immuno's attention turned towards that method, and
12 away from the chemical separation that they had been
13 previously discussing.

14 I have to say the chain of documents doesn't allow
15 for a full answer to that question. That is my
16 analysis of what was going on.

17 It's a pertinent point, sir, because although we
18 are focusing here on heat treatment, as we saw with
19 the earlier Hyland document, there were other made of
20 viral inactivation which had been considered and
21 worked upon by the companies as well. But by this
22 stage the heat treatment seems to have been the one
23 that had gained priority from all of the companies.
24 The New York Blood Center had worked on a solvent
25 detergent method in the 70s and the 80s and that was

74

1 non-A, non-B hepatitis; and the use of marker viruses
2 for non-A, non-B hepatitis and the difficulties
3 involved in using them. No consensus could be reached
4 on that point.

5 Non-A, non-B, at that stage, was known to exist,
6 but there was no test for it, which hampered an
7 ability to assess how effective your product was.

8 There was also the discussion about the use of
9 clinical trials, which -- including clinical trials
10 following on from chimpanzee trials.

11 So those were some of the difficulties that were
12 present in September 1982.

13 Turning back then to the period from 1983
14 and 1984, when the products began to come on the
15 market. The early heat-treated products were treated
16 with some scepticism by haemophilia clinicians. There
17 were doubts, which turned out to be justified, about
18 their effectiveness in inactivating hepatitis, and
19 particularly non-A, non-B hepatitis. And doctors were
20 concerned that heat treatment of the products could
21 give rise to the development of inhibitors in
22 patients. Again, Dr Middleton mentioned that in her
23 evidence.

24 Dr Evatt, in his Tragic History, I won't take
25 you to it, but I quote him from it, wrote that:

76

(19) Pages 73 - 76

1 "Because of the high cost and feared risk, the
2 [Hyland] product did not achieve widespread use."
3 Dr Kingdon gave similar evidence in his draft
4 witness statement from 1990, so there was a reluctance
5 from some haemophilia doctors to take on these
6 heat-treated products.
7 Just to re-emphasise, the three areas are --
8 that emerged from the evidence are: questions about
9 their effectiveness against hepatitis; concerns that
10 they may give rise to the development of inhibitors,
11 which would mean that patients could no longer be
12 treated with standard Factor VIII concentrates, be
13 they heat-treated or not; and also the factor of cost,
14 these products were more expensive.
15 Similar doubts were expressed in the
16 United Kingdom, and I've given some references in the
17 written presentation to, for example, the letter that
18 Dr Gunson wrote to Dr Walford on 29 June 1983. And
19 there was also a discussion of heat-treated products
20 on the 13 July 1983 meeting of the Biologicals
21 Subcommittee of the Committee on Safety of Medicines.
22 As late as June 1984, Dr Aledort, who was by
23 then working for the World Federation of Hemophilia,
24 or at least working with the World Federation of
25 Hemophilia, wrote, and I quote, that he was:

77

1 LAV inactivation by heat treatment. And, of course,
2 by August 1984 HTLV-III had been isolated as well, and
3 there was some debate about whether or not the two
4 were the same virus, but an increasing acceptance that
5 they were.
6 So that's August 1984, when those results are
7 presented.
8 According to Dr Evatt, clinicians still
9 expressed scepticism and that led to further
10 experiments taking place, particularly conducted by
11 Dr Steve McDougal, Dr Evatt's colleague at the CDC.
12 And Cutter and later Alpha were to provide concentrate
13 to Dr McDougal. That concentrate was then spiked with
14 virus, subjected to the heat inactivation techniques
15 in a laboratory setting, and the CDC demonstrated
16 there that there was a reduction in -- viral
17 inactivation. That was taking place in
18 September 1984.
19 Also in September 1984, Dr Jay Levy published
20 results of his work on inactivating mouse retrovirus
21 by heat treatment. That was reported in The Lancet,
22 and mouse retrovirus was thought to act in a similar
23 to retroviruses in humans.
24 So gathering evidence as of September 1984 as to
25 the effectiveness of heat treatment.

79

1 "... strongly opposed the industry's inclination
2 to stop manufacturing non-heat-treated FVIII and FIX
3 concentrates. He cites the possibility of neo-antigen
4 formation with [heat-treated] products, the extra cost
5 involved, and the fact that there is no direct
6 evidence that heat treatment eliminates or reduces the
7 risk of AIDS to haemophiliacs."
8 So that's June 1984.
9 Although the products were originally developed
10 to tackle hepatitis, it was the AIDS crisis that led
11 to them becoming more rapidly licensed and accepted
12 for use. As we've seen from that table, the time
13 lapse between an application for the licence from the
14 FDA and the licence being granted shortened
15 considerably as time passed, and we've mentioned as
16 well the UK position in that respect.
17 The work done by the CDC on developing an assay
18 to measure viral load in factor concentrates was also
19 an important catalyst. That goes back to the
20 cooperation that I mentioned before the break between
21 the CDC and Dr Montagnier and his team.
22 According to Dr Evatt, in his Tragic History, in
23 August 1984 the CDC presented results of studies at
24 a conference of the World Hemophilia Congress
25 Rio de Janeiro which showed that there was

78

1 Events then moved rapidly. In September 1984
2 a conference was held between haemophilia clinicians
3 and the CDC, at which there was agreement that
4 physicians should consider changing to heat-treated
5 factor concentrates.
6 In October 1984, the Medical and Scientific
7 Advisory Committee of the National Hemophilia
8 Foundation advised physicians to "strongly consider"
9 changing to heat-treated product. The CDC published
10 the results of Dr McDougal's experiments in MMWR on
11 26 October 1984, but of course preliminary results
12 have been discussed with the various bodies before
13 then.
14 The same edition of MMWR recorded 52 cases of
15 AIDS in people with haemophilia.
16 The Groningen conference of various haemophilia
17 clinicians and fractionators took place on
18 1 September 1984. Further presentations made there on
19 the efficacy of heat treatment.
20 In December 1984, an editorial in The Lancet
21 advised that it was reasonable to take a pragmatic
22 approach and switch haemophilia A patients to
23 heat-treated products, notwithstanding the lack of
24 clinical evidence of their efficacy against AIDS.
25 So until that stage the studies had been done on

80

(20) Pages 77 - 80

1 a laboratory basis showing viral inactivation, they
2 hadn't been traced clinically. But despite that,
3 The Lancet were saying that a pragmatic approach
4 should be taken.

5 In the same editorial, and in the context of
6 a call for additional funding to purchase such
7 products, the editorial suggested that it would be,
8 and I quote:

9 "... indefensible to allow prescription and home
10 use of material known to be at risk of HTLV-III when
11 apparently safer preparations are available."

12 That is December 1984.

13 In February 1985, they first publish reports
14 appeared in The Lancet again, showing the result of
15 a clinical trial of Hemofil-T, which appeared to
16 demonstrate that it did not transmit HTLV-III to the
17 patients that had used it. We heard something of that
18 from Dr Kingdon in September and October. That was
19 Professor Mannucci's trial. Dr Kingdon points out
20 that was the first clinical evidence of the efficacy
21 of heat treatment, to go with the laboratory evidence
22 which had been emerging since August 1984.

23 Dr Kingdon said that Hyland ceased the sale of
24 all non-heat-treated Factor VIII concentrates in the
25 United States in January 1985 and, on 13 March 1985,

81

1 Cutter wrote to Dr Geoffrey Savidge at St Thomas'
2 Hospital to say that the company felt that it was
3 "prudent to no longer affect sales of non-heat-treated
4 product for used in the United Kingdom".

5 From 15 to 19 April 1985 a conference was held
6 by the World Trade Organization in Atlanta. During
7 the conference, the positions that non-heat-treated
8 products should not be used was advocated but it's not
9 clear from the documents whether that generated
10 a consensus of opinion. The conference, however, did
11 endorse and recommend the use of heat-treated
12 products. So there is a distinction between
13 encouraging the use of heat-treated products and the
14 question of whether you should also stop the use of
15 non-heat-treated products.

16 Also in April 1985, the National Hemophilia
17 Foundation revised its treatment recommendations to
18 recognise that heat-treated concentrates "may be the
19 preferred products" for infants and children with
20 severe haemophilia and for newly identified and
21 previously untreated severe haemophilia patients.

22 It continued to advise the use of desmopressin
23 or cryoprecipitate in patients with mild or moderate
24 haemophilia, and it wasn't until December 1985 that
25 the NHF advised that only heat-treated products should

82

1 be available for all patients. Sorry, that's all
2 patients with severe haemophilia.

3 So, as well as these clinical recommendations
4 which are going to the clinicians, the availability
5 and use of heat-treated products and their apparent
6 efficacy led to discussions about whether or not there
7 should be a change in approach to the recall of
8 products that were known to have been contributed to
9 by a patient who later developed AIDS. In April 1985,
10 so around the time of the World Health Organization
11 conference, the National Hemophilia Foundation
12 reversed its previous position and declared that it no
13 longer recommended the recall of concentrates
14 contributed to by a donor later found to have AIDS if
15 those concentrates had been treated with the licensed
16 heat-treated process. The basis for that change in
17 position is that the heat treatment would have, and
18 I quote "adequately killed" -- that's the end of the
19 quote -- the virus contained in those concentrates.

20 The change in the NHF's position was cited by
21 Alpha in a letter to the FDA on 30 April 1985, in
22 which it explained that it didn't intend to withdraw
23 vials of factor concentrate that had been produced
24 using plasma from a donor later diagnosed with AIDS.
25 That letter sets out a series of calculations in which

83

1 the company shows that, even on a worst-case scenario,
2 the heat treatment proposed would, in their view, have
3 inactivated the amount of virus that was in that
4 product, and so they say there is no need then to
5 recall it, and they also point to the fact that the
6 NHF are no longer calling for such products to be
7 withdrawn.

8 The letter makes it clear that the company had
9 discussed this position with an official of the Bureau
10 of Biologics and counsel to the Inquiry haven't
11 identified any subsequent correspondence from the FDA
12 saying, "No, you shouldn't do this".

13 While this was going on, non-heat-treated
14 concentrates that were still in circulation continued
15 to be withdrawn by companies. On 3 May 1985, Armour
16 withdrew seven batches and, in June 1985, Hyland
17 announced a withdrawal of products. These are
18 non-heat-treated products that were still available.

19 **SIR BRIAN LANGSTAFF:** Was that in the States or here?

20 **MR HILL:** Those withdrawals were announced in the States,
21 it's not always clear from the documents where the
22 concentrate had gone to. We will be hearing tomorrow
23 about an Armour withdrawal that took -- specifically
24 of a product in the United Kingdom, and I'll refer to
25 that a little later, but I'm not going to pre-empt the

84

(21) Pages 81 - 84

1 evidence, so I won't go into that in great detail.
 2 This was then a period where heat-treated
 3 product was becoming increasingly available and
 4 increasingly used but non-heat-treated product was
 5 still in circulation, and there is some evidence that
 6 Cutter sought to sell non-heat-treated products,
 7 including from stock held in Britain, to overseas
 8 markets that had not at that time adopted heat-treated
 9 products. If we could have on screen, please,
 10 CGRA0000583.
 11 This is an internal memorandum from Cutter dated
 12 10 April 1985. It is entitled "Inventory of
 13 non-heat-treated Koate in the United Kingdom", and
 14 I'll read from the memorandum:
 15 "In a recent trip report from Jack Wood, Jack
 16 indicated that the transfer price value in US dollars
 17 of the non-heat-treated Koate inventoried in the
 18 [United Kingdom] is \$395,273.53. As you know we are
 19 attempting to sell some of this merchandise into
 20 Hong Kong and Taiwan. Jack indicated that Brian Dyos
 21 will be discussing with Trevor Barrowcliffe a dating
 22 extension allowing for relabel and continuous selling
 23 into markets not yet converted to the heat-treated
 24 Factor VIII products.
 25 "I'll keep you posted as we progress in this

85

1 countries not yet converted to heat-treated product.
 2 "Thank you again for your efforts and we look
 3 forward to the positive results that you will achieve
 4 on the rest of this inventory."
 5 We can take that down. A similar memorandum was
 6 sent, which is referred to at paragraph 233 of the
 7 written presentation, to another Cutter employee, and
 8 that memorandum referred to the fact that Cutter would
 9 be willing to subsidise the sale of the remaining
 10 non-heat-treated product on the basis that it was
 11 better to have a lower profit than a total loss.
 12 Such an approach is also evident within the
 13 United Kingdom in this period.
 14 If we could have on screen, please, CGRA0000561.
 15 We can see that this is sent to Dr Tuddenham, at the
 16 Royal Free Hospital, and it's sent by Linda Frith, the
 17 sales development manager at Cutter UK. It says this:
 18 "Dear Dr Tuddenham,
 19 "Brian Dyos asked if I would contact you
 20 regarding a lot of Koate regular products in our
 21 inventory. We have available a lot of 1,045 vials,
 22 260 [international units] with an expiry date of
 23 13.7.85. After speaking with our financial advisers I
 24 would like to lower the price of this material to
 25 4.75p per [international unit].

87

1 project."
 2 Jack Wood was a Cutter employee who was involved
 3 in distributing Cutter products in Europe and Trevor
 4 Barrowcliffe is a civil servant within the National
 5 Institute of Biological Standards and Control (NIBSC).
 6 We don't know at present how far those discussions
 7 with Mr Barrowcliffe got -- or Dr Barrowcliffe got.
 8 If we could go, please to CGRA0000581, we can
 9 see that this is a memorandum from Jack Wood, who was
 10 referred into the previous memorandum, dated
 11 15 April 1985. It's called "Koate Returns from
 12 United Kingdom". If we could just read this, it's
 13 addressed to a colleague called Gary:
 14 "Gary,
 15 "On behalf of Cutter UK I would like to express
 16 our appreciation for the efforts you have made in
 17 marketing to other countries their inventory of
 18 non-heat-treated Koate.
 19 "The 4,000 vials of 250 material will
 20 significantly help in reducing this inventory, but we
 21 still have on hand close to 4 million units as listed
 22 in your letter ... Two major lots are 2,877 vials of
 23 [the product reference number is given] and 1,434
 24 vials [of another lot of product]. We will do
 25 everything possible to sell this product in European

86

1 "I hope this price is more acceptable to you.
 2 If you are interested in this batch, could you let me
 3 know as soon as possible."
 4 Now, sir, we don't know whether or not this was
 5 heat-treated or non-heat-treated product. But the
 6 expiry date of 13 July 1985, the fact that this letter
 7 was being sent in May 1985, and in the context of the
 8 previous memoranda that we've looked at, and the very
 9 low price of the product, 4.75p per unit, might
 10 indicate that this is non-heat-treated product which
 11 is being offered on a discount basis. We don't know
 12 what Dr Tuddenham said in response.
 13 A later memorandum, dating from 1987, recorded
 14 that Cutter sold both heat-treated and
 15 non-heat-treated products in parallel in the
 16 United Kingdom until October of 1985. So that
 17 memorandum would certainly allow for the sale of
 18 non-heat-treated products within the UK as of
 19 May 1985.
 20 A formal letter that was subsequently sent by
 21 the company to a solicitors firm -- so one can infer
 22 that that was part of legal proceedings -- stated that
 23 after February 1985 non-heat-treated product was
 24 supplied, and I quote:
 25 "... only in response to specific requests for

88

(22) Pages 85 - 88

1 it from Haemophilia Centres."
 2 Sir, I'm about to move on to a meeting which
 3 took place in the United States in May 1985 on the
 4 question about what, if any, non -- what regulatory
 5 action should be taken over non-heat-treated products.
 6 That's the last section, as it were, really, on
 7 heat treatment, and will take a little bit of time to
 8 go through, so I wonder if now might be a --
 9 **SIR BRIAN LANGSTAFF:** Let's take a break then, shall we,
 10 and come back at 2? 2 o'clock.
 11 **(1.01 pm)**
 12 **(The luncheon adjournment)**
 13 **(2.00 pm)**
 14 **MR HILL:** Sir, before returning to heat treatment,
 15 I realised over lunch that I skipped over,
 16 inadvertently, a piece of information that I should
 17 have given you earlier. It is about Cutter and it's
 18 the hepatitis B testing.
 19 That testing continued until the end of
 20 October 1984. It was discontinued at that time,
 21 mainly because it was stated that there was sufficient
 22 confidence in the heat treatment process at that time
 23 to allow for the discontinuation of the anti-hepatitis
 24 testing. It was also noted in the internal company
 25 documents that a specific test for HTLV-III was

89

1 members of the FDA, and the figures from the industry
 2 that we've become accustomed to seeing at these
 3 meetings: Dr Ojala; Dr Holst of Hyland; Dr Carr from
 4 Alpha; from Armour there is a D Marcus rather than
 5 Dr Rodell, who was usually present; also
 6 representatives of Hoechst, Immuno, the American Red
 7 Cross, and Bob Reilly of the American Blood Resources
 8 Association trade body.
 9 If we can go back to the text:
 10 "Dr Meyer explained that the major manufacturers
 11 of coagulation products (AHF and PTC) have been
 12 approved for a viral inactivation process for some
 13 time, and the data demonstrated reasonable performance
 14 for eliminating HTLV-III virus from the final product.
 15 He questioned the utility for a non-treated process
 16 given the current situation and requested that we
 17 uniformly send letters to the FDA stating we would no
 18 longer produce or distribute non-heated product to
 19 preclude negative reaction from the medical community
 20 and the general public. He indicated that everyone
 21 spoke as though heat treating processes had eliminated
 22 the potential for HTLV-III viral exposure from these
 23 products, and no-one had really focused on the fact
 24 that the ability to produce non-treated products still
 25 remained possible with the current licences. He

91

1 expected shortly. That's at paragraph 203 of the
 2 written presentation.
 3 Moving back to heat treatment. On 30 May 1985,
 4 a meeting took place between the FDA and fractionators
 5 about the question of what, if any, regulatory action
 6 should be taken over non-heat-treated products. If we
 7 could have on screen, please, BAUM0000025. Please
 8 ignore the highlighting on this document, that's not
 9 ours. The date of the document is 30 May 1985, it's
 10 from Dr Ojala and, as we know, Dr Ojala is a regular
 11 source of our information for such meetings, and it's
 12 an internal Cutter memorandum.
 13 The memorandum says:
 14 "Dr Harry Meyer [who is a senior figure within
 15 the FDA] called this special meeting of all producers
 16 of coagulation products to discuss the
 17 use/productions/license of non-viral inactivated
 18 products."
 19 "Non-viral inactivated products" we take to mean
 20 heat-treated products.
 21 **SIR BRIAN LANGSTAFF:** No, not heat-treated products.
 22 **MR HILL:** Sorry, yes, non-heat-treated products, yes.
 23 Thank you.
 24 The attendees included Dr Petricciani and
 25 Dr Donohue from the FDA, as well as a number of other

90

1 explained that although the FDA could revoke these
 2 through the regulatory process, he did not want any
 3 attention paid to the fact that the FDA had allowed
 4 this situation to continue for so long, and he would
 5 like the issue quietly solved without alerting the
 6 Congress, medical community and the public. Implicit
 7 in the discussion was the concern that the FDA felt
 8 that this action was long overdue. He wanted a date
 9 (such as June 1), for the letters from us."
 10 Over the page, please:
 11 "Industry responded with a list of reasons why
 12 they had particular problems with the proposal,
 13 including the value of the inventory in our control,
 14 the lack of inhibitor indication for PTC, Alpha's
 15 pending dry-heat approval, Hyland's non-approval for
 16 Autoplex, etc. Everyone had a reason and Hyland
 17 mentioned an 18 million unit AHF inventory that would
 18 have to be reworked to heat-treat product.
 19 "The industry position was that that we would
 20 need rapid review of pending submissions and some time
 21 to review the situation with our management. Several
 22 proposed a staggered elimination of non-heat license,
 23 starting with AHF and moving into other areas as
 24 feasible, and the international situation was reviewed
 25 extensively.

92

(23) Pages 89 - 92

1 "Meyer replied that he understood the situation
2 and could sympathize with the difficulties but that
3 did not remove the overriding concern that no one
4 anywhere in the world should be allowed continued
5 exposure to HTLV-III for any of the reasons mentioned.
6 He specifically mentioned that the Japanese
7 registration would soon occur, and he would assist
8 with rapid review and approval for submissions, but
9 the de-licensure of all products had to occur soon.
10 "I spoke with Aronson following the meeting and
11 he reported the problem with the review was that
12 'there are those who seek to license heat treating
13 processes with low temperatures and short times, which
14 the FDA finds unacceptable'. This was briefly
15 reviewed during the meeting and Hyland (Holst) stated
16 that Cutter had made it difficult for the rest of the
17 industry by using such 'extreme' temperatures for so
18 long a duration and thus established precedent.
19 I could only respond that we had arrived at the time
20 and temperature following extensive development work,
21 and that our process was satisfactory for our product.
22 I sense that Hyland is seeking to increase the
23 severity of their inactivation step, the FDA is
24 concerned about the limitations of both the Alpha dry
25 heat and NY Blood inactivation processes. The FDA

93

1 exposed to HTLV-III.
2 **SIR BRIAN LANGSTAFF:** Yes.
3 **MR HILL:** It seems to be the same issue that we looked at
4 in the memorandum before is arising, that in countries
5 which have not yet adopted a requirement for
6 heat-treated products, non-heat-treated products might
7 still be sold, too.
8 **SIR BRIAN LANGSTAFF:** So the position was that, so long
9 as -- at least the implication is that the position is
10 that, so long as countries in the worlds which did not
11 themselves take a regulatory position which prevented
12 the use of non-heat-treated products, could be sold
13 and would accept non-heat-treated product?
14 **MR HILL:** That is certainly what I take from this
15 document, yes, sir.
16 **SIR BRIAN LANGSTAFF:** Yes. That would be a matter for
17 them, and their legislatures or organisations or their
18 executive, whatever the particular situation in
19 a particular country was.
20 **MR HILL:** And indeed for the doctors in those countries as
21 to whether or not they (a) wanted to use that product
22 and (b) had any choice in using that product.
23 **SIR BRIAN LANGSTAFF:** They may not have had clinical
24 freedom in the same way as doctors in the UK did.
25 **MR HILL:** Indeed, and they may not have had access to the

95

1 will meet internally during the interim to review the
2 special situations.
3 "We agreed to review this internally and meet
4 again with him on June 17 to finalize our actions and
5 the timetable. It is clear that Meyer intends to
6 solve this problem quickly, with or without our
7 cooperation."
8 That's where we will leave that document, sir.
9 **SIR BRIAN LANGSTAFF:** Well, just if we take away the
10 highlighting and go back to the top of that page, the
11 last in sentence, in the first paragraph:
12 "Everyone had a reason and Hyland mentioned
13 an 18 million unit AHF inventory that would have to be
14 reworked to heat-treat product."
15 Is the implication from that that Hyland, at
16 least, and possibly some of the others, had in stock
17 non-heat-treated products, which, despite the
18 comparative lack of safety, as it was thought, they
19 wanted to sell and intended to sell?
20 **MR HILL:** I think that is -- well, it's certainly an
21 inference that can be drawn and perhaps might be the
22 only inference from that sentence. I would also point
23 to the reference to the international situation being
24 reviewed extensively, and that is taken with
25 Dr Meyer's comments that nobody in the world should be

94

1 more expensive heat-treated products.
2 **SIR BRIAN LANGSTAFF:** Yes. Yes, thank you.
3 **MR HILL:** The situation at the end of that meeting is that
4 there is going to be another meeting on 17 June. We
5 don't have the minutes of that meeting, though we do
6 have other documents which demonstrate that it took
7 place. But even before 17 June we see some of the
8 fractionators pre-empting matters and taking their own
9 steps.
10 On 3 June 1985, Hyland announced that it was
11 discontinuing production of non-heat-treated Hemofil
12 and Proplex and that it would recover any used units
13 and replace them with heat-treated products. The
14 public statement commented that this was being despite
15 there being no clear scientific evidence that either
16 of the products was involved in the transmission of
17 AIDS. That's at paragraph 238.
18 I note that Dr Kingdon, in his 1990 statement,
19 had said that Hyland had stopped the sale of all
20 non-heat-treated Factor VIII concentrates in the USA
21 on 31 January 1985.
22 That might take us back to the point that you
23 have just made, sir, that these were still being
24 produced as of June 1985, presumably for sale
25 elsewhere; not necessarily Britain, I should add.

96

(24) Pages 93 - 96

1 **SIR BRIAN LANGSTAFF:** No.
 2 **MR HILL:** The Inquiry also has a document from Dr Rodell
 3 of Armour. He wrote on 12 July that Armour was "no
 4 longer manufacturing or distributing untreated
 5 Antihemophilic Factor (Human) for domestic
 6 utilization". So no longer making or selling unheated
 7 products in the US.
 8 He said that the company was still continuing to
 9 export unheated products to German. That was, and
 10 I quote, "for heat treatment at that site".
 11 That was being done because that was a more
 12 efficient way of providing that product to markets
 13 that were supplied out of Germany.
 14 There is no reference in Dr Rodell's letter to
 15 Armour withdrawing or replacing the non-heat-treated
 16 products.
 17 If we could have on screen, please, CGRA0000396.
 18 This is a Cutter document which tells us
 19 something of Cutter's response. If we could have
 20 page 2 of this, please. You can see it's entitled
 21 "Coagulation Update 28 June 1985". What it says is
 22 this:
 23 "Non Heat Action
 24 "Effective 21 June 1985 all non-heat-treated
 25 KOATE and KONYNE were discontinued for sale in the

97

1 Proplex and Autoplex."
 2 Now I pause there to say, sir, that that's not
 3 entirely consistent with the letter which we have and
 4 which I refer to at paragraph 238 of the written
 5 presentation, which does suggest that Proplex has been
 6 replaced. It may be that Hyland's position on it
 7 changed or it may be that Cutter have misunderstood
 8 the situation there.
 9 On 19 June -- sorry, returning to the document:
 10 "On 19 June 85, Hyland recalled four lots of
 11 Proplex due to an AIDS donor in the plasma pool.
 12 Armour is reportedly not withdrawing any non-heat
 13 treated products. Alpha has reportedly sold all
 14 existing non-heat treated Profilnine to the [New York
 15 Blood Center] leaving them with no existing inventory
 16 and no plans to make an announcement."
 17 I think we can take that document off the screen
 18 now.
 19 Counsel to the Inquiry haven't been able to
 20 identify any documents from Alpha itself setting out
 21 its position and actions at that time, but that Cutter
 22 note that we have just looked at would seem to imply
 23 that all of Alpha's Factor VIII product, Profilate,
 24 was being heat-treated at that time, so that may be
 25 why there is no specific announcement.

99

1 United States. A letter was sent to all customers who
 2 purchased these products in 1984 and 1985, announcing
 3 action and recommending return of any existing
 4 product. Internationally, a telex and bulletin were
 5 sent to all distributors and all affiliates announcing
 6 similar action. We are not requesting return of
 7 existing inventories of non-heat [treated] products
 8 internationally due to difficulties in customs
 9 licences, etc.
 10 "No estimation of the volume of returns to
 11 Clayton available to date."
 12 "The NHF and WHF [that's the National Hemophilia
 13 Foundation and World Federation of Haemophilia] --
 14 have complimented Cutter for the action. The phone
 15 calls received from Customers all have been very
 16 positive, none have been negative. Most common remark
 17 is that of appreciation and admiration for the
 18 responsibility shown by Cutter. Additional comments
 19 have been on the completeness of the announcement
 20 package as compared with Hyland's letter."
 21 If we go on, please. This is describing the
 22 situation of Cutter's competitors. This is Cutter's
 23 understanding of the situation:
 24 "Competitively, Hyland announced similar action
 25 on 11 June 1985 but did not remove non-heat treated

98

1 It appears that these steps that were taken by
 2 the fractionators were sufficient to avoid the
 3 imposition of a further regulatory requirements. In
 4 his --
 5 **SIR BRIAN LANGSTAFF:** Further?
 6 **MR HILL:** Or -- and, indeed, any regulatory requirements
 7 in this --
 8 **SIR BRIAN LANGSTAFF:** Because the earlier March plasma --
 9 that wasn't a regulation it was a recommendation.
 10 **MR HILL:** It was a recommendation, yes. And even,
 11 I think, "recommendation" can sometimes have
 12 a technical meaning and I don't think it even had that
 13 with the FDA; it was a public statement, as it were.
 14 **SIR BRIAN LANGSTAFF:** Yes.
 15 **MR HILL:** So these steps avoid the imposition of any
 16 regulatory requirements.
 17 Dr Kingdon said that he didn't recall any
 18 general product recall, and the Krevier Report recorded
 19 that it was not until 1989 that the FDA record the
 20 recall and destruction of all non-heat-treated factor
 21 products.
 22 In his Tragic History, Dr Evatt wrote that by
 23 the beginning of 1985 little non-heat-treated
 24 Factor VIII was being used anywhere.
 25 If we could bring up, please, CVHB0000042, and

100

(25) Pages 97 - 100

1 page 7 of it. If we could go down to the section just
2 above "Acknowledgements", and expand the final
3 paragraph.

4 There is a short explanation of some of the
5 meetings that we have discussed earlier. What
6 Dr Evatt goes on to say is this, and I quote from
7 about halfway through that final paragraph:

8 "The world's hemophilia community quickly
9 adopted the MASAC [that's National Hemophilia
10 Foundation] recommendation, so that by the beginning
11 of 1985 little non-heated clotting FVIII was used
12 anywhere. The AIDS epidemic in the hemophilic
13 patients thus suddenly ceased. Subsequent studies of
14 birth cohorts demonstrated that no hemophilic
15 patients, born in the USA in 1985 and later, were
16 [identified] with" --

17 **SIR BRIAN LANGSTAFF:** It's "infected".

18 **MR HILL:** I'm sorry, sir?

19 **SIR BRIAN LANGSTAFF:** "... no hemophilic patients, born in
20 the USA in 1985 and later, were infected ..."

21 **MR HILL:** "... were infected with LAV, later to be
22 renamed HIV."

23 So 1985 onwards no person with haemophilia in the
24 United States was found to be infected, if they were
25 born in 1985 or afterwards.

101

1 The Inquiry will hear further evidence on this
2 matter and I won't go into it in any further detail
3 now.

4 It's also important to note that, while heat
5 treatment, and particularly heat treatment in
6 combination with the HIV screening test, was effective
7 in inactivating HIV in these products, the
8 heat-treated -- first generation of heat-treated
9 products did not, in general, prevent hepatitis
10 infections.

11 By the mid-1980s, most such infections were of
12 non-A, non-B hepatitis, but there were still cases in
13 which heat-treated products were implicated in
14 infections of hepatitis B. The evidence of Dr Vivian
15 Mitchell from the Leicester haemophilia centre and
16 letter that he wrote to The Lancet in the 1980s are
17 evidence of such infections. You heard about those at
18 an earlier stage in the Inquiry.

19 That is where I will leave the story of heat
20 treatment but, of course, the Inquiry will be hearing
21 further evidence from domestic fractionators, and
22 about domestic fractionators, and heat treatment plays
23 an important part in that the story as well, of
24 course.

25 I should also flag that at the end of this

103

1 "Tragically, during the period 1981 to 1984, more
2 than 50% of the population of hemophiliac patients in
3 the [United States] had already become infected and
4 these individuals continued to present clinical
5 symptoms of AIDS during the next decade and many would
6 die."

7 It's on that note that Dr Evatt concludes his
8 Tragic History.

9 I would add to that that, while the epidemic of
10 AIDS cases may have been brought to an end by the use
11 of heat-treated products, there were still a number of
12 seroconversions that were associated with the use of
13 heat-treated products.

14 In a review article from 1995, which we looked
15 at in September and October, Professor Pier Mannucci
16 referred to 18 well-documented cases of HIV
17 transmission through concentrates that were subject to
18 dry heat treatment. Many of these were patients who
19 used batches of Factor VIII HT that had been subjected
20 to heat treatment but which contained plasma that had
21 been obtained before the HTLV-III screening test was
22 introduced. Armour withdrew such products from the UK
23 market following consultation with the DHSS in
24 September 1986. My understanding is that those
25 products weren't withdrawn from other markets.

102

1 presentation I will also briefly speak about what's
2 often referred to as the "Prince controversy" about
3 Dr Alfred Prince and his work on Armour's heat-treated
4 product, and we'll come on to that a little later.

5 For now, I'd like to turn to the screening test
6 for HTLV-III.

7 I stress that this part of the presentation is
8 about the situation in the United States, the Inquiry
9 will hear further evidence about the United Kingdom
10 position in due course.

11 We discussed earlier, sir, Secretary Heckler and
12 her announcement of the isolation of HTLV-III on
13 23 April 1984 and her prediction that a test would be
14 available within six months. That was to prove
15 optimistic.

16 In June of 1984, the United States authorities
17 announced that five firms had been invited to develop
18 and distribute HTLV-III antibody tests. They were
19 doing so in cooperation with the US federal
20 authorities, who were providing them with the assets.
21 The first application for a licence for a test was
22 made in December 1984.

23 The fractionation companies, of course, were
24 aware that this was going on and, in September 1984,
25 a conference call took place between representatives

104

(26) Pages 101 - 104

of the main companies, at which a common position was sought on issues including informed consent, the information to be provided to the rejected donors, and the ever contentious matter of the recall of previously fractionated products where plasma from a donor had tested to be HTLV-III positive.

Dr Hink provided a memorandum of the call, which he succinctly summed up by saying "There was a lot of talk ... which led to nothing conclusive". So that's September 1984.

By 15 February 1984, an industry position had emerged, and we can see that position being set out by Robert Reilly of the American Blood Resources Association in a letter to Dr Petricciani. If we could have on screen, please, BAYP0005650.

If we go down to the third paragraph, please, starting "With the advent", what Dr Reilly wrote is this:

"With the advent of anti-HTLV-III testing, the manufacturers of blood derivative products are faced with a dilemma similar to that which arose with HBsAg [hepatitis B surface antigen] testing, ie:

"1. What steps should be taken when a donor who is given plasma in the past is determined to be positive to a test for anti-HTLV-III?"

105

manufacturer's location and which are not yet 'in-process' would be segregated and disposed of as would any other plasma found to be anti-HTLV-III reactive, ie destroyed or used for other purposes as may be approved by the FDA.

"2. For 'in-process' products containing anti-HTLV-III reactive plasma, no action should be taken. The basis for this proposal is that it becomes obvious that if we were faced with the alternative, that is the removal of these lots of products from the market, there would be either a total lack of availability of these life saving products or, at the very least, a very acute shortage of them.

"There is a second dilemma still currently facing fractionation manufacturers and that is the disposition of lots of coagulation factors manufactured using a heat treatment process which has been shown to inactivate known amounts of viral contaminants and which has been made from a plasma pool which contains a donation or donations from a confirmed AIDS patient. Then is a case we propose that the manufacturer should take no action if he has data showing inactivation of the HTLV-III virus by this heat treatment process."

That is the position of the fractionation

107

"2. Further, what should be done with such a donor's plasma still stored at the plasma center and/or at the plasma product manufacturer's location?"

"3. What should be the disposition of 'in-process' plasma products containing such units of plasma?"

"There are several facts that have emerged which are pertinent to a discussion of the above. First, it is estimated that approximately .05% to 1.0% of the normal donors will react positively to the anti-HTLV-III test. Second, at the very minimum, pools of plasma used in plasma fractionation include at least 1,000 donations of plasma which would mean that it is reasonable to assume that currently all lots of product produced contain plasma with anti-HTLV-III. Third, the risk of transmitting the AIDS virus through plasma products is not nearly non-existent with the exception of non-heat-treated coagulation products."

Go over the page:

"Therefore, our proposal for the handling of the items listed above is as follows:

"1. Intact units of plasma collected from donors subsequently found to be anti-HTLV-III reactive in storage either at the plasma center or the

106

companies put forwards, and if we just go down we can see that the letter is copied to Penny Carr at Alpha, Steve Holst at Hyland, Steve Ojala at Cutter and Michael Rodell at Revlon/Armour.

So the proposal seems to be that if there is a unit of plasma which is found to be positive for HIV antibody, and which hasn't been used in any products and isn't being processed, then it would be destroyed. But if the HIV positive donor is found and the plasma from that donor is already being processed or is already in a product, so long as that product is heat-treated, there is no need to withdraw or recall or prevent it being distributed. That is the proposition that the companies were putting forward. That's on 15 February 1985.

On 22 February 1985, a public meeting took place on this issue -- sorry, forgive me. On 22 February, it wasn't specifically on this issue, it was a public meeting about HTLV-III screening. There is a memorandum which I summarise at paragraph 254 of the written presentation, and that comes from Dr Ojala. He refers to this as being, and I quote him:

"... almost a press conference rather than a scientific meeting, and I believe this approach was intentional."

108

(27) Pages 105 - 108

1 He goes on to explain that what he meant by that
2 was that he thought that this was the FDA and the CDC
3 using a public meeting to show their confidence in the
4 HTLV-III screening tests that they had helped to
5 produce. Dr Ojala said that that was necessary
6 because of the negativity that had been shown towards
7 the test by a number of representatives of the blood
8 banking industry and what he refers to as special
9 interest groups, which is presumably a reference to
10 gay rights organisations.

11 So there is a test which has been produced by
12 the FDA and the CDC and the companies involved, there
13 is hostility to that test from the blood bankers and
14 from gay rights organisations, but according to
15 Dr Ojala, Bob Reilly spoke of the plasma industry, "he
16 did not say very much specific other than we thought
17 prompt approval of the test was a good idea". So,
18 again, we see a distinction between the approach of
19 the fractionators and the blood banking industry.

20 At the request of the fractionators, a meeting
21 took place with the FDA on 26 February 1984. That was
22 to discuss the specific issues that had been raised in
23 Bob Reilly's letter, the question of product recall.
24 It was preceded by an industry-only meeting, as was
25 common and, according to a Cutter memorandum, there

109

1 was "no enthusiasm or desire" among their competitors
2 to contest the HTLV-III screening test.

3 They did say, however, that they didn't want
4 industry to be burdened, as it was put, by the
5 confirmatory test, the Western blot test, which would
6 be used to confirm that a donor was HIV positive. The
7 quotation contained in the memorandum indicates that
8 industry would simply tell a donor that they were
9 being excluded and, so far as they were concerned,
10 that was the end of the matter for them. The
11 quotation is, and I quote:

12 "... industry cannot afford to deal with running
13 confirmation tests."

14 So presumably donors would be left to go and
15 seek confirmation on their own.

16 The meeting also discussed the imposition of ALT
17 testing for the German market. That is something that
18 I'm going to come back to in a second. We can see
19 from the memorandum that Dr Rodell suggested that the
20 industry might want to put forward a proposal to the
21 FDA about ALT testing, in order to avoid regulatory
22 action being taken. We'll come on to see what that
23 discussion led to.

24 The reference to the memorandum to which I'm
25 taking this from is BAYP0005664. That's a reference

110

1 which I've omitted from the written presentation and
2 will seek to rectify that.

3 So the meeting took place with the FDA on
4 26 February 1984. I won't take you to any further
5 note of it, because, in essence, the fractionators set
6 out the position as per Dr Reilly's letter, and
7 Dr Petricciani listened but didn't commit the FDA to
8 any response on it.

9 Following that arranged meeting, an informal
10 meeting took place, and I am going to take you to
11 this, please, it's CGRA0000312. This is a memorandum
12 written by Dr Carr of Alpha. The memorandum is dated
13 1 March 1985, but it refers to the meeting with the
14 FDA on 26 February 1985. Reading from the top, this
15 is what Dr Carr wrote:

16 "I had requested a meeting with Dr Petricciani
17 after the Fractionation Industry meeting to include
18 only the four commercial manufacturers. Present were:
19 Bob Reilly [that's of the trade body], Mike Rodell
20 [Armour], Steve Holst [Hyland], and myself. Steve
21 Ojala [Cutter] had to catch a plane.

22 "We had all agreed that we would introduce the
23 subject by asking the status of the study we" --

24 I'm sorry, I should have said that the subject
25 heading is "Meeting with FDA on Prison Source Plasma.

111

1 "We had all agreed that we would introduce the
2 subject by asking the status of the study we had heard
3 FDA was performing on prison plasma and Bob Reilly did
4 so. Dr Petricciani went briefly into the background
5 of why they decided to institute such testing. He
6 became aware that they were receiving more
7 applications for Source Plasma establishments in
8 prisons. They had had problems in the past with the
9 shipment of [hepatitis B surface antigen] reactive
10 units from prison sources and falsification of
11 records. With the concern over AIDS and concern over
12 the conduct of any kind of studies or activities
13 associated with prisoners, they felt that if there
14 were more and more prison sources of plasma that they
15 were in a very uncomfortable position over how FDA
16 could justify these with no scientific data,
17 particularly in the socio/political atmosphere. If
18 challenged, he believes they must have a scientific
19 basis for allowing this to continue, otherwise this
20 could be a political bombshell."

21 I pause there, sir, to note -- and this brings
22 us back to the discussion we were having before --
23 that there is a continuation of the plasmapheresis
24 stations within prisons in the United States in this
25 period. It may be that the plasma being obtained is

112

(28) Pages 109 - 112

1 not being used in coagulation products, but it is
 2 still being obtained, and the FDA are now undertaking
 3 a study to see whether or not there is a difference
 4 between prison plasma and other plasma.
 5 **SIR BRIAN LANGSTAFF:** The implication, as I see it from
 6 the second paragraph there, is that there is not only
 7 a continuation, there is an expansion --
 8 **MR HILL:** Yes.
 9 **SIR BRIAN LANGSTAFF:** -- because that's the force of the
 10 word "more".
 11 **MR HILL:** Yes. Yes.
 12 **SIR BRIAN LANGSTAFF:** So whoever is collecting the plasma
 13 is marketing it somewhere --
 14 **MR HILL:** Yes.
 15 **SIR BRIAN LANGSTAFF:** -- or using it for some
 16 manufacturing purpose itself.
 17 **MR HILL:** Yes.
 18 The memorandum from Dr Carr then goes on to
 19 describe the parameters of the study and the way that
 20 the FDA are approaching it. There is a short
 21 paragraph, three paragraphs down, which says, and
 22 I quote:
 23 "If prison plasma can't be differentiated from
 24 non-prison plasma, they would then consider relaxing
 25 the guidelines."

113

1 I quote:
 2 "When asked as to what their reaction would be
 3 if a manufacturer wanted to do such a study, he stated
 4 that they would consider it good complementary
 5 information."
 6 Turning over the page:
 7 "I informed him that since we had made these
 8 [arrangements] two years ago ..."
 9 **SIR BRIAN LANGSTAFF:** It's "agreements".
 10 **MR HILL:** Sorry, "agreements".
 11 "I informed him that since we had made these
 12 agreements two years ago, much more had been learned,
 13 and with a shortage of plasma now and more expected
 14 with the advent of HTLV-III testing, industry
 15 management was questioning why the differentiation
 16 from other donor sources. I stated this for his
 17 information simply to prepare the way for any further
 18 enquiries we wish to make on our own.
 19 "Note that Armour apparently has absolutely no
 20 interest in this subject but was willing to be
 21 present. Steve Holst obviously believes Hyland does
 22 have an interest but was really nonparticipatory since
 23 he is so new to his job. Although Bob Reilly was
 24 willing to participate in discussions on this, he
 25 obviously considers this as stated, a potential

115

1 It's not entirely clear what the guidelines
 2 referred to are there, but it may be an inference that
 3 that is a reference to the guidelines from March 1983
 4 about the way in which fractionators should avoid
 5 high-risk areas.
 6 **SIR BRIAN LANGSTAFF:** Yes, but the high-risk areas there
 7 didn't include prisons, did they?
 8 **MR HILL:** I don't know if prisons were specifically
 9 mentioned, but there is -- what is referred to in this
 10 and other documents is a gentleman's agreement that
 11 prison plasma wasn't going to be used.
 12 **SIR BRIAN LANGSTAFF:** Yes.
 13 **MR HILL:** So it may be that the reference to guidelines is
 14 intended to capture that agreement. But there is
 15 certainly no regulatory action which has been taken
 16 about prison plasma. You'll recall from the letter or
 17 the memorandum from Hyland, there was a conversation
 18 with Dr Donohue about what Hyland's position was going
 19 to be, and Dr Donohue was offered a written statement
 20 from Hyland, and he said that that was not something
 21 that he would --
 22 **SIR BRIAN LANGSTAFF:** Yes.
 23 **MR HILL:** The memorandum then goes on to talk about the
 24 potential target date for the studies and then, at the
 25 bottom of that page, if we pick it up again, and

114

1 bombshell and does not want to press further since it
 2 does not represent the majority of his constituency."
 3 His constituency, I should add, is the American
 4 Blood Resources Association, so plasma manufacturers
 5 and plasmapheresis centres. Returning to the
 6 document:
 7 "If we wished to press further it would be my
 8 recommendation that we try to do so with Hyland and
 9 Cutter."
 10 End quotes.
 11 If we look at the marginalia on the document,
 12 written is the question:
 13 "Do we want to pursue?"
 14 In answer to that question, sent to Pete De Hart
 15 and signed by Vaughan, it says:
 16 "Pete,
 17 "How much material do we get currently ..."
 18 **SIR BRIAN LANGSTAFF:** "... (prison plasma)?"
 19 **MR HILL:** "(prison plasma)", thank you. My written note
 20 is somewhere else.
 21 "Could this represent an opportunity to ..."
 22 **SIR BRIAN LANGSTAFF:** "... source substantial increased
 23 amounts?"
 24 **MR HILL:** Thank you.
 25 "If yes, we probably do want to pursue."

116

(29) Pages 113 - 116

1 The reference there to getting "currently" might
 2 suggest that Alpha is one of the companies which is
 3 obtaining plasma from prisons, albeit they have
 4 entered into this "gentleman's agreement" not to
 5 fractionate it --

6 **SIR BRIAN LANGSTAFF:** Well, an agreement, let's call it.
 7 **MR HILL:** An agreement.

8 **SIR BRIAN LANGSTAFF:** Whether it was between gentlemen,
 9 we'll wait to see with the rest of the evidence.

10 **MR HILL:** There were quotation marks there because it's
 11 a phrase which is used in one of the other documents.
 12 So that is a memorandum from 1 March 1985,
 13 referring back to that meeting on 26 February, which
 14 was about both HTLV-III testing, and then, as
 15 a consequence of HTLV-III testing and heat treatment,
 16 the possibility of revisiting the issue of prison
 17 plasma with the FDA.

18 On 2 March 1985, the Department of Health and
 19 Human Services announced that the first HTLV-III
 20 antibody test kit that had been manufactured by Abbott
 21 had been licensed by the FDA.

22 In his 1990 draft witness statement, Dr Kingdon
 23 stated his opinion that the seven months that it took
 24 between the approval of the companies to begin working
 25 on this project and the licensing of this test kit

117

1 tests abroad."

2 End quote. I'll leave that there, it's no doubt
 3 a matter to which we will turn in due course.

4 **SIR BRIAN LANGSTAFF:** The tests were developed before
 5 being licensed, presumably.

6 **MR HILL:** Yes.

7 **SIR BRIAN LANGSTAFF:** Do we know when they were actually
 8 developed, and therefore being in use, at least for
 9 a testing point of view, in other jurisdictions?

10 **MR HILL:** I don't know that on the top of my head, but we
 11 can look into that. From memory, there is a helpful
 12 table in the Institute of Medicine report, I think,
 13 which provides a contrast between different
 14 jurisdictions and who is doing what when.

15 There is always a difficulty in comparing like
 16 with like in tabular form, but that's something that
 17 I can have a look at in the break and then we can also
 18 do further work on trying to understand --

19 **SIR BRIAN LANGSTAFF:** From what you showed me earlier,
 20 there was an LAV test.

21 **MR HILL:** Yes.

22 **SIR BRIAN LANGSTAFF:** And LAV -- which was exactly -- my
 23 understanding is it was exactly the same basic virus
 24 that Montagnier identified, as did Gallo.

25 **MR HILL:** Yes.

119

1 was, and I quote him, "in scientific terms ...
 2 a remarkably short period".

3 Dr Ojala, in a memorandum, refers to the CDC and
 4 the FDA considering that they have made, and I quote,
 5 "Herculean efforts" in order to get the test licensed
 6 so quickly.

7 Armour and Hyland began testing donors that
 8 month. However, according to Dr Kingdon's 1990 draft
 9 statement, there were insufficient test kits available
 10 to satisfy US demand until June of 1985.

11 The Krever Report says that HTLV-III testing
 12 became available in all centres by July 1985, and it
 13 had been available in the vast majority of centres by
 14 May 1985.

15 So just to give those dates in order again:
 16 March 1985, the FDA licence is granted; by May 1985,
 17 according to Krever, the testing is being done the
 18 vast majority of centres; and in either June or
 19 July 1985 there is full capacity for the US market.

20 A point to note now and come back to in the
 21 future is that Dr Kingdon expressed his view in his
 22 draft witness statement that, and I quote:
 23 "Until there were sufficient kits available to
 24 meet US demand it is unlikely that any of the test kit
 25 manufacturers would have been willing to export their

118

1 **SIR BRIAN LANGSTAFF:** So that was available in August.

2 **MR HILL:** August 1984, yes. The CDC had worked to develop
 3 that with the Paris team. They were using it --
 4 presenting results from it in the August, in order to
 5 do their laboratory work on viral inactivation through
 6 heat treatment. In the UK, we also have the
 7 development of some form of testing in 1984, from --

8 **SIR BRIAN LANGSTAFF:** Yes, I --

9 **MR HILL:** I won't try to remember the dates off the top of
 10 my head.

11 **SIR BRIAN LANGSTAFF:** That may also be August at the
 12 earliest.

13 **MR HILL:** Yes.

14 **SIR BRIAN LANGSTAFF:** But we may well hear from Dr Tedder
 15 in due course.

16 **MR HILL:** Sir, these are tests which can be done on
 17 individual samples.

18 **SIR BRIAN LANGSTAFF:** Of course.

19 **MR HILL:** But --

20 **SIR BRIAN LANGSTAFF:** But if they needed to be used as
 21 screening tests, there has to be sufficient quantity
 22 to enable the testing to be done.

23 **MR HILL:** Just so. And the licensing of the test is the
 24 licensing not just of a final test but of a process
 25 that leads to it, so it has to be a process of

120

(30) Pages 117 - 120

1 industrial scale in order to be able to roll the tests
 2 out across the country. That is what was licensed in
 3 March 1985.
 4 **SIR BRIAN LANGSTAFF:** Yes.
 5 **MR HILL:** On 12 April 1985 there is a fractionators
 6 meeting ahead of a Blood Products Advisory Panel
 7 meeting, so another one of these industry-only
 8 meetings. If we could have on screen, please,
 9 CGRA0000261.
 10 This meeting sees the debate moving on to
 11 a related topic, which is the introduction of ALT
 12 testing, that's so a form of liver function test.
 13 That was to be instigated in response to the
 14 requirements of the German regulators, that any plasma
 15 with ALT levels at more than twice the normal level
 16 should be excluded from plasma pools for factor
 17 products. The German regulator had put that
 18 requirement in place. The American firms who wished
 19 to sell in Germany therefore had to as the here to it
 20 if they were going to be able to licence their
 21 products there.
 22 It's apparent from the discussion that it was
 23 estimated that around 20 per cent of US plasma would
 24 be tested in this way, so that's about 20 per cent of
 25 US plasma would be used in products that were

121

1 a reference to Dr Gerety of the FDA] (or someone) will
 2 express concern to the Advisory panel that use of ALT
 3 positive plasma in domestic products will change the
 4 character of those products. Our formal presentation
 5 will state that we are simply hand selecting (via ALT
 6 screening) special plasma for a particular customer
 7 (the German market) and that all remaining plasma
 8 remains licensed source plasma which may be utilized
 9 in other products. The ALT test is not required by
 10 the FDA, nor do we want it to become so. We will
 11 state that any plasma 2 times normal will not be used
 12 for the particular customer."
 13 That's the German market.
 14 "We will further offer that any plasma with
 15 5 times the upper limit of normal will not be used in
 16 domestic product and the donor will be deferred until
 17 the ALT levels fall back to normal. We will use the
 18 argument that 5 times normal may indicate a donor
 19 health problem. This may not please all of you, but
 20 it was the only way to achieve industry consensus.
 21 Further, plasma in the over 2, but less than 5 range
 22 will be used randomly in production so as not to
 23 concentrate this plasma in any particular lots. All
 24 coagulation products will be heat-treated for an extra
 25 margin of safety. We will endeavour to call German

123

1 available for the German market.
 2 The issue for the fractionators -- the issues,
 3 sorry, for the fractionators were, first, what was to
 4 be done with plasma that was, to use the word in
 5 quotation marks, "positive" for being twice the normal
 6 ALT level. That plasma couldn't be used for a German
 7 product, so what do you do with it? But, second, how
 8 best to avoid the unwelcome, as the fractionators saw
 9 it, introduction of ALT testing for all of US plasma.
 10 With that introduction, we look at the document,
 11 which is again another memorandum from Dr Ojala of
 12 Cutter, and an internal Cutter memorandum reporting on
 13 the meeting. The first paragraph -- there is a list
 14 of attendees and then the first paragraph says:
 15 "Penny Carr (Alpha), Steve Holst (Hyland) and
 16 I met in the Osaka room at Alpha Headquarters from
 17 9 to 12 on April 12, 1985. We followed this meeting
 18 with a 2 hour conference call to Bob Reilly ... and
 19 Mike Rodell ... to confirm our plans for testing in
 20 the upcoming Blood and Blood Products Advisory Panel
 21 meeting. The following are salient conclusions.
 22 "ALT Testing:
 23 "The Ojala script for an industry position was
 24 accepted with enthusiasm from Alpha and some
 25 reluctance from the others. Gerety [that's

122

1 plasma 'special' or some other term to nullify the
 2 idea that greater than 2 times normal plasma is
 3 'positive' or other negative connotations.
 4 "In practice, Armour will discard all 2X cryo
 5 and Hyland will discard all 2X plasma from coagulation
 6 products and Fraction II products. We estimate that
 7 approximately 20% of total US plasma will be screened,
 8 but will vary between manufacturers. Armour
 9 requirements are modest, and Hyland will screen all
 10 plasma for the interim to 'fill the pipeline'. Alpha
 11 will screen only A and B plasma from select centers.
 12 Hyland's conservative position is due to Armour's
 13 decision (ie, they want to be perceived as
 14 conservative in any subsequent litigation) and because
 15 they had two patients develop Non A/Non B in
 16 a clinical trial of their IVIG in Seattle. Holst
 17 thinks it is because of procedures at the clinical
 18 site ..."
 19 That's a reference to why he thinks there are
 20 positive results there.
 21 "... but Penny thinks it is because of starting
 22 with 2 [plus] 3 paste for the Hyland product. The FDA
 23 has summoned Hyland to Washington for a 'summit
 24 conference' on the Seattle incident. This is delaying
 25 their [intravenous immunoglobulin] approval, until

124

(31) Pages 121 - 124

1 resolved.

2 "In summary, the minimum industry is:

3 "1) less than 2 X Normal -- German product

4 "2) 2 X normal -- 5 X Normal -- Random

5 distribution in domestic product

6 "3) greater than 5 X Normal -- discards plasma,

7 defer donor.

8 "This hasn't been approved by FDA, and Hyland

9 and Armour will react more conservatively. I suggest

10 this item be reviewed at the next BC [that's the

11 internal Cutter committee]. Bob Reilly also mentioned

12 that we will need to make some provisions in our

13 business arrangements with our contract centers to

14 preclude them from dumping 'high ALT' plasma on us.

15 "Prison Plasma:

16 "This subject [elicits] even more diverse

17 viewpoints. Cutter and Alpha believe that science has

18 [progressed] to the point that we can screen this

19 plasma through testing (HTLV-III E, etc) and we now

20 heat treat the products. Hyland says they have no

21 current prison plasma sources (!) and Armour states

22 that they will never have any. Reilly is perpetually

23 gloomy on the entire subject, and feels we are

24 destined to fail. Nevertheless, we agreed to hang

25 together for a try with the FDA. We will propose to

125

1 begin using prison plasma cryo and abandon our

2 'Gentleman's agreement' unless the FDA takes issue and

3 threatens regulatory action. We will further agree to

4 do whatever testing the FDA deems necessary to answer

5 any academic concerns. Sam Anderson will contact the

6 NHF to [ensure] there are no major obstacles there,

7 and I recommend Jack Ryan do likewise. It will not

8 serve our purposes to effect change with the FDA and

9 offend our customers. The argument for using prison

10 plasma is the additional testing (HTLV-III) and heat

11 treatment which provides product safety. Penny, Mike

12 and I will try to discuss with this Dr Petricciani in

13 Atlanta this week on a preliminary basis."

14 If we could go over to the next page, please.

15 Just one final extract from this minute:

16 "FDA Letter (attached):

17 "No-one likes the FDA response to our meeting in

18 February to review the position on recall. We will

19 lobby for a change to 3 or 6 months for unpooled units

20 (not 3 years), but in any event, the letter has not

21 been officially sent to the manufacturers. NY Blood

22 is doing retrospective testing on all plasma samples,

23 and we agreed it was a bad idea. (They will inform

24 transfusion victims of the results.)"

25 There is a little bit to unpack there, with

126

1 three distinct topics.

2 On the ALT testing our understanding of the idea

3 being put forward is that 20 per cent of US plasma,

4 approximately, was going to be tested for ALT. Where

5 plasma was found to have ALT levels that are less than

6 twice the normal limit, however "normal" was defined,

7 that plasma would be used in products that would be

8 sold to the German market.

9 Where plasma was above twice the normal limit,

10 but below five times the normal limit, that plasma

11 would then be placed in a general pool with the

12 untested plasma, and that would be used to make

13 products that would be available for the American

14 market, and presumably other international markets

15 that didn't have same regulatory requirements as the

16 German market.

17 That is why it's a reference to it being

18 randomly distributed across the plasma pool, rather

19 than that plasma alone being used to make products,

20 which would inevitably have a higher ALT level.

21 **SIR BRIAN LANGSTAFF:** Can you just help me with this: the

22 assumption may well be that the German requirement is

23 imposed to protect German consumers of blood products

24 from the risk that high ALT level blood is infected

25 with a virus which will transmit hepatitis.

127

1 **MR HILL:** Yes.

2 **SIR BRIAN LANGSTAFF:** So it's quite possible, if they're

3 right, that that blood has a hepatitis virus in it.

4 If blood with hepatitis virus in it is mixed in a pool

5 with other donations, it was the medical understanding

6 since the early 50s that it will take only one or two

7 donations to infect the whole pool.

8 **MR HILL:** That is certainly my understanding of the risk

9 assessment.

10 **SIR BRIAN LANGSTAFF:** So the proposal to mix high ALT

11 blood through all of the pools would render all the

12 pools, potentially, more hazardous than they might

13 have been.

14 **MR HILL:** Potentially, yes.

15 **SIR BRIAN LANGSTAFF:** Yes. Thank you.

16 **MR HILL:** The plasma that was more than five times the

17 normal limit would be discarded, but the reason for

18 that being discarded would be given as donor health,

19 and not a suggestion that the plasma was unsafe, but

20 a concern for the donor.

21 Sorry, the other point I should make about that

22 is that the German requirement for ALT testing may

23 well have been about hepatitis. There were also some

24 suggestions that ALT testing could be a surrogate

25 marker for HIV. I'm afraid I don't know the reason

128

(32) Pages 125 - 128

1 why the German authorities put in place this request,
2 whether it was hepatitis or AIDS, or both.
3 **SIR BRIAN LANGSTAFF:** Well, you may want to check this,
4 but I think it may be in his judgment in the *A v NBA*
5 case that Mr Justice Burton may have identified that
6 in Germany ALT testing of blood for transfusion, so
7 not the same as plasma for plasma products, was
8 introduced in the '70s, but that may need to be
9 checked.

10 **MR HILL:** I will have a look at that and, again, that may
11 be possible to do that over the break, otherwise we
12 can return to this topic.

13 **SIR BRIAN LANGSTAFF:** Well, in due course, it's not
14 a matter of immediate importance, but it's something
15 which I thought I'd better mention because it's
16 something which I recollect from memory, I may be
17 wrong. But you will want to check it out.

18 **MR HILL:** I will do so. What I would add, though, is
19 that, even if a stated reason of AIDS was given for
20 the test, ALT is about liver function.

21 **SIR BRIAN LANGSTAFF:** Yes.

22 **MR HILL:** Inevitably, hepatitis is a relevant
23 consideration when testing for ALT levels.

24 Sir, that's the ALT testing part of the
25 discussion. The prison plasma discussion leads to

129

1 a suggestion that, despite some disparate views within
2 the group, they are willing, all, to put forward
3 a proposal to the FDA to see what the FDA will say in
4 response to a proposal going back on the supposed
5 gentleman's agreement on the use of prison plasma, and
6 there are suggestions of making contact with the
7 National Hemophilia Foundation. I will come back to
8 that in a second.

9 The third issue is the FDA's response to the
10 letter that had been sent in February, and the meeting
11 that had taken place in February, about product
12 recall. I'm afraid our documentation, or at least the
13 documentation we've identified, is limited on this.
14 So we have a rather opaque minute, and I'm wary about
15 trying to decipher that. It appears that the FDA have
16 come up with a counterproposal, which involves some
17 kind of period of look back or of quarantine for
18 products, and the industry is going to lobby for
19 a change to three or six months, it says "not
20 three years". I don't know if that is the period that
21 the FDA had proposed or whether or not that had come
22 from somewhere else. But I'm afraid, because of the
23 limitations of the documentation, I can't assist much
24 further on that point.

25 What we do know is that Jack Ryan, who was

130

1 referred to in this minute, did make contact about
2 prison plasma with Dr Charles Carman and Dr Peter
3 Levine of the National Hemophilia Foundation. On
4 1 May 1985 there was a conversation between the three
5 men. From a Cutter document, it's recorded that
6 Dr Levine responded to the proposal on a personal
7 basis, a personnel basis that he thought reflected the
8 views of the NHF. What he said was, and I quote:

9 "... he still feels that ... we are taking risks
10 that are not justified. Specifically increased risks
11 for hepatitis non-A non-B as well as hepatitis B."

12 Just referring back to the discussion that we
13 have looked at, there is -- the justification for
14 returning to prison plasma is framed in respect of
15 both heat treatment and the introduction of HTLV-III
16 testing. Heat treatment had been demonstrated by that
17 period to be effective in respect of HIV, and HTLV-III
18 testing was, of course, concerned with AIDS, but there
19 is still a hepatitis risk which, as we know now, had
20 not been addressed by either of those measures, or
21 not -- certainly not fully addressed. Hepatitis
22 viruses were not inactivated by most first generation
23 heat-treated products.

24 Jack Ryan of Cutter informed Dr Levine and
25 Dr Carman that Cutter would continue their dialogue

131

1 with the FDA, as they thought that the company's
2 position was, and I quote "safe ... and justified".

3 Counsel to the Inquiry having identified any
4 further documents in which the use of prison plasma
5 was raised. We are unable to comment on what, if any,
6 changes in practice were made. Similarly, it's not
7 clear from the documents seen by counsel to the
8 Inquiry what decisions were reached on ALT testing,
9 although it does seem that it became more prevalent in
10 the years that follow.

11 I'm afraid that the presentation rather ends
12 here, because it is a presentation primarily about the
13 response to AIDS, and some of these issues obviously
14 continue into the '80s.

15 It's perhaps worth referring back to a document
16 that we looked at in September from Dr Carl E Brook,
17 who was the president of Hyland and who sent a letter
18 to the National Hemophilia Foundation in 1987. You
19 may recall, sir, it's a letter which sticks in the
20 memory with Dr Brook criticising the National
21 Hemophilia Foundation for seeking low-cost product
22 which, on his argument, had pushed the fractionators
23 to look for low-cost sources of plasma.

24 In that letter Dr Brook, defending Hyland's
25 position, stated that the company had been, and

132

(33) Pages 129 - 132

1 I quote:
2 "[The] first manufacturer to screen all plasma
3 in compliance with German BGA requirements in 1985."

4 I pause there note to that this is the
5 conservative position, as it was referred to by
6 Dr Ojala, now being used a couple of years later in
7 support of Hyland's position.

8 He also claimed that Hyland had behaved in
9 a responsible fashion by not using material rejected
10 for Germany's ALT requirements in any other market, as
11 several other US manufacturers did. So that was
12 Dr Brook's comments.

13 As I say, sir, we have reached the end of the
14 chronological period covered by this presentation.

15 Just to summarise the position as of July 1985:
16 all US fractionators, by that time, were producing
17 heat-treated factor concentrates from plasma screened
18 for HTLV-III antibodies. Donors were subjected to
19 screening regimes that were intended to exclude
20 high-risk donations, including from gay donors. This
21 led to a high level of protection against transmission
22 of HIV but not, in most cases, for these first
23 generation heat-treated products against non-A, non-B
24 hepatitis. The protection against AIDS afforded by
25 these measures had led to the reversal of the previous

133

1 that either had not been tested or was known to have
2 higher ALT levels.

3 That, sir, is where the main part of the
4 presentation ends. There is a short appendix about
5 Dr Prince, and I note the time. I don't know if that
6 is a something which I imagine would take about
7 20 minutes.

8 **SIR BRIAN LANGSTAFF:** Well, shall we go ahead and deal
9 with it?

10 **MR HILL:** Very well, sir.

11 In December 1984 -- so we've gone back in time
12 a little -- December 1984, Armour commissioned
13 Dr Alfred Prince of The New York Blood Center to
14 undertake studies on the efficacy of its heat
15 treatment process for Factor VIII. The purpose was to
16 see whether a measured quantity of HTLV-III would be
17 inactivated by the heat processes that Armour were
18 using. The proposed approach was to take a known
19 amount of the virus and add it to the concentrate, so
20 to spike the concentrate, before the concentrate was
21 freeze-dried or lyophilized, and before it was then
22 heated.

23 Following that process the product would be
24 tested to see how much residual virus it contained.
25 Virus reduction was measured by determining how many

135

1 approach to withdrawing batches of factor concentrate
2 that were known to be contributed to by donors who
3 were later guide of AIDS so such products were not
4 recalled if a product had been heat-treated. But some
5 fractionators were considering going further and had
6 opened a dialogue with the FDA with a view to
7 reintroducing the fractionation of plasma from prison
8 donors and coagulation products.

9 This was an issue that had split the
10 pharmaceutical companies, not least because of the
11 anticipated increased risk of hepatitis, but as we
12 have seen from that last memorandum from Dr Ojala,
13 even those companies that were not proposing to do
14 this themselves were willing to -- as Dr Ojala put
15 it -- hang together in an approach to the FDA.

16 The introduction of ALT testing in respect of
17 plasma destined for the German market has posed a new
18 set of problems for the fractionators. A consensus
19 had been put forward for a probably that was intended
20 to ward off mandatory testing of all US plasma for ALT
21 levels. That proposal, if it were to be implemented,
22 would have meant that products exported to German
23 would be produced from plasma specifically selected as
24 being relatively low in a marker for hepatitis,
25 whereas domestic products would be drawn from plasma

134

1 logs of inactivation had been achieved so if a sample
2 in which the amount of virus is reduced in size by 10
3 to the power of 4 millilitres is achieved, and it is
4 said that there has been a four log reduction, or
5 a four log kill. The industry standard at the time
6 was a five log reduction.

7 It was anticipated that virus could be
8 inactivated both by the freeze-drying process itself
9 and by the subsequent heating of the product.
10 Armour's heating technique involved dry heat at 60°C
11 for 30 hours. We looked at this earlier in the table.
12 Hyland's equivalent product was dry heat 60 degrees
13 for 72 to 74 hours, and Cutter's product was dry heat,
14 68 degrees for 72 hours.

15 Just as a point of comparison, the heat-treated
16 product produced by BPL in the UK, 8Y was heated at
17 80°C for 72 hours. I note in parenthesis here, sir,
18 that although figures of 60 degrees and 10 hours were
19 given for some of the other products, those were
20 products which were not dry heated but were heated
21 either in solution or in suspension, and so forth.

22 So Armour, 60°C for 30 hours, is a less robust
23 heat treatment than its rival dry heat competitors at
24 the time.

25 Dr Prince provided the results of his first

136

(34) Pages 133 - 136

1 study in January 1985. He wrote, and I quote:
 2 "Disappointingly, we were unable to show the
 3 greater than 5 log kill as had been hoped. The most
 4 that can be concluded from the study is that the
 5 combined effect of lyophilisation and heating
 6 inactivated more than or equal to 2.5 to 3 logs."
 7 Dr Prince's results were at odds with those that
 8 had previously been obtained by experiments conducted
 9 by the Centers for Disease Control. On
 10 29 November 1984, Dr Evatt had written to Armour with
 11 the results of those studies, and Dr Evatt said that
 12 they indicated that heat treatment at 60 degrees for
 13 24 hours, so less time than Armour used, had left no
 14 detectable virus in a sample of Factor VIII
 15 concentrate. His letter concluded, and I quote:
 16 "Because LAV appeared to be extremely heat
 17 labile, we believe that the procedures presently used
 18 by the manufacturers for heat treatment of hepatitis
 19 virus would adequately inactivate the LAV virus."
 20 That's Dr Evatt's view, as expressed in late
 21 November.
 22 The CDC results were subsequently published in
 23 the Journal of Clinical Investigation in August 1985,
 24 the lead authors were Dr Evatt and Dr McDougal, who we
 25 heard about earlier.

137

1 Dr Prince's team had been provided with samples with
 2 a higher level of virus, which would be used in
 3 further experiments in the coming weeks. The company
 4 would also go on to commission further studies from
 5 other respected sources.
 6 Dr Prince and his team did indeed conduct the
 7 further studies, and they reported them to Armour
 8 during the course of 1985. His findings were that
 9 heating at 60 degrees in the dry state had only, and
 10 I quote:
 11 "... a modest process efficacy for inactivation
 12 of HTLV-III/LAV."
 13 This, he said, was a finding that was in
 14 contrast to the results obtained by Dr McDougal of the
 15 CDC, and he said that this was, and I quote,
 16 "difficult to explain".
 17 The implication of Dr Prince's results, though,
 18 was that Armour's established heat-treatment process
 19 main not be sufficiently robust to inactivate HTLV-III
 20 to the industry standard of 5 logs. Dr Prince wanted
 21 to publish his results and he sent a draft article to
 22 Armour. The company invoked a clause in their
 23 contract that required him to obtain Armour's
 24 permission for any publication. That permission was
 25 not forthcoming.

139

1 In October 1985, they had joined with Dr John
 2 Petricciani of the FDA in writing a letter to
 3 The Lancet which advocated heat treatment on the basis
 4 that heating at 60°C for 20 hours would result in
 5 a 20 log reduction.
 6 **SIR BRIAN LANGSTAFF:** A 20 log?
 7 **MR HILL:** A 20 log reduction. Now, Dr Prince would later
 8 criticise the assumptions that lay behind that
 9 article, but it was an article that was published in
 10 The Lancet in October 1985.
 11 Going back in time to Dr Prince's initial
 12 studies, that's January 1985, so at this stage Armour
 13 have been informed of the CDC's experiments in
 14 November 1984, but it's obviously before that Lancet
 15 article is published later in the year.
 16 At that point, January 1985, Armour was left
 17 with conflicting studies concerning the safety of
 18 their heat treatment process. In an internal company
 19 memorandum, on 11 February 1985, Dr Rodell identified
 20 for his colleagues at Armour limitations in
 21 Dr Prince's study. In particular, he identified the
 22 low quantity of active virus that was included in the
 23 sample that was used by Dr Prince.
 24 Dr Rodell considered that the experiment should
 25 be considered preliminary in nature. He said that

138

1 If we could have on screen, please, CGRA0000512.
 2 This is a memorandum from 8 November 1985, and is from
 3 Dr William Terry of Armour, and it is noted to be for
 4 the record. If we could expand the main text, please:
 5 "Through the efforts of Bernie Loev we were able
 6 to determine that there is a contractual arrangement
 7 with Dr Prince which precludes him from publishing,
 8 without our approval, data from experiments supported
 9 by RHCG."
 10 That's Revlon Health Care Group, the parent
 11 company of Armour.
 12 **SIR BRIAN LANGSTAFF:** Yes.
 13 **MR HILL:** "Dr Prince submitted a manuscript to me entitled
 14 'Safety of Blood Derivatives Pasteurized in the Dry
 15 State'. The data in this manuscript indicate that
 16 Generation I, Generation II and Factor IX are not
 17 rendered virus-free when they have been contaminated
 18 with HTLV-III and heated in the dry state at 60° for
 19 even as much as 72 hours."
 20 I pause there to note that Generation I and
 21 Generation II are different types of Factor VIII:
 22 "I told Dr Prince that while our foremost
 23 concern was the safety of patients receiving these
 24 products, these data taken in isolation could only be
 25 confusing to the scientific community, the treatment

140

(35) Pages 137 - 140

1 community and the public and that we therefore were
2 not prepared to give him permission to publish. I
3 pointed out the discrepancies between both his test
4 system and his test system results when compared with
5 the data reported by McDougal and others. I have
6 indicated that we certainly wished to continue working
7 with him and hoped that we could do a more
8 comprehensive study, utilizing his sensitive test
9 system, but applying it to the heating conditions and
10 the products of all the major suppliers.

11 "While Dr Prince was obviously disappointed and
12 somewhat contentious, he accepted the fact that he
13 would not be able to publish these data and the
14 conversation ended on a reasonably cordial note."

15 In later litigation, Dr Prince said that he had
16 been annoyed with Armour, and that he set out to
17 repeat his experiments outside of his contract with
18 the company, so that he could publish the results. He
19 did so in a letter to The Lancet on 31 May 1986. In
20 that letter he said that he found viral inactivation
21 from heating at 60 degrees was, on its own, and
22 I quote, "surprisingly modest".

23 He identified viral inactivation of between 0
24 and 1 log, when the sample was heated at 60 degrees
25 for 10 hours, and between 2 and 4 logs, observed after

141

1 need for caution in relying on the efficacy of
2 dry-heat sterilisation. Long-term surveillance of
3 recipients of such products for seroconversion to
4 anti-HIV is still required."

5 If you could take that down, please.

6 The approach taken by Armour to Dr Prince's work
7 has been the source of intense controversy for
8 decades, not at least because, as we have heard,
9 heat-treated Factorate came to be associated with
10 a number of seroconversions. Dr Peter Jones gave
11 evidence to the Lindsay Inquiry in Ireland about --

12 **SIR BRIAN LANGSTAFF:** Can I just mention for the sake of
13 the [draft] transcript that they've rendered your
14 "Factorate" as "Factor VIII", whereas what you meant
15 it to be was the name of the product itself,
16 Factorate.

17 **MR HILL:** Yes, Factorate Heat Treated, the Armour product,
18 was associated, as we've heard, with
19 18 seroconversions by Professor Mannucci.

20 **SIR BRIAN LANGSTAFF:** I mention that so that when the
21 [draft] transcript is perfected that can be picked up.

22 **MR HILL:** I'm grateful, sir, thank you.

23 Peter Jones gave evidence to the Lindsay Inquiry
24 about a particularly contentious meeting of Armour
25 executives and scientists that was held in

143

1 72 hours of heating. The freeze drying process on its
2 own resulted in an additional 0.5 to 1 log of
3 inactivation.

4 If we could have PRSE0002534, please. This is
5 the letter to The Lancet, "The effect of heat
6 treatment of lyophilised blood derivatives on
7 infectivity of human immunodeficiency", and if we
8 could turn to the second page, please. If we could
9 just expand the final paragraph of the left-hand
10 column, beginning "The finding". Dr Prince wrote
11 this:

12 "The finding of only modest sterilisation
13 process efficacy for HIV adds to the concern about the
14 efficacy of this procedure. It should, however, be
15 stressed that this finding does not mean that dry
16 heat-treated products are unsafe with respect to the
17 transmission of AIDS. Indeed three studies have
18 reported absence of anti-HIV seroconversion in
19 recipients of dry-heat treated [Factor VIII]
20 preparations. Purification and processing steps
21 before lyophilisation can remove or inactivate virus
22 and lyophilisation alone under commercial conditions
23 probably inactivates more virus than is observed with
24 shell freezing. Furthermore some products are heated
25 above 60°C. Nevertheless, these findings indicate the

142

1 October 1985. In Dr Jones' opinion, and I quote, the
2 record of that meeting, appeared to -- the company:

3 "... appeared to consider it ethical to continue
4 to market unsafe product whilst attempting to
5 manipulate the results of their laboratory tests in
6 order to throw doubt on the safety of their
7 competitor's products in the eyes of the FDA. They're
8 doing this in order to protect their share of the
9 market."

10 That was evidence given by Peter Jones to the
11 Lindsay Inquiry.

12 Mr Justice Krever came to the following
13 conclusion in his report. Can we have, please,
14 KREV0000001, electronic page 529. It's the final
15 paragraph above the subheading, beginning "Not only".
16 The reference to the "bureau" here is to the Canadian
17 regulator, the Bureau of Biologics. I quote:

18 "Not only did Armour not transmit Dr Prince's
19 data to the bureau but it prohibited Dr Prince from
20 publishing his research on the safety of its products.
21 Armour reasoned that the publication of Dr Prince's
22 research 'in isolation could only be confusing to the
23 scientific community, the treatment community and the
24 public.' Armour was also concerned about the negative
25 impact that publication of Dr Prince's findings could

144

(36) Pages 141 - 144

1 have on its competitive position. Armour's obligation
 2 was to convey safety-related information about its
 3 products to the bureau promptly. It could have
 4 addressed risk, if any, of confusion by including in
 5 a timely report to the bureau all the contradictory
 6 and inconsistent data it believed qualified
 7 Dr Prince's findings."
 8 So that is the view of Mr Justice Krever in his
 9 report.
 10 A criminal case was later brought in Canada
 11 against Armour, and against Dr Rodell personally, and
 12 against a number of other defendants as well. Part of
 13 the prosecution case was to allege that there had been
 14 a duty to disclose Dr Prince's studies.
 15 The case was heard by Madam Justice Benotto.
 16 She acquitted the defendants, and she came to
 17 a different conclusion to Mr Justice Krever. In her
 18 view, Armour and Dr Rodell had been justified in their
 19 position, particularly in light of the other studies
 20 that the company had considered and commissioned.
 21 If we could have MDUN0000020 _ 250.
 22 This is paragraph 90 of Madam Justice Benotto's
 23 judgment in the criminal trial in Canada. I quote:
 24 "This was a time of great uncertainty. In the
 25 face of this, and in light of the clearly articulated

145

1 **SIR BRIAN LANGSTAFF:** That would follow, I think,
 2 logically.
 3 **MR HILL:** Yes. So, Mr Justice Krever's critique is about
 4 not providing it to the regulator.
 5 **SIR BRIAN LANGSTAFF:** Yes.
 6 **MR HILL:** But Madam Justice Benotto, when considering --
 7 **SIR BRIAN LANGSTAFF:** Is dealing with the conduct as
 8 opposed to -- the conduct apart from not sending it to
 9 the regulator, which they didn't do.
 10 **MR HILL:** I think she is dealing generally with
 11 the allegation that was made by the prosecution that
 12 there was a duty to disclose this both to the
 13 regulator and to the --
 14 **SIR BRIAN LANGSTAFF:** What was nature of the charge?
 15 **MR HILL:** It was -- I don't have the exact Canadian
 16 statute to hand, but I can -- if you give me a second,
 17 I will try to find the ... *(Pause)*
 18 Sir, the charges were of criminal negligence and
 19 common nuisance, and they were brought against Armour,
 20 Dr Rodell, the director of the Bureau of Biologics,
 21 the chief of the Blood Products Division and the
 22 national director of the Blood Products Service of the
 23 Canadian Red Cross.
 24 The corporation is also charged with -- that's
 25 Armour -- with failing to report a deficiency under

147

1 studies of the CDC, supported by the FDA, it would
 2 have been unreasonable, if not irresponsible, for
 3 Armour to have thrust such confusing, incomplete and
 4 inconclusive information into the community."
 5 Thank you, we can take that down.
 6 **SIR BRIAN LANGSTAFF:** Did she say anything about the
 7 central thesis in Mr Justice Krever's comments, which
 8 was that there was a duty on Armour to report the
 9 studies, whatever they were, to the Bureau?
 10 **MR HILL:** Off the top of my head I cannot remember if she
 11 specifically addresses that point. But what she does
 12 do is emphasise that she's coming to her conclusions
 13 not just on the criminal standard of proof, but she
 14 says that, in her view, having listened to one and
 15 a half years of evidence, the conduct of Dr Rodell was
 16 reasonable, responsible and professional, and
 17 Dr Rodell himself was, and I quote, "responsible and
 18 professional throughout, consistent with his
 19 well-deserved reputation for integrity".
 20 **SIR BRIAN LANGSTAFF:** I follow that. But if the
 21 suggestion is correct in what Mr Justice Krever says
 22 that the obligation on Armour was to report to the
 23 bureau the studies which they had available to them,
 24 then they should have sent all of them to the Bureau.
 25 **MR HILL:** Yes, I think it's fair --

146

1 the Food and Drug Act. Those accused were involved
 2 with the manufacturing, licensing and distribution of
 3 heat-treated Factorate, Factorate the product.
 4 **SIR BRIAN LANGSTAFF:** So it was acquitted of a failure to
 5 report?
 6 **MR HILL:** Well, the acquittal is of a charge of criminal
 7 negligence and common nuisance, and the part --
 8 **SIR BRIAN LANGSTAFF:** I think we may need to have look at
 9 that in due course, but thank you for that.
 10 **MR HILL:** I think it's fair to say that Madam Justice
 11 Benotto went -- deliberately stepped outside the legal
 12 test which she was required to apply in the criminal
 13 court in order to give her view that Dr Rodell had
 14 behaved reasonably and responsibly throughout,
 15 including in respect of the Prince allegations.
 16 The presentation, sir, doesn't attempt to scale
 17 the mountain of evidence and opinion that have been
 18 formed in the wake of this controversy. Several of
 19 the protagonists have given extensive testimony, and
 20 indeed we've referred to the fact that the criminal
 21 trial, of which this was one part, lasted over a year
 22 and a half. Previous inquiries have considered and
 23 commented on this matter. There are references to
 24 some of the documents in some of the inquiries in the
 25 written presentation. The technical details involved

148

(37) Pages 145 - 148

1 are complex. They deal with the sensitivity of
 2 assays, alleged arithmetic errors, the questionable
 3 assumptions that underpinned some of the work.
 4 I'm not going to try to go into that level of
 5 detail now. This is merely a preliminary sketch, as
 6 it were, of this issue and this controversy which has
 7 been well documented elsewhere. Certainly counsel to
 8 the Inquiry do not make any comment on either
 9 Mr Justice Krever or Madam Justice Benotto's view of
 10 matters.
 11 That, sir, concludes the presentation today, and
 12 includes this round of presentations on the
 13 pharmaceutical companies. As I said at the start of
 14 these presentations, they are the result of a great
 15 deal of work done by other members of your legal team,
 16 and Ms Richards and I are very grateful for the
 17 assistance that we've received from them.
 18 **SIR BRIAN LANGSTAFF:** Well, thank you very much indeed.
 19 That leaves us then with tomorrow we hear from
 20 Mr Bishop, do we?
 21 **MR HILL:** We do, sir.
 22 **SIR BRIAN LANGSTAFF:** So 10 o'clock tomorrow. 10 o'clock.
 23 (3.40 pm)
 24 (Adjourned until 10.00 am on Thursday, 4 November 2021)
 25

149

1	I N D E X	
2	Presentation by Counsel to the Inquiry	1
3	relating to knowledge of and response to risk	
4	by pharmaceutical companies involved in blood	
5	products	
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

150

<p>COURT: [1] 9/23</p> <p>MR HILL: [117] 1/7 3/22 5/23 6/18 7/13 7/16 8/12 8/15 8/23 9/24 14/4 14/6 14/9 14/13 26/7 26/9 26/11 30/8 30/15 31/1 31/11 43/23 44/24 46/23 47/4 47/9 47/20 47/25 48/6 48/23 49/2 49/9 49/15 49/17 49/23 51/12 58/18 59/5 59/8 61/10 62/3 62/6 62/9 65/2 65/4 65/7 65/10 65/13 69/8 70/1 70/11 70/22 71/3 71/10 71/14 73/21 73/24 74/4 84/20 89/14 90/22 94/20 95/3 95/14 95/20 95/25 96/3 97/2 100/6 100/10 100/15 101/18 101/21 113/8 113/11 113/14 113/17 114/8 114/13 114/23 115/10 116/19 116/24 117/7 117/10 119/6 119/10 119/21 119/25 120/2 120/9 120/13 120/16 120/19 120/23 121/5 128/1 128/8 128/14 128/16 129/10 129/18 129/22 135/10 138/7 140/13 143/17 143/22 146/10 146/25 147/3 147/6 147/10 147/15 148/6 148/10 149/21</p> <p>SIR BRIAN LANGSTAFF: [118] 1/6 3/19 5/19 6/12 7/9 7/14 8/10 8/13 8/22 14/1 14/5 14/8 14/12 26/5 26/8 26/10 30/3 30/9 30/16 31/10 43/21 44/23 46/16 46/24 47/7 47/16 47/22 48/5 48/16 48/24 49/6 49/12 49/16 49/20 51/7 58/15 58/22 59/6 61/7 61/24 62/4 62/8 64/25 65/3 65/5 65/8 65/12 69/6 69/10 70/10 70/18 70/25 71/7 71/12 73/18 73/22 74/1 74/3 84/19 89/9 90/21 94/9 95/2 95/8 95/16 95/23 96/2 97/1 100/5 100/8 100/14 101/17 101/19 113/5</p>	<p>113/9 113/12 113/15 114/6 114/12 114/22 115/9 116/18 116/22 117/6 117/8 119/4 119/7 119/19 119/22 120/1 120/8 120/11 120/14 120/18 120/20 121/4 127/21 128/2 128/10 128/15 129/3 129/13 129/21 135/8 138/6 140/12 143/12 143/20 146/6 146/20 147/1 147/5 147/7 147/14 148/4 148/8 149/18 149/22</p> <p>\$</p> <p>\$0.03 [1] 56/11 \$100 [1] 50/21 \$100,000 [1] 56/10 \$102,000 [1] 68/14 \$13.25 [1] 55/24 \$150 [1] 50/21 \$150 million [1] 50/21 \$293,000 [1] 68/8 \$395,273.53 [1] 85/18 \$4.2 [1] 68/8 \$4.2 million [1] 68/8 \$4.27 [1] 68/8 \$4.27 million [1] 68/8 \$4.9 [1] 60/3 \$4.9 million [1] 60/3 \$558,000 [1] 68/11 \$632,000 [1] 68/20</p> <p>'</p> <p>'70s [2] 69/23 129/8 '80s [2] 70/15 132/14 '84 [2] 55/3 58/25 'AIDS [1] 3/5 'at [1] 54/4 'belt [1] 57/16 'casual [1] 2/3 'complex [1] 44/7 'contaminated [1] 53/14 'contamination [1] 56/23 'extreme [1] 93/17 'fill [1] 124/10 'Gentleman's [1] 126/2 'high [2] 53/24 125/14 'in [4] 106/5 107/2 107/6 144/22 'in-process [3] 106/5 107/2 107/6 'marker [2] 54/9 55/14 'positive [1] 124/3 'provide [1] 17/15 'Safety [1] 140/14</p>	<p>'special [1] 124/1 'sufficient [1] 16/25 'summit [1] 124/23 'there [1] 93/12</p> <p>.</p> <p>.05 [1] 106/9</p> <p>0</p> <p>0.5 [1] 142/2 010 [1] 37/21</p> <p>1</p> <p>1 log [2] 141/24 142/2 1 March 1985 [2] 111/13 117/12 1 May 1985 [1] 131/4 1 September 1984 [1] 80/18 1,000 [2] 26/18 106/13 1,045 [1] 87/21 1,434 [1] 86/23 1.0 [1] 106/9 1.01 pm [1] 89/11 1.5 million [1] 57/9 1.d [1] 60/7 10 [2] 32/14 136/2 10 April 1985 [1] 85/12 10 hours [4] 67/11 72/23 136/18 141/25 10 million [1] 2/9 10 o'clock [2] 149/22 149/22 10 years [1] 69/14 10.00 am [2] 1/2 149/24 100 per cent [2] 48/7 60/21 106 [1] 71/17 11 [1] 138/19 11 in [2] 26/1 26/3 11 June 1985 [1] 98/25 11 months [1] 57/11 11.23 [1] 51/9 11.55 [3] 51/8 51/8 51/11 12 [3] 121/5 122/17 122/17 12 July [1] 97/3 13 [3] 40/11 50/4 81/25 13 July 1983 [1] 77/20 13 July 1984 [1] 62/24 13 July 1985 [1] 88/6 13 months [1] 72/7 13.7.85 [1] 87/23 13th [1] 10/6 14 [1] 50/13</p>	<p>15 [10] 15/8 18/10 19/22 44/12 44/24 50/13 56/13 82/5 105/11 108/15 15 April 1985 [1] 86/11 15 per cent [1] 44/19 16 [5] 9/10 14/14 14/21 60/1 63/8 16 December [1] 18/10 16 lots [1] 60/4 17 [3] 94/4 96/4 96/7 173 [1] 25/11 18 [2] 63/3 102/16 18 AIDS [1] 23/5 18 million [1] 92/17 18 seroconversions [1] 143/19 184 [1] 25/17 19 [5] 3/10 3/14 18/7 82/5 99/10 19 June [1] 99/9 1970s [4] 65/25 70/20 70/23 71/9 1972 [2] 69/13 70/21 1977 [2] 66/6 66/9 1978 [2] 66/11 66/13 1979 [2] 66/22 67/7 198 [1] 52/5 1980s [3] 70/3 103/11 103/16 1981 [4] 67/10 67/20 68/5 102/1 1982 [16] 6/21 7/1 47/25 49/11 60/15 60/18 60/21 60/24 68/11 71/24 72/5 72/6 72/15 75/11 75/19 76/12 1983 [58] 1/7 2/14 5/25 6/11 7/18 7/20 7/25 8/23 9/1 9/6 11/2 11/5 11/7 11/15 11/19 12/2 13/19 14/14 14/21 15/3 15/6 15/8 15/21 17/22 17/25 21/1 21/4 21/19 22/4 22/5 22/11 22/19 22/22 23/22 23/23 23/23 26/12 28/10 31/18 31/21 37/14 38/2 43/19 45/13 68/2 68/20 68/24 71/25 72/5 72/24 73/1 73/3 73/19 74/10 76/13 77/18 77/20 114/3 1984 [75] 20/23 22/23 23/3 23/19 23/24 24/4 24/9 28/23 31/22 31/23 37/10 37/16 37/18 38/1 40/11</p>	<p>49/10 51/2 51/22 52/7 52/18 57/3 58/13 58/19 59/9 59/23 60/10 60/23 61/2 62/22 62/24 63/21 64/2 64/7 64/20 65/3 65/11 72/7 72/15 72/25 73/2 73/12 73/16 76/14 77/22 78/8 78/23 79/2 79/6 79/18 79/19 79/24 80/1 80/6 80/11 80/18 80/20 81/12 81/22 89/20 98/2 102/1 104/13 104/16 104/22 104/24 105/10 105/11 109/21 111/4 120/2 120/7 135/11 135/12 137/10 138/14 1985 [64] 59/20 61/17 73/13 81/13 81/25 81/25 82/5 82/16 82/24 83/9 83/21 84/15 84/16 85/12 86/11 88/6 88/7 88/16 88/19 88/23 89/3 90/3 90/9 96/10 96/21 96/24 97/21 97/24 98/2 98/25 100/23 101/11 101/15 101/20 101/23 101/25 108/15 108/16 111/13 111/14 117/12 117/18 118/10 118/12 118/14 118/16 118/16 118/19 121/3 121/5 122/17 131/4 133/3 133/15 137/1 137/23 138/1 138/10 138/12 138/16 138/19 139/8 140/2 144/1 1986 [2] 102/24 141/19 1987 [2] 88/13 132/18 1989 [1] 100/19 1990 [4] 77/4 96/18 117/22 118/8 1995 [1] 102/14 1:00 [1] 10/5</p> <p>2</p> <p>2 April [1] 58/24 2 o'clock [1] 89/10 2,877 [1] 86/22 2.00 pm [1] 89/13 2.2 million [1] 9/11 2.2 MIO [1] 9/11 2.5 [1] 137/6 20 [3] 124/7 138/6 138/7 20 hours [2] 72/19 138/4 20 minutes [1] 135/7</p>	<p>20 October 1983 [1] 12/2 20 per cent [4] 63/12 121/23 121/24 127/3 20,000 litres [1] 26/19 202 [1] 58/14 2021 [2] 1/1 149/24 203 [1] 90/1 205 [1] 63/6 207 [1] 63/25 21 [2] 26/2 26/14 21 April [1] 58/25 21 June 1985 [1] 97/24 21 people [1] 25/25 21 such [1] 60/21 215 [1] 68/4 219 [1] 75/16 22 [3] 11/2 108/16 108/17 22 October 1983 [1] 11/5 23 April 1984 [2] 59/9 104/13 233 [1] 87/6 238 [2] 96/17 99/4 24 hours [1] 137/13 24 January 1983 [1] 73/19 25 [5] 52/18 54/14 58/19 59/23 63/3 25 June 1984 [1] 58/13 25 May '84 [1] 58/25 250 [2] 86/19 145/21 254 [1] 108/20 26 [6] 26/6 26/8 26/8 26/9 26/13 66/13 26 February [1] 117/13 26 February 1984 [2] 109/21 111/4 26 February 1985 [1] 111/14 26 October 1984 [1] 80/11 26 patients [2] 7/20 7/21 260 [1] 87/22 28 [1] 97/21 29 [1] 77/18 29 November 1984 [1] 137/10 2X [2] 124/4 124/5</p> <p>3</p> <p>3 May 1985 [1] 84/15 3 months [1] 19/13 3 November 2021 [1] 1/1 3 PM [1] 10/6 3.40 pm [1] 149/23</p>
--	---	---	--	---	---

(39) COURT: - 3.40 pm

3	68 degrees [2] 73/6 136/14	141/13	acquiring [2] 2/5 2/7	advent [3] 105/17 105/19 115/14	115/10 115/12
30 [3] 90/9 136/11 136/22	7	about [82] 1/12 7/2 7/15 8/9 9/15 9/16 10/1 15/20 17/1 17/22 25/20 31/2 32/5 32/15 32/16 32/22 34/3 36/24 43/1 43/18 44/1 44/20 49/9 49/18 50/14 51/4 51/15 59/15 62/21 64/6 64/7 66/17 67/20 67/22 70/7 70/8 71/1 73/8 73/22 76/8 76/17 77/8 79/3 83/6 84/23 89/2 89/4 89/17 90/5 93/24 101/7 103/17 103/22 104/1 104/2 104/8 104/9 108/19 110/21 114/4 114/16 114/18 114/23 117/14 121/24 128/21 128/23 129/20 130/11 130/14 131/1 132/12 135/4 135/6 137/25 142/13 143/11 143/24 144/24 145/2 146/6 147/3	acquittal [1] 148/6	advice [1] 7/2	agrees [1] 42/24
30 April 1985 [1] 83/21	7 January 1983 [2] 14/14 14/21	above [8] 28/3 44/16 101/2 106/8 106/22 127/9 142/25 144/15	acquitted [2] 145/16 148/4	advise [2] 37/7 82/22 advised [4] 22/1 80/8 80/21 82/25	ahead [3] 52/23 121/6 135/8
30 hours [1] 72/13	7 November 1983 [1] 9/6	absent [1] 119/1	across [6] 14/20 48/25 50/20 59/17 121/2 127/18	advisers [1] 87/23	AHF [13] 4/2 4/5 4/12 9/10 9/11 18/22 36/15 56/15 68/18 91/11 92/17 92/23 94/13
30 May 1985 [1] 90/3	7.7 per cent [1] 16/14	absence [3] 3/2 30/20 142/18	act [2] 79/22 148/1	advisory [8] 3/15	AIDS [126] 1/12 1/21 1/23 2/3 2/5 2/7 2/10 2/11 2/20 2/21 3/6 4/1 4/6 6/1 6/4 6/5 6/9 6/13 6/14 7/5 7/22 8/4 8/25 9/14 10/20 11/9 11/10 14/15 14/25 15/1 16/23 19/8 22/25 23/5 23/15 23/21 25/24 26/2 26/24 26/25 27/3 28/5 28/7 28/11 29/17 29/22 29/25 30/25 31/20 32/8 32/24 33/8 33/13 33/22 34/7 35/3 35/4 38/22 39/8 40/5 42/16 42/22 43/1 43/25 44/9 46/11 48/1 48/2 48/6 48/8 48/9 48/12 48/18 49/5 50/8 52/1 53/16 53/17 53/20 54/1 54/2 54/4 55/20 56/20 56/20 56/21 56/23 56/24 57/1 59/2 60/12 60/17 60/20 60/24 61/3 61/19 61/21 62/6 62/22 63/20 64/21 75/9 75/10 75/13 78/7 78/10 80/15 80/24 83/9 83/14 83/24 96/17 99/11 101/12 102/5 102/10 106/17 107/21 112/11 129/2 129/19 131/18 132/13 133/24 134/3 142/17
30 transfusions [1] 19/9	70s [1] 74/25	absolutely [1] 115/19	action [15] 33/17 33/18 89/5 90/5 92/8 97/23 98/3 98/6 98/14 98/24 107/7 107/22 110/22 114/15 126/3	advised [2] 82/8 138/3	air [1] 2/2
306 [1] 1/19	72 [2] 72/12 136/13	absent [3] 3/2 30/20 142/18	activities [2] 32/6 112/12	advocates [1] 64/13	Airport [1] 73/18
31 [2] 58/17 141/19	72 hours [6] 73/1 73/7 136/14 136/17 140/19 142/1	abroad [1] 119/1	activity [3] 69/17 69/18 70/19	Advocating [2] 52/25 53/7	albeit [1] 117/3
31 January 1985 [1] 96/21	74 [1] 136/13	absolutely [1] 115/19	actually [6] 10/19 48/18 64/25 70/25 72/3 119/7	afford [1] 110/12	albumin [1] 66/4
31 May [1] 52/23	74 hours [1] 72/12	absolutely [1] 115/19	adamant [1] 41/20	afforded [1] 133/24	Aledort [2] 11/13 77/22
325 [1] 3/9	75 [2] 42/15 44/11	abstained [3] 41/6 41/11 45/11	add [8] 18/19 56/11 61/14 96/25 102/9 116/3 129/18 135/19	affected [4] 21/14 30/24 33/1 33/4	Aledort's [1] 22/7
33 [1] 9/12	76 [1] 14/17	abundance [1] 65/24	addition [3] 18/17 19/21 68/13	affects [1] 3/5	alerting [1] 92/5
340 [1] 29/9	770 [1] 15/18	abusers [1] 14/24	additional [13] 12/13 17/10 28/14 38/13 39/17 42/9 42/24 66/14 70/4 81/6 98/18 126/10 142/2	affiliates [1] 98/5	Alfred [2] 104/3 135/13
36 per cent [2] 48/19 68/22	772 [1] 61/15	academic [1] 126/5	additionally [2] 4/24 35/4	afford [1] 110/12	all [61] 3/20 4/3 16/6 18/18 19/16 20/6 21/2 22/21 25/16 29/12 29/22 34/2 35/8 36/21 38/11 41/5 50/15 51/24 54/7 56/11 56/21 60/21 61/10 61/21 65/15 74/23 81/24 83/1 83/1 90/15
38 [1] 46/9	78 [1] 54/2	accelerated [2] 5/2 20/14	address [3] 6/1 6/8 7/12	afforded [1] 133/24	
38 per cent [1] 50/1	78 per cent [1] 61/2	accept [1] 95/13	addressed [5] 39/18 86/13 131/20 131/21 145/4	afraid [5] 26/12 128/25 130/12 130/22 132/11	
4	8	acceptance [2] 54/22 79/4	addressed [5] 39/18 86/13 131/20 131/21 145/4	after [11] 2/5 3/20 11/2 11/3 12/23 21/11 32/19 87/23 88/23 111/17 141/25	
4 million [1] 86/21	8,000 [1] 46/3	accepted [4] 63/16 78/11 122/24 141/12	addresses [1] 146/11	afterwards [1] 101/25	
4 November 2021 [1] 149/24	8,049 [1] 16/18	access [1] 95/25	adds [1] 142/13	again [11] 11/23 40/17 76/22 81/14 87/2 94/4 109/18 114/25 118/15 122/11 129/10	
4,000 [1] 86/19	80 [1] 136/17	according [9] 7/18 50/23 61/14 78/22 79/8 109/14 109/25 118/8 118/17	adequate [1] 5/7	against [15] 25/22 25/23 41/13 44/5 49/15 52/10 77/9 80/24 133/21 133/23 133/24 145/11 145/11 145/12 147/19	
4.75p [2] 87/25 88/9	80 per cent [2] 48/22 63/16	account [3] 18/14 30/4 40/9	adequately [2] 83/18 137/19	age [1] 16/13	
42 states [1] 29/10	80s [1] 74/25	accounted [1] 148/1	adjudgment [1] 149/24 89/12	agent [7] 2/23 3/1 27/4 27/10 52/1 53/17 57/1	
42.9 per cent [1] 48/15	81.3 [1] 61/1	accustomed [1] 91/2	Administration [2] 38/10 38/18	agent' [1] 3/5	
49 [1] 62/22	85 [1] 99/10	achieve [3] 77/2 87/3 123/20	Administration's [2] 15/22 17/5	agents [1] 3/1	
5	850,000 liters [1] 50/14	achievement [3] 20/23 136/1 136/3	admiration [1] 98/17	ago [2] 115/8 115/12	
5 liters [1] 9/15	86 per cent [1] 48/8	Acknowledgements [1] 101/2	adopted [5] 27/21 28/9 85/8 95/5 101/9	agree [3] 11/14 53/14 126/3	
5 times [2] 123/15 123/18	88 [2] 53/25 60/11	Acquired [1] 38/15	advantage [5] 10/13 20/15 20/18 41/22 55/9	agreed [14] 17/15 19/1 19/15 19/19 20/4 25/15 33/22 42/20 58/11 94/3 111/22 112/1 125/24 126/23	
5.1 per cent [1] 68/16	88 per cent [1] 48/6			agreement [10] 33/7 33/25 34/4 80/3 114/10 114/14 117/4 117/6 117/7 130/5	
5.5 [1] 16/12	88.2 per cent [1] 60/18			agreement' [1] 126/2	
50 [5] 44/11 46/10 50/8 54/14 102/2	89 per cent [1] 16/22			agreements [3] 115/9	
50 per cent [1] 49/4	8Y [1] 136/16				
50s [1] 128/6	9				
52 [1] 80/14	9 February [1] 51/3				
529 [1] 144/14	9 September 1982 [2] 75/11 75/19				
6	9 to [1] 122/17				
6 March [1] 37/19	9.2 per cent [1] 68/13				
6,000 [1] 29/10	90 [3] 18/18 45/2 145/22				
6,400 [1] 9/10	90 per cent [2] 28/7 46/14				
6-7 [1] 19/22	96 [2] 54/1 60/12				
6.9 per cent [1] 68/9	96 per cent [1] 60/23				
60 [8] 63/15 67/11 72/19 136/10 136/22 138/4 140/18 142/25	A				
60 degrees [8] 72/11 72/22 136/12 136/18 137/12 139/9 141/21 141/24	abandon [1] 126/1				
62 per cent [2] 61/18 61/20	Abbott [1] 117/20				
68 [1] 72/25	ability [2] 76/7 91/24				
	able [9] 28/4 35/25 56/1 71/14 99/19 121/1 121/20 140/5				

A	133/8 139/4 144/24 147/24 ALT [28] 110/16 110/21 121/11 121/15 122/6 122/9 122/22 123/2 123/5 123/9 123/17 127/2 127/4 127/5 127/20 127/24 128/10 128/22 128/24 129/6 129/20 129/23 129/24 132/8 133/10 134/16 134/20 135/2 ALT' [1] 125/14 altered [1] 27/7 alternative [1] 107/9 although [15] 2/9 2/21 10/18 17/4 20/3 25/10 28/5 29/21 38/16 74/17 78/9 92/1 115/23 132/9 136/18 always [2] 84/21 119/15 am [6] 1/2 10/1 51/9 51/11 111/10 149/24 America [1] 6/15 American [15] 3/13 8/24 11/3 21/15 40/17 40/21 40/22 45/15 46/6 91/6 91/7 105/13 116/3 121/18 127/13 Americans [1] 2/9 among [6] 1/24 15/1 22/25 24/14 64/21 110/1 amongst [1] 70/8 amount [6] 44/6 44/18 68/6 84/3 135/19 136/2 amounts [2] 107/18 116/23 an 18 million [1] 94/13 an abundance [1] 65/24 an account [1] 40/9 an Armour [1] 84/23 an end [1] 102/10 an estimated [1] 68/11 an increased [1] 63/13 an industry [1] 105/11 an industry-only [1] 109/24 an infectious [1] 2/23 an inference [1] 114/2 an informal [1] 111/9 an interim [1] 38/19 an internal [5] 34/16 40/9 52/12 85/11 90/12	an issue [1] 36/17 an obligation [1] 54/7 an open [1] 32/18 analogous [1] 39/24 analysis [1] 74/16 analyte [1] 40/4 Anderson [1] 126/5 animal [1] 35/21 animals [1] 3/2 announce [2] 59/4 59/6 announced [9] 51/23 52/15 59/1 84/17 84/20 96/10 98/24 104/17 117/19 announcement [6] 62/20 65/13 98/19 99/16 99/25 104/12 announcements [1] 57/1 announcing [2] 98/2 98/5 annoyed [1] 141/16 another [8] 7/5 19/10 27/5 86/24 87/7 96/4 121/7 122/11 answer [4] 69/24 74/15 116/14 126/4 anti [62] 3/21 15/14 16/1 16/9 16/10 16/22 17/1 17/7 17/10 18/15 18/19 20/21 22/17 28/6 37/13 38/13 38/22 39/3 39/7 39/14 41/3 41/19 42/2 42/13 42/25 43/3 43/8 43/18 44/1 44/2 44/8 45/3 45/17 45/21 45/25 46/9 46/12 48/4 48/21 49/18 50/6 50/9 51/16 51/24 52/15 58/23 61/20 61/22 63/9 63/18 64/8 64/17 89/23 105/19 105/25 106/11 106/16 106/24 107/3 107/7 142/18 143/4 anti-body [1] 20/21 anti-core [6] 16/1 16/9 16/10 17/7 18/15 18/19 anti-haemophilic [1] 3/21 anti-HBc [33] 16/22 17/10 38/13 38/22 39/3 39/7 39/14 41/3 41/19 42/2 42/13 42/25 43/3 43/8 44/2 44/8 45/3 45/17 45/21 45/25 46/9 46/12 48/4 48/21 50/6 50/9 51/16 52/15 58/23 61/20	61/22 63/9 64/17 anti-HBc, [1] 17/1 anti-HBs [1] 44/1 anti-hepatitis [3] 28/6 63/18 89/23 anti-hepatitis B [6] 15/14 37/13 43/18 49/18 51/24 64/8 anti-hepatitis B core [1] 22/17 anti-HIV [2] 142/18 143/4 anti-HTLV-III [7] 105/19 105/25 106/11 106/16 106/24 107/3 107/7 antibodies [3] 15/15 55/14 133/18 antibody [27] 16/13 28/6 33/24 34/1 37/23 38/5 41/3 42/21 45/4 53/1 53/4 53/8 53/9 54/2 54/5 54/9 54/12 54/15 54/18 55/16 57/2 57/18 58/6 58/7 104/18 108/7 117/20 anticipated [3] 15/2 134/11 136/7 anticipating [1] 58/16 antigen [12] 15/14 15/15 22/17 44/7 46/19 51/25 54/20 55/15 55/17 78/3 105/22 112/9 Antihæmophilic [1] 67/2 antihemophilic [1] 3/18 antihemophilic [3] 3/20 3/23 97/5 anxiety [1] 6/6 any [61] 4/6 6/15 6/24 7/1 7/11 9/16 10/12 10/24 11/16 12/13 12/22 13/3 13/4 13/8 13/21 13/22 13/24 14/10 14/10 19/4 30/14 39/2 44/14 52/1 55/4 70/25 84/11 89/4 90/5 92/2 93/5 95/22 96/12 98/3 99/12 99/20 100/6 100/15 100/17 103/2 107/3 108/7 111/4 111/8 112/12 115/17 118/24 121/14 123/11 123/14 123/23 124/14 125/22 126/5 126/20 132/3 132/5 133/10 139/24 145/4 149/8 anything [6] 7/9 7/14 53/2 73/22 73/23	146/6 anyway [1] 70/19 anywhere [4] 26/18 93/4 100/24 101/12 apart [1] 147/8 apparent [3] 37/1 83/5 121/22 apparently [3] 9/16 81/11 115/19 appear [1] 73/10 appeared [5] 81/14 81/15 137/16 144/2 144/3 appears [9] 2/8 18/4 40/4 45/19 51/14 66/16 74/7 100/1 130/15 appendix [1] 135/4 application [6] 17/9 23/11 71/24 73/12 78/13 104/21 applications [3] 68/23 73/16 112/7 applied [9] 22/21 70/3 70/13 70/16 71/20 72/14 72/20 72/24 73/1 apply [1] 148/12 applying [1] 141/9 appreciate [2] 6/12 10/24 appreciation [3] 12/9 86/16 98/17 approach [15] 20/4 20/24 22/8 28/9 51/5 80/22 81/3 83/7 87/12 108/24 109/18 134/1 134/15 135/18 143/6 approaching [2] 57/8 113/20 approaching/plasma [1] 57/8 appropriate [3] 10/14 38/24 54/23 approval [9] 17/12 20/16 92/15 92/15 93/8 109/17 117/24 124/25 140/8 approved [5] 72/24 73/13 91/12 107/5 125/8 approximately [8] 2/11 19/22 28/8 29/10 56/11 106/9 124/7 127/4 April [15] 51/22 58/24 58/25 59/9 66/13 69/13 82/5 82/16 83/9 83/21 85/12 86/11 104/13 121/5 122/17 April 12 [1] 122/17 April 1978 [1] 66/13	April 1984 [1] 51/22 April 1985 [4] 82/5 82/16 83/9 121/5 are [106] 2/17 2/22 2/24 3/2 4/7 5/3 9/13 10/2 13/5 14/24 16/6 24/1 25/8 25/11 25/13 27/11 28/4 28/4 29/9 29/11 29/13 29/19 32/5 33/22 36/2 39/11 39/14 40/13 41/9 42/11 42/16 47/5 48/19 48/21 48/22 48/24 53/21 54/1 54/3 55/5 55/22 55/23 56/4 56/22 57/25 58/9 58/10 60/12 61/3 61/5 61/11 62/6 62/9 63/6 63/25 65/22 67/6 67/8 68/25 71/1 71/3 71/5 71/5 73/3 73/24 74/18 77/7 79/6 81/11 83/4 84/6 84/17 85/18 86/22 88/2 93/12 98/6 103/16 105/20 106/7 106/8 107/1 113/2 113/20 114/2 120/16 122/21 123/5 124/9 124/19 125/23 126/6 127/5 130/2 130/6 131/9 131/10 132/5 140/16 140/21 142/16 142/24 148/23 149/1 149/14 149/16 are: [1] 77/8 are: questions [1] 77/8 area [3] 7/8 16/20 30/2 areas [9] 6/2 15/25 29/21 29/23 39/20 77/7 92/23 114/5 114/6 aren't [1] 50/22 argued [3] 21/22 22/13 63/15 argument [3] 123/18 126/9 132/22 arguments [6] 21/25 52/10 52/25 53/3 53/7 56/5 arising [1] 95/4 arithmetic [1] 149/2 ARMO000302 [1] 9/5 Armour [59] 9/4 9/8 10/15 17/8 19/11 22/20 23/25 25/2 40/24 41/13 41/20 50/14 51/17 64/10 72/6 73/6 73/8 84/15 84/23 91/4 97/3 97/3 97/15 99/12 102/22
----------	--	---	---	--	--

(41) all... - Armour

F:

A	assumptions [2] 138/8 149/3 assure [1] 58/7 asymptomatic [1] 63/3 Atlanta [2] 82/6 126/13 atmosphere [1] 112/17 attached [2] 12/5 126/16 attempt [1] 148/16 attempting [2] 85/19 144/4 Armour's [8] 24/2 50/19 104/3 124/12 136/10 139/18 139/23 145/1 Aronson [1] 93/10 arose [1] 105/21 around [2] 83/10 121/23 arranged [1] 111/9 arrangement [1] 140/6 arrangements [2] 115/8 125/13 arrived [1] 93/19 article [6] 23/12 102/14 138/9 138/9 138/15 139/21 articulated [1] 145/25 as [162] ascertain [1] 39/20 Ashworth [4] 25/2 29/4 29/5 29/15 ask [1] 25/6 asked [8] 6/23 10/2 12/10 16/24 33/1 36/9 87/19 115/2 asking [3] 30/18 111/23 112/2 aspects [2] 6/1 38/12 assay [1] 78/17 assays [2] 8/6 149/2 assess [1] 76/7 assessed [1] 25/21 assessment [1] 128/9 assets [1] 104/20 assist [2] 93/7 130/23 assistance [1] 149/17 Assistant [1] 1/16 associated [6] 33/12 38/15 102/12 112/13 143/9 143/18 Association [6] 40/21 40/22 46/6 91/8 105/14 116/4 assume [1] 106/14 assumed [1] 56/25 assumption [1] 127/22	assumptions [2] 138/8 149/3 assure [1] 58/7 asymptomatic [1] 63/3 Atlanta [2] 82/6 126/13 atmosphere [1] 112/17 attached [2] 12/5 126/16 attempt [1] 148/16 attempting [2] 85/19 144/4 attempts [1] 5/6 attended [3] 8/1 24/13 25/5 attendees [4] 25/1 36/21 90/24 122/14 attention [2] 74/11 92/3 audience [1] 19/9 August [16] 1/7 1/10 5/25 6/11 7/20 26/12 72/24 78/23 79/2 79/6 81/22 120/1 120/2 120/4 120/11 137/23 August 1 [1] 5/25 August 1983 [3] 1/7 7/20 72/24 August 1984 [5] 78/23 79/2 79/6 81/22 120/2 August 1985 [1] 137/23 August 3 [1] 6/11 author [1] 23/8 authorities [4] 21/16 104/16 104/20 129/1 authors [1] 137/24 automatic [3] 11/7 21/23 22/6 Autoplex [3] 66/24 92/16 99/1 autumn [2] 7/18 73/16 availability [3] 57/7 83/4 107/12 available [31] 1/22 2/25 5/3 10/9 38/20 42/12 55/2 55/4 55/5 56/25 57/3 57/11 59/10 59/13 59/17 62/16 81/11 83/1 84/18 85/3 87/21 98/11 104/14 118/9 118/12 118/13 118/23 120/1 122/1 127/13 146/23 avenue [1] 74/10 avoid [7] 10/19 45/8 100/2 100/15 110/21 114/4 122/8	avoiding [1] 29/20 aware [6] 8/17 19/6 31/8 71/1 104/24 112/6 away [3] 53/2 74/12 94/9 B back [35] 4/22 5/17 20/24 24/7 31/11 37/11 40/12 46/16 47/16 49/21 54/6 55/1 58/10 60/5 61/13 75/15 76/13 78/19 89/10 90/3 91/9 94/10 96/22 110/18 112/22 117/13 118/20 123/17 130/4 130/7 130/17 131/12 132/15 135/11 138/11 background [1] 112/4 bad [1] 126/23 Bank [1] 16/19 bankers [2] 19/24 109/13 banking [4] 40/23 64/11 109/8 109/19 banks [6] 15/24 19/23 21/5 40/22 43/11 46/6 Barr [1] 16/3 Barrowcliffe [4] 85/21 86/4 86/7 86/7 based [2] 1/22 35/9 basic [1] 119/23 basis [15] 11/18 22/3 35/9 45/6 71/15 81/1 83/16 87/10 88/11 107/8 112/19 126/13 131/7 131/7 138/3 batch [1] 88/2 batches [6] 29/18 33/1 33/3 84/16 102/19 134/1 BAUM0000025 [1] 90/7 Baxter [2] 71/23 72/5 BAYP0003708 [1] 69/11 BAYP0005158 [1] 28/18 BAYP0005650 [1] 105/15 BAYP0005664 [1] 110/25 BC [1] 125/10 be [250] became [3] 112/6 118/12 132/9 because [28] 3/16 7/4 8/25 9/14 35/10 36/1 52/9 61/25 69/10 71/7 74/17 77/1 89/21	97/11 100/8 109/6 111/5 113/9 117/10 124/14 124/17 124/21 129/15 130/22 132/12 134/10 137/16 143/8 become [5] 17/17 19/20 91/2 102/3 123/10 becomes [2] 27/10 107/8 becoming [2] 78/11 85/3 been [112] 3/12 5/2 7/4 7/21 8/13 8/15 8/17 8/18 11/3 14/15 15/2 15/11 15/12 15/25 16/2 16/7 18/11 18/22 19/15 21/10 21/14 21/21 24/18 26/6 27/23 31/4 31/8 31/8 33/3 33/5 34/22 37/13 46/14 47/12 48/2 51/14 52/1 52/22 53/23 54/4 56/13 59/24 62/2 62/2 62/7 62/12 62/16 62/23 63/8 64/7 65/11 69/15 69/16 70/20 74/12 74/20 74/22 79/2 80/12 80/25 81/2 81/22 83/8 83/15 83/23 91/11 98/15 98/16 98/19 99/5 99/19 102/10 102/19 102/21 104/17 107/18 107/19 108/7 109/6 109/11 109/22 114/15 115/12 117/20 117/21 118/13 118/25 125/8 126/21 128/13 128/23 130/10 131/16 131/20 132/25 134/4 134/19 135/1 136/1 136/4 137/3 137/8 138/13 139/1 140/17 141/16 143/7 145/13 145/18 146/2 148/17 149/7 before [26] 1/10 11/4 11/22 13/14 14/14 17/20 25/9 31/12 37/4 51/13 52/14 55/4 69/6 72/17 78/20 80/12 89/14 95/4 96/7 102/21 112/22 119/4 135/20 135/21 138/14 142/21 began [4] 8/4 42/6 76/14 118/7 begin [6] 40/25 41/20 51/17 51/18 117/24 126/1 beginning [7] 3/10	41/2 66/10 100/23 101/10 142/10 144/15 begun [4] 20/12 22/16 45/17 66/11 behalf [1] 86/15 behaved [2] 133/8 148/14 behind [1] 138/8 Behringwerke [5] 66/6 66/10 66/18 67/9 72/23 Behringwerke's [1] 67/14 being [46] 21/16 22/20 26/17 31/24 32/1 35/9 36/18 41/12 43/12 49/8 53/4 59/12 68/17 70/15 75/21 75/22 78/14 88/7 88/11 94/23 96/14 96/15 96/23 97/11 99/24 100/24 105/12 108/8 108/10 108/13 108/22 110/9 110/22 112/25 113/1 113/2 118/17 119/5 119/8 122/5 127/3 127/17 127/19 128/18 133/6 134/24 belief [1] 30/23 believe [6] 1/23 2/13 41/6 108/24 125/17 137/17 believed [3] 19/4 41/11 145/6 believes [2] 112/18 115/21 believing [1] 38/23 Belize [1] 29/14 below [1] 127/10 benefits [1] 25/21 Benotto [3] 145/15 147/6 148/11 Benotto's [2] 145/22 149/9 Berlin [3] 9/23 9/24 9/25 Bernie [1] 140/5 best [2] 1/22 122/8 Beta [2] 16/1 40/3 Beta-2-microglobulin [1] 40/3 Beta-2-microglobulin s [1] 16/1 Bethesda [1] 27/20 better [5] 43/12 45/18 45/22 87/11 129/15 between [23] 8/4 8/19 26/13 27/8 58/23 61/22 62/19 78/13 78/20 80/2 82/12 90/4 104/25 109/18 113/4	117/8 117/24 119/13 124/8 131/4 141/3 141/23 141/25 BGA [3] 9/19 9/24 133/3 Bill [1] 19/3 Biochemical [1] 69/12 Biological [2] 24/10 86/5 Biologicals [1] 77/20 Biologics [6] 15/10 28/9 40/18 84/10 144/17 147/20 birth [1] 101/14 bisexual [1] 48/7 bisexuals [4] 53/21 53/25 60/11 60/17 Bishop [2] 9/7 149/20 bit [3] 61/25 89/7 126/25 Blending [1] 58/5 blood [89] 1/5 1/25 1/25 2/6 2/8 2/15 3/14 5/5 5/7 5/7 6/14 8/25 15/9 15/22 15/24 16/11 16/19 17/5 17/5 17/13 19/6 19/23 19/23 19/24 21/5 21/19 23/1 23/6 23/15 24/12 24/23 24/25 27/3 27/3 28/13 28/15 31/4 32/8 32/22 38/3 38/4 38/8 39/16 39/25 40/1 40/16 40/20 40/21 40/22 40/22 42/19 43/6 43/10 43/11 46/6 46/11 48/13 48/14 49/4 54/15 64/6 64/10 70/6 74/24 91/7 93/25 99/15 105/13 105/20 109/7 109/13 109/19 116/4 121/6 122/20 122/20 126/21 127/23 127/24 128/3 128/4 128/11 129/6 135/13 140/14 142/6 147/21 147/22 150/3 Bloom [3] 35/17 36/9 36/10 blot [1] 110/5 Bob [9] 40/20 91/7 109/15 109/23 111/19 112/3 115/23 122/18 125/11 bodies [1] 80/12 body [5] 20/21 37/15 40/23 91/8 111/19 bombshell [2] 112/20 116/1 born [3] 101/15 101/19 101/25
----------	--	---	---	--	--	--

(42) Armour... - born

B	34/4 35/10 37/6 37/18 39/15 42/11 43/2 43/7 43/19 47/4 49/2 49/18 49/20 49/25 50/20 51/4 52/13 53/2 56/16 58/20 60/22 61/5 61/16 62/9 62/12 63/16 63/25 66/18 68/3 69/22 70/4 70/11 71/21 72/18 72/19 74/21 75/15 76/6 76/25 79/4 80/11 81/2 82/8 84/25 85/4 86/20 88/5 93/2 93/8 96/7 98/25 99/21 102/20 103/12 103/20 108/9 109/14 111/7 111/13 113/1 114/2 114/6 114/9 114/14 115/20 115/22 119/10 119/16 120/14 120/19 120/20 120/24 122/7 123/19 123/21 124/8 124/21 126/20 127/10 128/17 128/19 129/4 129/8 129/14 129/17 130/22 131/18 133/22 134/4 134/11 136/20 138/9 138/14 141/9 144/19 146/11 146/13 146/20 147/6 147/16 148/9 by [153]	C calculations [1] 83/25 call [6] 81/6 104/25 105/7 117/6 122/18 123/25 called [6] 22/5 25/22 46/21 86/11 86/13 90/15 calling [1] 84/6 calls [2] 64/11 98/15 came [3] 143/9 144/12 145/16 campaign [2] 63/23 63/24 can [56] 7/17 11/22 12/15 14/21 15/4 17/3 17/24 32/13 34/16 36/22 37/22 40/6 42/4 42/7 42/13 47/9 47/16 47/18 47/21 48/11 49/19 52/18 52/25 54/15 55/9 55/20 55/21 58/19 69/2 71/10 86/8 87/5 87/15 88/21 91/9 94/21 97/20 99/17 100/11 105/12 108/1 110/18 119/11 119/17 119/17 120/16 125/18 127/21	129/12 137/4 142/21 143/12 143/21 144/13 146/5 147/16 can't [4] 7/13 26/12 113/23 130/23 Canada [2] 145/10 145/23 Canadian [3] 144/16 147/15 147/23 candidate [1] 43/1 cannot [4] 10/12 55/10 110/12 146/10 capacity [1] 118/19 capture [1] 114/14 care [3] 6/6 61/10 140/10 Carl [1] 132/16 Carman [2] 131/2 131/25 Carr [13] 25/3 34/11 34/22 40/14 41/19 45/23 51/16 91/3 108/2 111/12 111/15 113/18 122/15 Carr's [2] 34/19 37/9 carried [2] 34/2 42/13 carrier [1] 28/5 carriers [1] 29/17 case [14] 11/18 11/18 22/3 22/3 35/8 35/8 37/3 61/19 84/1 107/21 129/5 145/10 145/13 145/15 case-by-case [1] 11/18 cases [23] 2/12 4/6 14/14 14/19 22/25 23/5 28/7 29/25 43/3 43/25 48/1 48/18 60/21 61/21 62/2 62/7 62/22 64/21 80/14 102/10 102/16 103/12 133/22 Cash [2] 24/24 32/4 Castaldi [1] 12/1 casting [1] 46/13 catalyst [1] 78/19 catch [1] 111/21 causative [1] 57/1 cause [7] 2/20 2/21 3/6 27/13 54/15 59/2 70/6 caution [1] 143/1 CDC [31] 2/11 8/5 8/5 8/17 8/19 19/7 23/9 42/15 46/10 49/3 53/25 60/9 60/11 61/17 61/18 62/15 63/1 78/17 78/21 78/23 79/11 79/15 80/3 80/9 109/2 109/12 118/3 120/2	137/22 139/15 146/1 CDC position [1] 60/9 CDC's [1] 138/13 cease [1] 11/20 ceased [2] 81/23 101/13 cell [1] 16/4 cellular [1] 27/1 cent [31] 16/12 16/14 16/22 28/7 28/8 44/19 46/14 48/6 48/7 48/8 48/15 48/19 48/22 49/4 50/1 60/18 60/21 60/23 61/1 61/2 61/18 61/20 63/12 63/16 68/9 68/13 68/16 68/22 121/23 121/24 127/3 center [10] 28/13 39/25 40/16 40/20 43/6 74/24 99/15 106/2 106/25 135/13 centers [10] 12/7 12/21 12/22 13/2 20/12 50/13 50/16 124/11 125/13 137/9 central [1] 146/7 centre [4] 29/14 30/6 30/13 103/15 centres [14] 10/16 21/7 28/10 29/6 29/11 29/20 30/13 31/7 31/8 89/1 116/5 118/12 118/13 118/18 certain [6] 27/11 43/1 43/3 44/15 46/19 69/19 certainly [16] 7/13 14/6 19/25 31/7 45/12 69/22 71/5 71/14 88/17 94/20 95/14 114/15 128/8 131/21 141/6 149/7 CGRA0000222 [1] 66/20 CGRA0000261 [1] 121/9 CGRA0000291 [1] 11/25 CGRA0000312 [1] 111/11 CGRA0000319 [1] 40/11 CGRA0000362 [2] 52/17 60/7 CGRA0000396 [1] 97/17 CGRA0000512 [1] 140/1 CGRA0000561 [1] 87/14 CGRA0000581 [1]	86/8 CGRA0000583 [1] 85/10 CGRA0000610 [1] 34/14 chain [1] 74/14 chair [3] 37/16 40/8 40/24 chaired [1] 63/9 chairman [3] 19/3 20/7 37/24 challenged [1] 112/18 change [9] 11/16 75/24 83/7 83/16 83/20 123/3 126/8 126/19 130/19 changed [3] 18/1 53/19 99/7 changes [1] 132/6 changing [2] 80/4 80/9 character [1] 123/4 characteristics [1] 11/10 charge [2] 147/14 148/6 charged [1] 147/24 charges [1] 147/18 Charles [1] 131/2 check [2] 129/3 129/17 checked [1] 129/9 chemical [3] 36/7 73/20 74/12 chief [1] 147/21 children [1] 82/19 chimp [1] 54/24 chimpanzee [2] 75/22 76/10 choice [1] 95/22 chosen [1] 12/21 chronological [2] 64/4 133/14 chronologically [1] 72/4 chronology [1] 75/7 circulated [1] 25/12 circulation [2] 84/14 85/5 circumstances [2] 10/4 10/10 cited [5] 43/5 46/14 61/12 63/11 83/20 cites [2] 47/4 78/3 civil [1] 86/4 claim [2] 59/24 60/3 claimed [2] 59/2 133/8 claims [1] 56/1 clause [1] 139/22 Clayton [1] 98/11 clear [11] 13/15 35/1	50/17 75/6 82/9 84/8 84/21 94/5 96/15 114/1 132/7 clearly [2] 39/6 145/25 clinical [12] 67/21 76/9 76/9 80/24 81/15 81/20 83/3 95/23 102/4 124/16 124/17 137/23 clinically [1] 81/2 clinicians [6] 70/8 76/16 79/8 80/2 80/17 83/4 close [1] 86/21 closely [1] 37/2 clots [1] 70/6 clotting [2] 5/1 101/11 coagulation [26] 11/21 13/1 13/4 13/8 13/16 14/2 42/10 42/20 44/10 53/10 53/14 54/17 54/21 56/14 57/9 57/15 57/19 90/16 91/11 97/21 106/19 107/16 113/1 123/24 124/5 134/8 coalition [1] 64/9 cogitate [1] 52/14 cohort [1] 47/25 cohorts [1] 101/14 collaborative [1] 4/24 colleague [3] 24/24 79/11 86/13 colleagues [1] 138/20 collected [3] 35/21 53/15 106/23 collecting [4] 30/22 36/2 50/13 113/12 collection [2] 29/5 38/9 collections [1] 40/1 column [2] 48/3 142/10 combination [2] 28/3 103/6 combined [1] 137/5 come [18] 20/21 20/24 24/7 47/16 49/17 54/6 58/10 59/20 73/23 76/14 89/10 104/4 110/18 110/22 118/20 130/7 130/16 130/21 comes [7] 1/9 6/20 7/15 15/3 49/11 52/19 108/21 coming [2] 139/3 146/12 commence [1] 51/23 commenced [3] 42/2
----------	---	---	---	--	--	---

(43) both - commenced

F:

C					
commenced... [2] 66/6 67/25	comparison [1] 136/15	conclusion [5] 4/8 20/20 41/17 144/13 145/17	considerable [1] 70/8 considerably [2] 57/24 78/15	65/9 65/10 82/22 84/14 89/19 93/4 102/4	37/23 38/5 41/2 42/21 46/19 49/18 51/5 51/24 53/1 53/4 53/7 53/9 54/1 54/9 54/11 54/15 54/17 54/20 55/4 55/9 55/18 56/2 57/18 63/18 64/8
comment [4] 26/22 41/24 132/5 149/8	compelled [1] 39/1	conclusions [2] 122/21 146/12	consideration [2] 22/13 129/23	continues [1] 4/23 continuing [5] 4/15 13/18 21/24 56/5 97/8	core-screened [1] 20/17
commented [3] 32/4 96/14 148/23	competition [2] 55/7 55/10	conclusive [1] 105/9	considerations [2] 7/6 35/11	continuous [1] 85/22	corporation [1] 147/24
commenting [1] 9/4	competitively [1] 98/24	condition [1] 33/14	considered [15] 4/9 15/13 16/7 22/2 27/23 30/1 36/15 54/4 57/16 66/1 74/20 138/24 138/25 145/20 148/22	contract [9] 2/4 29/12 30/6 30/9 30/12 50/15 125/13 139/23 141/17	correct [2] 62/3 146/21
comments [4] 94/25 98/18 133/12 146/7	competitor [2] 41/21 51/18	conditions [3] 27/11 141/9 142/22	considers [1] 115/25	contracted [3] 6/14 26/2 29/22	corrections [1] 25/13 correlation [2] 40/5 61/22
commercial [4] 38/7 57/7 111/18 142/22	competitor's [1] 144/7	conduct [5] 112/12 139/6 146/15 147/7 147/8	consistent [3] 47/5 99/3 146/18	contracting [2] 16/23 32/8	correspondence [1] 84/11
commercially [1] 57/10	competitors [3] 98/22 110/1 136/23	conducted [5] 18/23 45/25 69/15 79/10 137/8	constituency [2] 116/2 116/3	contracts [1] 12/22	cost [13] 16/15 16/16 17/2 18/21 50/10 50/18 56/8 56/9 77/1 77/13 78/4 132/21 132/23
commission [1] 139/4	complementary [1] 115/4	conducting [1] 46/3	constituted [1] 16/24	contractual [1] 140/6	costly [1] 42/11
commissioned [2] 135/12 145/20	completely [1] 20/3	conference [12] 8/1 59/3 78/24 80/2 80/16 82/5 82/7 82/10 83/11 104/25 108/23 122/18	consistent [3] 47/5 99/3 146/18	contractually [1] 13/6	costs [6] 50/19 50/19 55/22 55/23 56/17 59/25
commit [1] 111/7	completeness [1] 98/19	conference' [1] 124/24	constituted [1] 16/24	contradictory [1] 145/5	could [72] 3/8 3/9 5/19 9/5 9/24 12/14 14/16 16/22 18/12 18/24 20/17 26/18 26/20 29/3 31/7 33/18 34/14 36/11 37/20 41/23 42/11 43/2 45/17 47/9 52/17 57/10 59/15 60/5 60/7 66/20 69/4 69/16 69/20 71/16 76/3 76/20 77/11 85/9 86/8 86/12 87/14 88/2 90/7 92/1 93/2 93/19 95/12 97/17 97/19 100/25 101/1 105/15 112/16 112/20 116/21 121/8 126/14 128/24 136/7 140/1 140/4 140/24 141/7 141/18 142/4 142/8 142/8 143/5 144/22 144/25 145/3 145/21
commitment [1] 21/13	complex [1] 149/1	conferences [1] 74/6	consultant [1] 35/18	contrasts [1] 60/14	couldn't [2] 51/20 122/6
committee [17] 1/11 3/15 4/3 15/22 16/24 17/6 17/13 19/1 19/6 24/15 31/19 37/17 38/3 52/20 77/21 80/7 125/11	complexes [1] 16/3	confidence [4] 18/20 61/9 89/22 109/3	consultation [1] 102/23	contributed [5] 33/10 33/15 83/8 83/14 134/2	counsel [7] 1/3 84/10 99/19 132/3 132/7 149/7 150/2
common [5] 98/16 105/1 109/25 147/19 148/7	complimented [1] 98/14	Confidential [1] 66/22	consumers [1] 127/23	contribution [3] 45/14 46/5 46/15	counterparts [1] 29/1
communities [1] 62/5	comply [2] 58/1 58/1	confined [1] 39/14	consumption [1] 52/13	contributions [2] 42/5 44/22	counterproposal [1] 130/16
community [15] 3/13 6/7 23/14 38/8 61/23 62/9 64/24 91/19 92/6 101/8 140/25 141/1 144/23 144/23 146/4	components [1] 23/7	confirm [2] 110/6 122/19	contact [7] 2/3 8/19 48/13 87/19 126/5 130/6 131/1	control [5] 24/11 58/2 86/5 92/13 137/9	countries [6] 9/12 86/17 87/1 95/4 95/10 95/20
companies [25] 1/5 9/3 29/7 29/11 29/19 64/10 64/15 65/16 67/25 74/21 74/23 75/1 75/18 84/15 104/23 105/1 108/1 108/14 109/12 117/2 117/24 134/10 134/13 149/13 150/3	comprehensive [2] 65/20 141/8	confirm [2] 110/6 122/19	contact [7] 2/3 8/19 48/13 87/19 126/5 130/6 131/1	controls [2] 36/6 48/22	country [5] 7/10 15/13
concentrate [12] 55/19 55/21 79/12 79/13 83/23 84/22 123/23 134/1 135/19 135/20 135/20 137/15	concentrated [1] 7/11	confirmation [2] 110/13 110/15	contain [6] 4/5 13/2 13/8 29/18 39/4 106/15	controversy [4] 104/2 143/7 148/18 149/6	
concentrates [20] 5/1 23/20 25/21 31/3 56/16 66/8 70/16 77/12 78/3 78/18 80/5 81/24 82/18 83/13 83/15 83/19 84/14 96/20 102/17 133/17	concern [17] 3/16 4/15 6/16 17/1 35/2 36/17 44/3 70/8 70/22 92/7 93/3 112/11 112/11 123/2 128/20 140/23 142/13	confirmatory [1] 110/5	contained [7] 4/19 58/10 60/19 83/19 102/20 110/7 135/24	convened [1] 15/8 convening [1] 24/17 conventional [1] 54/19	
concerned [11] 10/1 30/13 33/22 44/1 69/25 71/2 76/20 93/24 110/9 131/18 144/24	concerning [2] 56/2 138/17	confirmed [1] 107/21	containing [2] 106/5 107/6	convention [5] 12/23 31/1 114/17 131/4 141/14	
concerns [5] 6/9 35/16 42/7 77/9 126/5	concluded [2] 137/4 137/15	conflicting [1] 138/17	contains [3] 5/14 59/23 107/20	converted [2] 85/23 87/1	
concludes [2] 102/7 149/11		confusing [3] 140/25 144/22 146/3	contaminants [1] 107/19	convey [1] 145/2	
		confusion [1] 145/4	contaminated [1] 140/17	cooperation [4] 8/4 78/20 94/7 104/19	
		Congress [3] 4/19 78/24 92/6	contamination [1] 54/13	cooperative [2] 5/4 8/20	
		Congressional [2] 1/9 5/12	contentious [4] 57/6 105/4 141/12 143/24	copied [1] 108/2	
		conjunction [1] 20/16	contest [1] 110/2	copy [1] 51/1	
		connect [1] 28/10	context [4] 11/23 52/11 81/5 88/7	cordial [1] 141/14	
		connotations [1] 124/3	continuation [4] 56/10 58/12 112/23 113/7	core [49] 15/14 15/15 16/1 16/9 16/10 16/13 17/7 17/23 18/15 18/19 18/23 19/19 19/21 19/25 20/12 20/13 20/17 20/21 20/25 22/17 28/6 33/24 34/1 37/13	
		cons [2] 53/4 58/9	continue [11] 1/7 5/5 31/7 52/15 59/22 92/4 112/19 131/25 132/14 141/6 144/3		
		consensus [5] 21/21 76/3 82/10 123/20 134/18	continued [19] 11/17 21/6 21/18 22/24 23/2 45/22 53/1 53/7 56/22 58/21 63/10 64/19		
		consent [1] 105/2			
		consequence [1] 117/15			
		consequences [2] 6/17 7/12			
		conservative [3] 124/12 124/14 133/5			
		conservatively [1] 125/9			
		consider [7] 15/10 17/9 80/4 80/8 113/24 115/4 144/3			

(44) commenced... - country

<p>C</p> <p>country... [3] 59/17 95/19 121/2</p> <p>couple [5] 7/23 36/23 73/24 74/4 133/6</p> <p>course [20] 5/11 7/15 20/25 24/8 33/17 59/21 71/7 79/1 80/11 103/20 103/24 104/10 104/23 119/3 120/15 120/18 129/13 131/18 139/8 148/9</p> <p>court [1] 148/13</p> <p>cover [2] 32/12 59/25</p> <p>covered [1] 133/14</p> <p>Craske [1] 24/21</p> <p>create [1] 42/11</p> <p>creation [1] 14/6</p> <p>criminal [7] 145/10 145/23 146/13 147/18 148/6 148/12 148/20</p> <p>crisis [1] 78/10</p> <p>criticise [1] 138/8</p> <p>criticising [1] 132/20</p> <p>critique [1] 147/3</p> <p>Cross [8] 8/24 11/4 19/3 23/23 40/17 45/15 91/7 147/23</p> <p>cryo [2] 124/4 126/1</p> <p>cryoprecipitate [1] 82/23</p> <p>Curran [1] 23/8</p> <p>current [8] 2/16 18/17 26/23 27/21 43/1 91/16 91/25 125/21</p> <p>currently [9] 5/2 28/3 39/25 46/3 50/14 106/14 107/14 116/17 117/1</p> <p>customer [3] 54/22 123/6 123/12</p> <p>customers [4] 10/14 98/1 98/15 126/9</p> <p>customs [1] 98/8</p> <p>cut [2] 44/11 44/11</p> <p>Cutter [75] 9/1 9/4 9/10 10/7 10/11 11/4 18/5 18/9 20/11 20/12 22/15 22/21 23/23 23/25 24/5 25/2 29/5 29/23 31/16 34/17 40/9 40/19 41/10 42/1 51/23 52/2 52/8 52/20 53/8 54/7 54/24 55/3 55/6 57/13 58/5 58/21 58/24 59/22 60/8 62/16 64/16 68/1 69/24 71/5 72/20 79/12 82/1 85/6 85/11 86/2 86/3 86/15 87/7 87/8 87/17 88/14</p>	<p>89/17 90/12 93/16 97/18 98/14 98/18 99/7 99/21 108/3 109/25 111/21 116/9 122/12 122/12 125/11 125/17 131/5 131/24 131/25</p> <p>Cutter's [8] 9/13 20/24 51/5 69/12 97/19 98/22 98/22 136/13</p> <p>CVHB0000042 [3] 47/10 47/14 100/25</p> <p>cytomegalovirus [2] 16/2 55/14</p> <p>D</p> <p>D Castaldi [1] 12/1</p> <p>Dallas [2] 31/19 32/1</p> <p>data [15] 16/18 16/24 35/19 35/21 54/24 91/13 107/23 112/16 140/8 140/15 140/24 141/5 141/13 144/19 145/6</p> <p>date [8] 45/22 66/9 87/22 88/6 90/9 92/8 98/11 114/24</p> <p>dated [10] 9/6 12/1 18/7 40/11 52/18 66/13 75/9 85/11 86/10 111/12</p> <p>dates [2] 118/15 120/9</p> <p>dating [2] 85/21 88/13</p> <p>day [2] 18/6 46/4</p> <p>days [1] 59/2</p> <p>de [3] 78/25 93/9 116/14</p> <p>de-licensure [1] 93/9</p> <p>deal [6] 32/18 71/13 110/12 135/8 149/1 149/15</p> <p>dealing [6] 2/22 6/12 27/17 34/15 147/7 147/10</p> <p>Dear [1] 87/18</p> <p>debate [8] 11/24 23/16 28/22 42/6 52/7 64/6 79/3 121/10</p> <p>debates [1] 3/12</p> <p>decade [1] 102/5</p> <p>decades [1] 143/8</p> <p>December [19] 6/21 7/1 15/6 15/8 15/21 17/25 18/8 18/10 37/14 38/2 72/6 72/15 73/12 80/20 81/12 82/24 104/22 135/11 135/12</p> <p>December 1982 [3] 7/1 72/6 72/15</p>	<p>December 1983 [5] 15/6 15/8 15/21 17/25 37/14</p> <p>December 1984 [6] 73/12 80/20 81/12 104/22 135/11 135/12</p> <p>December 1985 [1] 82/24</p> <p>decided [3] 12/24 30/5 112/5</p> <p>deciding [1] 52/14</p> <p>decipher [1] 130/15</p> <p>decision [5] 11/20 12/19 58/19 59/22 124/13</p> <p>decisions [4] 35/8 35/9 52/21 132/8</p> <p>declared [2] 51/25 83/12</p> <p>decrease [2] 2/15 61/2</p> <p>deems [1] 126/4</p> <p>defendants [2] 145/12 145/16</p> <p>defending [1] 132/24</p> <p>defensive [1] 68/18</p> <p>defer [1] 125/7</p> <p>deferred [3] 7/1 7/4 123/16</p> <p>deficiency [3] 27/1 38/15 147/25</p> <p>define [1] 12/5</p> <p>defined [1] 127/6</p> <p>definite [1] 33/9</p> <p>degree [3] 4/9 20/14 40/5</p> <p>degrees [10] 72/11 72/22 73/6 136/12 136/14 136/18 137/12 139/9 141/21 141/24</p> <p>delayed [2] 55/6 58/19</p> <p>delaying [5] 17/16 19/18 22/15 37/15 124/24</p> <p>deliberate [1] 19/12</p> <p>deliberately [1] 148/11</p> <p>deliberations [1] 38/17</p> <p>demand [2] 118/10 118/24</p> <p>demonstrate [3] 57/14 81/16 96/6</p> <p>demonstrated [6] 16/20 61/18 79/15 91/13 101/14 131/16</p> <p>denaturation [1] 75/20</p> <p>dense [1] 65/21</p> <p>Department [3] 1/17 69/12 117/18</p>	<p>depend [1] 52/4</p> <p>derivative [2] 4/13 105/20</p> <p>derivatives [3] 3/16 140/14 142/6</p> <p>derived [4] 3/18 3/24 54/17 57/9</p> <p>derives [1] 50/15</p> <p>describe [2] 68/17 113/19</p> <p>described [4] 29/5 29/15 35/22 75/22</p> <p>describes [1] 28/20</p> <p>describing [1] 98/21</p> <p>description [1] 49/7</p> <p>deserved [1] 146/19</p> <p>designed [1] 40/3</p> <p>desirable [1] 42/15</p> <p>desire [1] 110/1</p> <p>desired [1] 33/18</p> <p>desmopressin [1] 82/22</p> <p>despite [6] 30/23 64/18 81/2 94/17 96/14 130/1</p> <p>destined [2] 125/24 134/17</p> <p>destroyed [2] 107/4 108/8</p> <p>destruction [2] 4/5 100/20</p> <p>detail [7] 25/14 29/15 30/3 59/24 85/1 103/2 149/5</p> <p>detailed [3] 9/18 10/8 29/17</p> <p>details [2] 19/12 148/25</p> <p>detectable [1] 137/14</p> <p>detergent [1] 74/25</p> <p>determine [1] 140/6</p> <p>determined [1] 105/24</p> <p>determining [2] 38/13 135/25</p> <p>devastating [1] 64/23</p> <p>develop [4] 36/11 104/17 120/2 124/15</p> <p>developed [13] 4/6 29/25 32/24 36/10 43/13 45/18 48/12 63/2 70/2 78/9 83/9 119/4 119/8</p> <p>developing [4] 4/25 8/6 23/21 78/17</p> <p>development [16] 5/4 8/20 36/5 39/9 55/19 65/20 68/6 68/7 68/10 69/9 70/2 76/21 77/10 87/17 93/20 120/7</p> <p>DHSS [5] 5/17 21/9 21/15 73/15 102/23</p>	<p>diagnosed [3] 7/22 53/15 83/24</p> <p>diagnosis [2] 4/10 33/8</p> <p>diagnostic [1] 33/13</p> <p>dialogue [2] 131/25 134/6</p> <p>did [31] 9/1 11/16 13/13 21/15 22/1 25/5 26/5 36/11 37/8 63/5 73/23 77/2 81/16 82/10 92/2 93/3 95/10 95/24 98/25 103/9 109/16 110/3 112/3 114/7 119/24 131/1 133/11 139/6 141/19 144/18 146/6</p> <p>didn't [11] 6/18 11/14 59/19 70/6 83/22 100/17 110/3 111/7 114/7 127/15 147/9</p> <p>die [1] 102/6</p> <p>died [1] 9/14</p> <p>difference [2] 26/13 113/3</p> <p>different [18] 14/19 15/12 16/6 17/19 24/5 34/12 61/11 61/25 62/4 62/6 62/9 67/5 67/13 67/14 72/10 119/13 140/21 145/17</p> <p>differentiate [1] 54/25</p> <p>differentiated [1] 113/23</p> <p>differentiation [1] 115/15</p> <p>differently [2] 13/24 14/10</p> <p>difficult [4] 2/4 49/6 93/16 139/16</p> <p>difficulties [8] 70/4 75/18 75/20 75/21 76/2 76/11 93/2 98/8</p> <p>difficulty [1] 119/15</p> <p>dilemma [2] 105/21 107/14</p> <p>direct [1] 78/5</p> <p>directed [1] 70/18</p> <p>directly [1] 30/14</p> <p>director [4] 17/4 24/22 147/20 147/22</p> <p>disagree [1] 61/10</p> <p>disappointed [1] 141/11</p> <p>Disappointingly [1] 137/2</p> <p>discard [2] 124/4 124/5</p> <p>discarded [3] 44/18 128/17 128/18</p> <p>discarding [1] 16/16</p> <p>discards [1] 125/6</p>	<p>discern [1] 69/2</p> <p>disclose [2] 145/14 147/12</p> <p>discontinuation [1] 89/23</p> <p>discontinue [2] 12/20 12/25</p> <p>discontinued [2] 89/20 97/25</p> <p>discontinuing [3] 53/3 56/6 96/11</p> <p>discount [1] 88/11</p> <p>discovered [1] 52/2</p> <p>discovery [1] 59/1</p> <p>discrepancies [1] 141/3</p> <p>discuss [5] 3/12 38/3 90/16 109/22 126/12</p> <p>discussed [16] 3/15 13/14 16/19 21/21 25/19 31/19 32/1 35/7 44/3 72/17 75/17 80/12 84/9 101/5 104/11 110/16</p> <p>discussing [4] 1/8 18/11 74/13 85/21</p> <p>discussion [32] 8/8 15/6 16/8 26/15 27/12 32/4 32/14 32/19 32/21 33/7 34/3 34/20 35/12 35/23 36/4 36/20 36/24 41/4 44/20 51/14 63/22 75/13 76/8 77/19 92/7 106/8 110/23 112/22 121/22 129/25 129/25 131/12</p> <p>discussions [4] 32/16 83/6 86/6 115/24</p> <p>disease [7] 2/2 2/4 9/17 39/9 45/3 47/2 137/9</p> <p>diseases [3] 31/6 45/7 54/11</p> <p>disparate [1] 130/1</p> <p>disposed [1] 107/2</p> <p>disposition [2] 106/4 107/16</p> <p>disproportionately [1] 30/24</p> <p>disputed [1] 32/7</p> <p>disqualify [1] 10/3</p> <p>dissension [1] 19/2</p> <p>distinct [2] 51/4 127/1</p> <p>distinction [2] 82/12 109/18</p> <p>distribute [2] 91/18 104/18</p> <p>distributed [3] 9/12 108/13 127/18</p> <p>distributing [2] 86/3 97/4</p>
--	--	--	--	---	--

(45) country... - distributing

F:

D	74/7 104/19 119/14 126/22 144/8 dollars [3] 16/15 50/18 85/16 domestic [7] 97/5 103/21 103/22 123/3 123/16 125/5 134/25 don't [19] 7/10 31/25 48/10 49/24 58/18 63/24 68/25 73/10 86/6 88/4 88/11 96/5 100/12 114/8 119/10 128/25 130/20 135/5 147/15 donate [1] 2/15 donated [3] 9/15 11/8 51/24 donation [3] 4/11 44/14 107/20 donations [7] 36/2 48/17 106/13 107/20 128/5 128/7 133/20 done [19] 11/24 15/11 15/25 16/11 32/22 35/2 35/6 37/2 64/12 70/15 78/17 80/25 97/11 106/1 118/17 120/16 120/22 122/4 149/15 Donohue [18] 12/3 12/6 12/17 13/13 17/4 17/21 18/13 18/15 20/2 20/3 40/15 41/5 41/8 42/6 43/19 90/25 114/18 114/19 Donohue's [2] 4/20 17/25 donor [47] 4/6 6/22 6/23 6/23 7/1 7/2 7/3 9/18 16/17 21/3 23/20 28/11 29/15 29/19 29/24 30/6 31/14 31/19 31/23 31/25 32/1 33/8 33/10 33/11 35/3 35/3 35/4 39/15 43/11 46/22 53/15 53/20 83/14 83/24 99/11 105/6 105/23 108/9 108/10 110/6 110/8 115/16 123/16 123/18 125/7 128/18 128/20 donor's [1] 106/2 donors [54] 3/25 9/14 9/19 10/2 10/3 16/12 16/18 16/20 18/19 19/22 19/23 27/22 27/25 28/12 28/14 29/22 30/1 31/15 32/5 32/6 32/8 32/10 32/11 32/23 34/2 34/24 35/14 35/14 36/3 38/4	38/14 39/16 39/21 41/3 46/11 47/1 49/4 50/8 50/10 53/24 55/13 61/18 62/1 62/6 62/10 105/3 106/10 106/24 110/14 118/7 133/18 133/20 134/2 134/8 dosage [1] 36/9 doubt [3] 46/13 119/2 144/6 doubts [2] 76/17 77/15 down [12] 5/19 7/17 15/4 27/18 40/6 87/5 101/1 105/16 108/1 113/21 143/5 146/5 dozen [2] 2/11 7/23 Dr [257] Dr Aledort [2] 11/13 77/22 Dr Aledort's [1] 22/7 Dr Alfred [2] 104/3 135/13 Dr Ashworth [4] 25/2 29/4 29/5 29/15 Dr Barrowcliffe [1] 86/7 Dr Bloom [3] 35/17 36/9 36/10 Dr Bob [1] 40/20 Dr Brandt [4] 1/20 3/11 4/22 7/24 Dr Brandt's [3] 4/19 5/13 5/14 Dr Brian McClelland [1] 24/24 Dr Brook [2] 132/20 132/24 Dr Brook's [1] 133/12 Dr Carl [1] 132/16 Dr Carman [1] 131/25 Dr Carr [9] 25/3 34/11 34/22 45/23 51/16 91/3 111/12 111/15 113/18 Dr Carr's [2] 34/19 37/9 Dr Cash [1] 32/4 Dr Charles [1] 131/2 Dr Craske [1] 24/21 Dr Curran [1] 23/8 Dr Donohue [13] 12/3 12/6 12/17 13/13 17/4 17/21 40/15 41/8 42/6 43/19 90/25 114/18 114/19 Dr Donohue's [2] 4/20 17/25 Dr Edward Brandt [1] 1/16 Dr Eibl [1] 25/5	Dr Evatt [12] 7/19 49/3 60/15 76/24 78/22 79/8 100/22 101/6 102/7 137/10 137/11 137/24 Dr Evatt's [5] 26/7 26/11 47/5 79/11 137/20 Dr Gallo [1] 62/20 Dr Geoffrey [1] 82/1 Dr Gerety [6] 41/11 43/17 45/1 45/10 45/19 123/1 Dr Gunson [1] 77/18 Dr Harry [1] 90/14 Dr Hink [8] 40/10 40/19 41/1 41/11 45/11 51/13 51/21 105/7 Dr Holst [1] 91/3 Dr Jay Levy [1] 79/19 Dr Johanna [1] 16/9 Dr Johanna Pindyck [1] 40/19 Dr John [1] 138/1 Dr John Cash [1] 24/24 Dr Jones' [1] 144/1 Dr Joseph Smith [1] 34/25 Dr Kingdon [9] 67/23 77/3 81/18 81/19 81/23 96/18 100/17 117/22 118/21 Dr Kingdon's [1] 118/8 Dr Lane [1] 32/15 Dr Levine [2] 131/6 131/24 Dr Luc Montagnier [1] 8/1 Dr Marilyn [1] 40/15 Dr McDougal [3] 79/13 137/24 139/14 Dr McDougal's [1] 80/10 Dr Meyer [1] 91/10 Dr Meyer's [1] 94/25 Dr Michael [1] 17/7 Dr Middleton [2] 70/7 76/22 Dr Mike [1] 40/24 Dr Miller [1] 19/4 Dr Montagnier [4] 8/5 8/19 63/3 78/21 Dr Ojala [14] 18/5 22/14 37/15 90/10 90/10 91/3 108/21 109/5 109/15 118/3 122/11 133/6 134/12 134/14 Dr Ojala's [1] 18/13	Dr Peter [2] 131/2 143/10 Dr Peter Page [1] 40/16 Dr Peter Page of [1] 45/14 Dr Petricciani [12] 25/1 28/20 33/1 33/4 35/4 36/15 90/24 105/14 111/7 111/16 112/4 126/12 Dr Petricciani's [1] 27/17 Dr Pindyck [1] 43/5 Dr Prince [13] 135/5 136/25 138/7 138/23 139/6 139/20 140/7 140/13 140/22 141/11 141/15 142/10 144/19 Dr Prince's [11] 137/7 138/11 138/21 139/1 139/17 143/6 144/18 144/21 144/25 145/7 145/14 Dr Reilly [1] 105/17 Dr Reilly's [1] 111/6 Dr Richard Lane [1] 24/22 Dr Richard Tedder [1] 24/22 Dr Rick Srigley [1] 40/23 Dr Robert Gerety [1] 40/17 Dr Rodell [21] 10/8 25/3 32/6 37/16 40/8 50/5 50/12 50/25 51/17 63/9 91/5 97/2 110/19 138/19 138/24 145/11 145/18 146/15 146/17 147/20 148/13 Dr Rodell's [1] 97/14 Dr Simon [6] 46/13 47/4 47/20 49/3 49/10 49/24 Dr Smith [5] 25/20 34/25 36/4 36/9 36/19 Dr Snape [1] 32/15 Dr Srigley [4] 12/1 41/10 42/23 51/19 Dr Steve McDougal [1] 79/11 Dr Tedder [4] 26/22 26/24 27/14 120/14 Dr Terry Snape [1] 24/23 Dr Thomas [6] 24/18 25/7 25/12 33/1 37/4 51/1 Dr Thomas Zuck [1] 23/12 Dr Toby Simon [1]	40/21 Dr Tuddenham [3] 87/15 87/18 88/12 Dr Vivian [1] 103/14 Dr Walford [1] 77/18 Dr William [1] 140/3 Dr Zuck's [1] 23/17 draft [8] 25/10 77/3 117/22 118/8 118/22 139/21 143/13 143/21 drawbacks [1] 67/19 drawn [4] 13/2 18/4 94/21 134/25 draws [1] 4/20 dried [1] 135/21 drug [13] 14/24 15/21 17/5 38/10 38/18 48/8 53/21 54/1 60/12 60/20 62/11 68/7 148/1 dry [21] 24/2 24/6 57/13 72/9 72/9 72/25 73/4 92/15 93/24 102/18 136/10 136/12 136/13 136/20 136/23 139/9 140/14 140/18 142/15 142/19 143/2 dry-heat [3] 92/15 142/19 143/2 dry-heated [2] 24/2 24/6 drying [2] 136/8 142/1 due [15] 7/15 20/25 24/8 27/4 56/23 59/20 71/7 98/8 99/11 104/10 119/3 120/15 124/12 129/13 148/9 dumping [1] 125/14 Duncan [1] 24/17 Duncan Thomas [1] 24/17 duration [1] 93/18 during [17] 2/10 9/17 9/19 20/23 22/22 26/17 35/11 45/11 65/25 70/19 71/9 82/6 93/15 94/1 102/1 102/5 139/8 during 1983 [1] 22/22 duty [3] 145/14 146/8 147/12 dying [1] 45/3 Dyos [2] 85/20 87/19
					E each [3] 28/11 29/24 47/17 earlier [18] 26/5 30/4 32/2 46/8 60/3 61/22 65/6 65/7 69/14 74/19 89/17 100/8 101/5 103/18 104/11 119/19

(46) distribution - earlier

F:

E					
earlier... [2] 136/11 137/25	elsewhere [3] 46/14 96/25 149/7	equivalent [1] 136/12	exactly [2] 119/22 119/23	36/2 54/10 91/22 93/5	factorate [7] 10/21 143/9 143/14 143/16 143/17 148/3 148/3
earliest [1] 120/12	emerged [4] 21/22 77/8 105/12 106/7	errors [1] 149/2	examination [1] 26/15	express [2] 86/15 123/2	factors [7] 11/21 13/1 13/4 13/8 13/16 14/3 107/16
early [13] 7/8 7/12 22/23 59/19 61/17 65/11 67/10 67/20 69/23 70/3 70/15 76/15 128/6	emergence [1] 64/14	essence [1] 111/5	examine [1] 28/12	expressed [12] 12/8 17/1 17/22 22/8 35/2 35/16 43/18 59/14 77/15 79/9 118/21 137/20	facts [1] 106/7
earmarked [1] 68/23	emerging [2] 25/23 81/22	essential [1] 4/13	examined [1] 4/7	extend [1] 39/15	fail [1] 125/24
easy [1] 29/18	emotional [4] 6/5 6/8 6/9 35/11	established [3] 37/14 93/18 139/18	example [6] 7/6 16/10 29/23 55/20 66/4 77/17	extension [1] 85/22	failed [1] 9/16
EBV [1] 16/2	emphasise [2] 77/7 146/12	establishments [1] 112/7	excellent [1] 10/17	extensive [2] 93/20 148/19	failing [1] 147/25
echoed [1] 47/1	emphasize [2] 3/25 4/14	estimate [1] 124/6	exception [2] 41/6 106/18	extensively [2] 92/25 94/24	failure [1] 148/4
economic [1] 31/6	emphasized [1] 10/20	estimated [6] 16/15 68/11 68/14 68/14 106/9 121/23	exclude [3] 29/16 50/8 133/19	extract [1] 126/15	fair [3] 70/1 146/25 148/10
edition [1] 80/14	emphatically [1] 35/12	etc [3] 92/16 98/9 125/19	excluded [5] 10/13 44/2 44/17 110/9 121/16	extra [2] 78/4 123/24	fairly [1] 71/11
editorial [3] 80/20 81/5 81/7	employed [1] 39/14	ethical [1] 144/3	excluding [1] 44/14	extract [1] 126/15	fallen [1] 60/22
educate [1] 6/23	employee [3] 20/11 86/2 87/7	Europe [3] 26/1 26/3 86/3	exclusion [11] 27/22 27/24 28/12 34/23 38/17 42/17 53/9 54/21 55/23 56/14 57/18	extremely [2] 2/8 137/16	falsification [1] 112/10
Edward [1] 1/16	employees [1] 58/5	European [2] 25/4 86/25	executive [1] 95/18	extremes [1] 27/9	family [1] 6/7
effect [7] 4/11 11/6 25/23 44/4 126/8 137/5 142/5	employing [1] 29/10	evaluation [1] 16/18	executives [1] 143/25	eyes [1] 144/7	far [8] 33/21 49/19 63/24 64/5 69/24 71/1 86/6 110/9
effective [8] 21/25 50/7 53/23 54/8 76/7 97/24 103/6 131/17	empt [1] 84/25	Evatt [14] 7/19 46/10 46/17 49/3 60/15 76/24 78/22 79/8 100/22 101/6 102/7 137/10 137/11 137/24	exist [2] 29/17 76/5	face [1] 145/25	fashion [1] 133/9
effectiveness [4] 39/21 76/18 77/9 79/25	emptying [1] 96/8	Evatt's [5] 26/7 26/11 47/5 79/11 137/20	existence [1] 21/24	faced [2] 105/20 107/9	favor [2] 41/5 41/7
effects [2] 6/2 6/4	enable [1] 120/22	even [16] 21/24 30/10 35/25 45/18 55/7 56/21 64/13 75/13 84/1 96/7 100/10 100/12 125/16 129/19 134/13 140/19	existent [1] 106/18	facilities [1] 20/1	favour [2] 41/9 56/4
efficacy [9] 80/19 80/24 81/20 83/6 135/14 139/11 142/13 142/14 143/1	encourage [2] 28/11 36/5	event [1] 126/20	existing [5] 12/22 98/3 98/7 99/14 99/15	facing [1] 107/15	FDA [76] 2/19 12/3 17/21 21/4 21/25 23/12 23/25 24/4 27/19 27/20 27/21 29/14 30/17 30/23 31/7 33/2 33/5 38/2 40/15 41/9 53/13 64/12 73/10 78/14 83/21 84/11 90/4 90/15 90/25 91/1 91/17 92/1 92/3 92/7 93/14 93/23 93/25 100/13 100/19 107/5 109/2 109/12 109/21 110/21 111/3 111/7 111/14 111/25 112/3 112/15 113/2 113/20 117/17 117/21 118/4 118/16 123/1 123/10 124/22 125/8 125/25 126/2 126/4 126/8 126/16 126/17 130/3 130/3 130/15 130/21 132/1 134/6 134/15 138/2 144/7 146/1
efficient [1] 97/12	encouraged [2] 6/2 66/18	eventually [1] 19/20	exists [1] 4/3	fact [13] 7/3 32/10 36/1 59/18 67/19 78/5 84/5 87/8 88/6 91/23 92/3 141/12 148/20	FDA [76] 2/19 12/3 17/21 21/4 21/25 23/12 23/25 24/4 27/19 27/20 27/21 29/14 30/17 30/23 31/7 33/2 33/5 38/2 40/15 41/9 53/13 64/12 73/10 78/14 83/21 84/11 90/4 90/15 90/25 91/1 91/17 92/1 92/3 92/7 93/14 93/23 93/25 100/13 100/19 107/5 109/2 109/12 109/21 110/21 111/3 111/7 111/14 111/25 112/3 112/15 113/2 113/20 117/17 117/21 118/4 118/16 123/1 123/10 124/22 125/8 125/25 126/2 126/4 126/8 126/16 126/17 130/3 130/3 130/15 130/21 132/1 134/6 134/15 138/2 144/7 146/1
efficiently [1] 55/12	endeavour [1] 123/25	evening [2] 17/14 19/16	expand [3] 101/2 140/4 142/9	factor [58] 2/12 3/18 3/20 3/20 3/23 5/1 11/1 14/6 14/9 14/11 19/25 23/6 23/20 24/3 25/21 31/2 33/20 65/25 65/25 66/8 67/1 69/7 69/16 69/17 69/20 70/3 70/4 70/5 70/13 70/14 70/15 70/17 70/17 72/6 72/9 72/12 77/12 77/13 78/18 80/5 81/24 83/23 85/24 96/20 97/5 99/23 100/20 100/24 102/19 121/16 133/17 134/1 135/15 137/14 140/16 140/21 142/19 143/14	feared [1] 77/1
effort [3] 5/4 7/11 65/19	ended [1] 141/14	event [1] 126/20	expanded [1] 46/17	Factor IX [9] 65/25 69/16 69/17 69/20 70/4 70/5 70/14 70/17 140/16	feasible [1] 92/24
efforts [7] 4/25 16/17 66/18 86/16 87/2 118/5 140/5	endorse [1] 82/11	events [2] 65/22 80/1	expansion [1] 113/7	Factor VIII [23] 11/1 24/3 33/20 65/25 67/1 69/7 70/3 70/13 70/17 72/6 72/9 72/12 77/12 81/24 85/24 96/20 99/23 100/24 102/19 135/15 137/14 142/19 143/14	February [25] 24/4 24/9 28/23 31/18 31/21 31/23 37/10 51/3 72/15 73/2 73/13 81/13 88/23 105/11 108/15 108/16 108/17 109/21 111/4 111/14 117/13 126/18 130/10
Eibl [1] 25/5	ends [2] 132/11 135/4	ever [1] 105/4	expect [1] 9/18	expense [1] 55/25	
either [11] 34/5 34/6 36/13 96/15 106/25 107/11 118/18 131/20 135/1 136/21 149/8	enhanced [2] 21/3 21/12	every [1] 48/24	expected [5] 17/17 19/21 54/12 90/1 115/13	expenses [1] 32/12	
electronic [7] 1/19 3/9 15/18 43/23 47/14 61/15 144/14	enlarge [2] 47/18 47/23	Everybody [1] 41/12	expensive [2] 77/14 96/1	experiment [2] 69/21 138/24	
electronically [1] 42/4	enough [3] 35/19 36/12 47/18	everyone [3] 91/20 92/16 94/12	experienced [2] 44/12 44/25	experiments [9] 69/15 75/22 79/10 80/10 137/8 138/13 139/3 140/8 141/17	
element [1] 7/4	enquiries [1] 115/18	everything [2] 43/7 86/25	expired [1] 30/12	expiry [2] 87/22 88/6	
elicits [1] 125/16	ensure [1] 126/6	evidence [34] 2/1 2/22 7/24 16/25 23/11 23/17 33/23 64/23 65/24 66/5 67/23 70/20 76/23 77/3 77/8 78/6 79/24 80/24 81/20 81/21 85/1 85/5 96/15 103/1 103/14 103/17 103/21 104/9 117/9 143/11 143/23 144/10 146/15 148/17	explain [3] 26/12 109/1 139/16	explain [5] 35/7 50/3 83/22 91/10 92/1	
eliminate [2] 18/24 19/22	entered [1] 117/4	eventually [1] 19/20	experiment [2] 69/21 138/24	explanation [5] 27/2 27/5 27/8 35/20 101/4	
eliminated [1] 91/21	entire [1] 125/23	ever [1] 105/4	explains [5] 35/7 50/3 83/22 91/10 92/1	export [2] 97/9 118/25	
eliminates [1] 78/6	entirely [2] 99/3 114/1	every [1] 48/24	explained [5] 35/7 50/3 83/22 91/10 92/1	exported [1] 134/22	
eliminating [2] 53/23 91/14	entitled [5] 24/11 37/22 85/12 97/20 140/13	everybody [1] 41/12	explanation [5] 27/2 27/5 27/8 35/20 101/4	exposed [1] 95/1	
elimination [2] 44/7 92/22	epidemic [4] 1/12 2/10 101/12 102/9	everyone [3] 91/20 92/16 94/12	export [2] 97/9 118/25	exposure [5] 23/6	
else [3] 41/12 116/20 130/22	Epstein [1] 16/3	evident [1] 87/12	ex [1] 71/15		
	Epstein-Barr [1] 16/3	ex [1] 71/15	ex tempore [1] 71/15		
	equal [1] 137/6	exact [2] 47/1 147/15	exact [2] 47/1 147/15		

(47) earlier... - February

F:

F	34/16 39/18 40/13 47/25 63/1 64/6 64/19 68/24 72/21 81/13 81/20 94/11 103/8 104/21 106/8 117/19 122/3 122/13 122/14 131/22 133/2 133/22 136/25 fit [1] 58/22 fits [1] 9/25 five [10] 16/13 16/14 21/8 23/7 28/8 48/24 104/17 127/10 128/16 136/6 five per cent [1] 28/8 five years [1] 23/7 FIX [1] 78/2 flag [5] 8/8 17/20 28/23 31/13 103/25 Flexibility [1] 57/23 focused [4] 1/13 16/8 32/21 91/23 focusing [1] 74/18 follow [9] 30/12 30/16 37/3 39/2 46/24 46/25 132/10 146/20 147/1 followed [2] 35/23 122/17 following [23] 7/25 12/23 20/2 21/3 24/3 31/11 31/22 37/18 41/4 51/2 53/2 57/11 59/20 62/24 66/11 76/10 93/10 93/20 102/23 111/9 122/21 135/23 144/12 follows [1] 106/22 food [6] 2/2 15/21 17/4 38/9 38/18 148/1 force [10] 17/9 17/15 19/11 19/17 20/4 20/7 22/14 37/12 37/17 113/9 forced [1] 51/18 forecast [1] 68/12 foreign [2] 27/7 36/14 foremost [1] 140/22 forgive [1] 108/17 form [7] 10/14 24/2 42/2 66/12 119/16 120/7 121/12 formal [7] 11/6 22/1 32/19 33/5 40/7 88/20 123/4 formally [1] 22/5 formation [1] 78/4 formed [2] 38/1 148/18 forth [1] 136/21 forthcoming [2] 59/7 139/25 forward [9] 3/8 21/9	75/2 87/3 108/14 110/20 127/3 130/2 134/19 forwards [1] 108/1 found [11] 3/7 33/11 46/12 83/14 101/24 106/24 107/3 108/6 108/9 127/5 141/20 Foundation [11] 11/5 53/13 80/8 82/17 83/11 98/13 101/10 130/7 131/3 132/18 132/21 four [16] 15/25 27/23 29/6 32/8 32/21 35/6 35/13 48/24 65/2 65/5 65/7 65/15 99/10 111/18 136/4 136/5 fourth [1] 23/21 Fraction [2] 58/7 124/6 fractionate [3] 21/18 55/18 117/5 fractionated [2] 8/24 105/5 fractionation [12] 26/16 32/15 35/15 36/6 38/7 64/9 104/23 106/12 107/15 107/25 111/17 134/7 fractionators [27] 18/4 19/16 20/2 21/2 21/22 22/9 22/12 24/14 75/11 80/17 90/4 96/8 100/2 103/21 103/22 109/19 109/20 111/5 114/4 121/5 122/2 122/3 122/8 132/22 133/16 134/5 134/18 fractions [1] 13/9 framed [1] 131/14 fraught [1] 75/23 free [4] 68/10 69/8 87/16 140/17 freedom [1] 95/24 freeze [3] 135/21 136/8 142/1 freeze-dried [1] 135/21 freeze-drying [1] 136/8 freezing [1] 142/24 frequently [1] 1/24 Frith [1] 87/16 from [238] front [3] 5/20 47/20 70/19 full [5] 28/19 37/17 38/16 74/15 118/19 fully [2] 10/16 131/21 function [2] 121/12	129/20 funding [2] 66/14 81/6 furnished [1] 38/17 further [35] 6/25 13/7 16/17 17/16 18/20 19/13 19/18 21/5 22/13 30/20 53/11 66/18 79/9 80/18 100/3 100/5 103/1 103/2 103/21 104/9 106/1 111/4 115/17 116/1 116/7 119/18 123/14 123/21 126/3 130/24 132/4 134/5 139/3 139/4 139/7 Furthermore [2] 32/10 142/24 future [5] 18/25 38/18 39/8 56/25 118/21 FVIII [2] 78/2 101/11	127/23 128/22 129/1 133/3 134/17 134/22 Germany [3] 97/13 121/19 129/6 Germany's [1] 133/10 get [2] 116/17 118/5 getting [2] 47/17 117/1 give [8] 28/10 53/2 76/21 77/10 118/15 141/2 147/16 148/13 given [17] 6/22 26/14 49/2 60/14 60/24 70/20 74/5 77/16 86/23 89/17 91/16 105/24 128/18 129/19 136/19 144/10 148/19 gives [1] 34/11 globulin [1] 36/25 globulins [1] 45/5 gloomy [1] 125/23 Glycine [1] 67/4 go [38] 3/8 5/19 17/3 19/14 20/9 26/20 27/18 29/8 32/13 36/8 36/13 36/23 41/16 42/3 42/7 43/6 44/23 46/16 60/5 60/7 75/15 81/21 85/1 86/8 89/8 91/9 94/10 98/21 101/1 103/2 105/16 106/20 108/1 110/14 126/14 135/8 139/4 149/4 goes [7] 41/13 44/20 78/19 101/6 109/1 113/18 114/23 going [28] 4/22 17/19 21/9 25/6 25/16 30/11 30/17 31/11 32/3 64/3 66/15 74/16 83/4 84/13 84/25 96/4 104/24 110/18 111/10 114/11 114/18 121/20 127/4 130/4 130/18 134/5 138/11 149/4 gone [2] 84/22 135/11 good [3] 44/21 109/17 115/4 got [2] 86/7 86/7 government [2] 1/11 75/12 Government's [2] 1/13 5/15 granted [11] 22/22 24/4 71/20 71/25 72/5 72/7 72/15 73/1 73/3 78/14 118/16 granting [1] 65/14 grateful [2] 143/22 149/16 gratefully [1] 51/21	great [3] 85/1 145/24 149/14 greater [6] 16/11 46/18 54/13 124/2 125/6 137/3 greatest [1] 53/20 Groningen [1] 80/16 group [24] 37/13 37/19 37/24 38/1 38/6 38/21 38/23 38/25 39/6 39/11 39/13 39/18 39/19 40/1 40/8 40/14 41/16 48/10 48/14 48/18 48/19 63/8 130/2 140/10 Group's [1] 38/16 groups [16] 2/14 6/4 6/24 14/20 14/21 15/1 27/24 38/14 42/16 43/25 46/19 46/20 49/1 56/19 62/10 109/9 grow [1] 23/2 guide [1] 134/3 guidelines [5] 36/10 113/25 114/1 114/3 114/13 Gunson [1] 77/18
				H	
				had [176] hadn't [3] 8/13 8/15 81/2 haemophilia [22] 7/20 23/1 26/1 39/24 52/4 62/23 63/4 64/21 76/16 77/5 80/2 80/15 80/16 80/22 82/20 82/21 82/24 83/2 89/1 98/13 101/23 103/15 haemophilic [2] 3/16 3/21 haemophiliacs [3] 26/10 45/2 78/7 Haitian [1] 61/23 Haitians [2] 48/9 48/19 half [3] 64/7 146/15 148/22 halfway [1] 101/7 hampered [1] 76/6 hand [5] 48/3 86/21 123/5 142/9 147/16 handling [1] 106/21 hang [2] 125/24 134/15 happened [4] 32/25 58/23 74/8 74/8 happening [1] 10/12 Harry [1] 90/14 Hart [1] 116/14 has [37] 3/11 7/11	

(48) February... - has

F:

H	100/17 103/16 105/8 107/22 108/22 109/1 109/1 109/2 109/8 109/15 112/5 112/18 114/20 114/21 115/3 115/23 115/24 124/19 131/7 131/8 131/9 133/8 137/1 138/21 138/25 139/13 139/15 139/21 141/12 141/12 141/15 141/16 141/18 141/18 141/20 141/20 141/23 He's [1] 9/8 head [3] 119/10 120/10 146/10 headed [1] 52/25 heading [2] 53/3 111/25 Headquarters [1] 122/16 health [18] 1/17 1/17 2/17 2/24 4/14 4/16 5/22 5/24 6/1 6/6 6/10 6/16 59/4 83/10 117/18 123/19 128/18 140/10 hear [4] 103/1 104/9 120/14 149/19 heard [12] 5/11 7/11 20/10 67/22 70/6 81/17 103/17 112/2 137/25 143/8 143/18 145/15 hearing [9] 1/9 1/12 1/15 5/12 5/17 9/7 9/19 84/22 103/20 Heart [1] 15/9 heat [170] heat-treat [3] 20/16 92/18 94/14 heat-treated [53] 8/7 11/1 22/19 24/1 35/17 35/20 65/15 65/16 68/1 73/11 73/17 76/15 77/6 77/13 77/19 78/4 80/4 80/9 80/23 82/11 82/13 82/18 82/25 83/5 83/16 85/2 85/8 85/23 87/1 88/5 88/14 90/20 90/21 95/6 96/1 96/13 99/24 102/11 102/13 103/8 103/8 103/13 104/3 108/12 123/24 131/23 133/17 133/23 134/4 136/15 142/16 143/9 148/3 heat-treatment [1] 139/18 heated [23] 24/2 24/6 67/11 67/16 72/9	72/10 72/10 72/11 72/12 72/17 72/22 72/25 73/5 73/7 91/18 101/11 135/22 136/16 136/20 136/20 140/18 141/24 142/24 Heathrow [1] 73/18 Heathrow Airport [1] 73/18 heating [8] 136/9 136/10 137/5 138/4 139/9 141/9 141/21 142/1 Heckler [4] 59/9 59/16 62/21 104/11 held [8] 5/25 6/10 24/9 40/12 80/2 82/5 85/7 143/25 help [2] 86/20 127/21 helped [1] 109/4 helpful [7] 15/17 28/23 52/9 71/19 71/22 72/3 119/11 helpfully [1] 14/18 Hemofil [6] 22/20 66/12 67/22 72/11 81/15 96/11 Hemofil-T [3] 22/20 67/22 81/15 hemophilia [15] 11/5 53/13 77/23 77/25 78/24 80/7 82/16 83/11 98/12 101/8 101/9 130/7 131/3 132/18 132/21 hemophiliac [4] 4/2 4/15 36/3 102/2 hemophiliacs [2] 36/13 42/12 hemophilic [3] 101/12 101/14 101/19 hepatitis [87] 15/14 15/15 17/22 18/15 20/21 20/25 22/17 25/23 28/6 30/25 32/16 33/23 34/7 36/25 37/13 37/23 38/5 41/2 42/16 42/18 43/16 43/18 44/5 44/8 44/9 46/19 48/20 48/21 49/18 51/5 51/24 52/11 53/1 53/3 53/7 54/9 54/10 54/11 54/15 54/16 54/17 54/20 55/13 56/2 56/18 57/18 57/22 58/5 58/6 63/13 63/18 64/8 66/8 67/2 68/10 69/8 75/4 75/9 75/13 75/25 76/1 76/2 76/18 76/19 77/9 78/10 89/18 89/23 103/9	103/12 103/14 105/22 112/9 127/25 128/3 128/4 128/23 129/2 129/22 131/11 131/11 131/19 131/21 133/24 134/11 134/24 137/18 hepatitis B [34] 15/15 17/22 18/15 20/25 32/16 33/23 36/25 37/23 38/5 41/2 44/5 44/8 46/19 48/20 51/5 52/11 53/1 53/3 53/7 54/9 54/11 54/15 54/17 54/20 56/18 57/18 57/22 58/5 58/6 63/13 75/25 89/18 103/14 131/11 hepatitis-free [1] 68/10 her [8] 43/14 76/22 104/12 104/13 145/17 146/12 146/14 148/13 Herculean [1] 118/5 here [7] 61/14 74/18 84/19 121/19 132/12 136/17 144/16 high [28] 6/4 6/24 15/25 18/18 27/22 27/24 27/25 29/20 34/23 38/14 38/23 39/10 42/13 42/15 43/25 45/2 46/20 54/3 54/22 55/13 60/22 77/1 114/5 114/6 127/24 128/10 133/20 133/21 high-risk [11] 6/24 15/25 27/22 27/24 27/25 29/20 34/23 46/20 114/5 114/6 133/20 higher [6] 40/4 46/20 73/5 127/20 135/2 139/2 highest [1] 10/18 highlight [2] 3/9 65/23 highlighting [2] 90/8 94/10 highly [1] 66/1 him [16] 12/9 12/10 12/14 40/18 46/10 49/3 76/25 94/4 108/22 115/7 115/11 118/1 139/23 140/7 141/2 141/7 himself [2] 40/19 146/17 Hink [12] 20/10 40/10 40/19 41/1 41/5 41/11 42/8 45/11 51/13 51/21 52/19 105/7 hinting [1] 74/6	his [57] 1/20 3/11 7/19 8/2 8/10 9/17 12/8 18/6 22/8 22/15 22/18 23/17 24/23 27/17 37/7 41/23 41/24 42/6 45/12 51/1 51/20 59/1 76/24 77/3 78/21 78/22 79/20 96/18 100/4 100/22 102/7 104/3 115/16 115/23 116/2 116/3 117/22 117/23 118/21 118/21 129/4 132/22 136/25 137/15 138/20 139/6 139/8 139/21 141/3 141/4 141/8 141/17 141/17 144/13 144/20 145/8 146/18 History [5] 7/19 76/24 78/22 100/22 102/8 HIV [13] 101/22 102/16 103/6 103/7 108/6 108/9 110/6 128/25 131/17 133/22 142/13 142/18 143/4 Hoechst [1] 91/6 hold [1] 9/13 Holst [7] 91/3 93/15 108/3 111/20 115/21 122/15 124/16 home [1] 81/9 homosexual [3] 1/24 48/7 63/16 homosexually [1] 16/21 homosexuals [7] 14/24 48/22 53/21 53/25 60/11 60/17 62/11 homosexuals/bisexuals [3] 53/21 53/25 60/11 Hong [1] 85/20 Hong Kong [1] 85/20 hope [1] 88/1 hoped [2] 137/3 141/7 Horowitz [1] 40/16 Hospital [3] 26/24 82/2 87/16 host [1] 27/11 hostility [1] 109/13 Hotel [1] 10/7 hour [1] 122/18 hours [19] 41/4 67/11 72/12 72/13 72/19 72/23 73/1 73/7 136/11 136/13 136/14 136/17 136/18 136/22 137/13 138/4 140/19 141/25 142/1 House [1] 1/10 how [15] 1/21 6/4 7/6	10/19 25/21 36/11 63/24 64/25 76/7 86/6 112/15 116/17 122/7 135/24 135/25 however [15] 3/25 10/11 11/14 22/10 33/25 38/25 44/6 64/15 65/13 66/5 82/10 110/3 118/8 127/6 142/14 HT [7] 10/21 11/1 24/2 24/3 24/6 24/6 102/19 HTLV [51] 55/2 55/5 55/6 55/20 56/25 57/2 57/10 57/14 59/1 62/21 63/19 64/15 65/14 79/2 81/10 81/16 89/25 91/14 91/22 93/5 95/1 102/21 104/6 104/12 104/18 105/6 105/19 105/25 106/11 106/16 106/24 107/3 107/7 107/23 108/19 109/4 110/2 115/14 117/14 117/15 117/19 118/11 125/19 126/10 131/15 131/17 133/18 135/16 139/12 139/19 140/18 HTLV-III [43] 55/2 55/5 55/6 55/20 56/25 57/2 57/10 57/14 59/1 62/21 63/19 64/15 65/14 79/2 81/10 81/16 89/25 91/14 91/22 93/5 95/1 102/21 104/6 104/12 104/18 105/6 107/23 108/19 109/4 110/2 115/14 117/14 117/15 117/19 118/11 125/19 126/10 131/15 131/17 133/18 135/16 139/19 140/18 HTLV-III/LAV [1] 139/12 human [4] 1/17 97/5 117/19 142/7 humans [3] 3/5 67/21 79/23 humoral [1] 27/1 Hyland [57] 8/23 11/3 11/19 12/2 13/15 21/18 23/22 23/22 25/4 30/4 30/6 30/14 30/18 31/1 40/23 41/10 43/2 51/20 64/16 66/11 66/21 66/23 67/21 71/23 72/9 73/6 73/9 74/19 77/2 81/23 84/16 91/3 92/16 93/15 93/22
----------	--	--	---	---	---

(49) has... - Hyland

F:

H	47/18 49/19 55/16 58/16 59/11 62/1 69/20 70/1 70/18 71/12 72/3 94/20 99/17 100/11 119/12 129/4 146/25 147/1 147/10 148/8 148/10 I thought [1] 129/15 I understand [1] 70/22 I will [5] 49/17 58/9 65/23 126/12 147/17 I'd [3] 32/17 104/5 129/15 I'll [6] 53/5 60/15 84/24 85/14 85/25 119/2 I'm [21] 8/16 9/21 15/4 25/6 25/16 26/12 47/13 51/4 84/25 89/2 101/18 110/18 110/24 111/24 128/25 130/12 130/14 130/22 132/11 143/22 149/4 I've [3] 71/21 77/16 111/1 idea [5] 44/21 109/17 124/2 126/23 127/2 identification [5] 27/22 29/18 34/23 58/3 63/19 identified [21] 4/7 11/9 23/6 26/6 35/3 46/9 48/2 50/1 62/23 63/15 64/21 82/20 84/11 101/16 119/24 129/5 130/13 132/3 138/19 138/21 141/23 identify [7] 16/22 18/18 28/5 29/16 55/12 56/21 99/20 identifying [2] 38/22 39/10 ie [6] 36/7 55/14 57/8 105/22 107/4 124/13 if [121] 3/8 3/9 4/3 5/23 7/14 9/4 12/13 12/14 14/16 17/3 18/12 19/23 20/9 26/20 27/16 27/18 29/3 30/19 32/13 33/8 33/11 34/14 36/23 37/20 39/2 39/13 41/16 42/3 42/4 42/7 42/14 42/19 43/24 44/1 44/16 45/3 45/17 45/18 45/22 45/24 46/1 47/9 47/11 47/18 50/6 52/17 52/24 55/2 55/6 55/19 58/20 59/16 60/5 60/7 64/1 66/15 66/20 69/4	69/15 69/19 71/16 83/14 85/9 86/8 86/12 87/14 87/19 88/2 89/4 89/8 90/5 90/6 91/9 94/9 97/17 97/19 98/21 100/25 101/1 101/24 105/14 105/16 107/9 107/22 108/1 108/5 108/9 112/13 112/17 113/23 114/8 114/25 115/3 116/7 116/11 116/25 120/20 121/8 121/20 126/14 128/2 128/4 129/19 130/20 132/5 134/4 134/21 135/5 136/1 140/1 140/4 142/4 142/7 142/8 143/5 145/4 145/21 146/2 146/10 146/20 147/16 ignore [1] 90/8 Il [4] 58/7 124/6 140/16 140/21 Ill [51] 55/2 55/5 55/6 55/20 56/25 57/2 57/10 57/14 59/1 62/21 63/19 64/15 65/14 79/2 81/10 81/16 89/25 91/14 91/22 93/5 95/1 102/21 104/6 104/12 104/18 105/6 105/19 105/25 106/11 106/16 106/24 107/3 107/7 107/23 108/19 109/4 110/2 115/14 117/14 117/15 117/19 118/11 125/19 126/10 131/15 131/17 133/18 135/16 139/12 139/19 140/18 illness [2] 3/2 23/8 imagine [1] 135/6 immediate [2] 4/12 129/14 immediately [3] 6/16 11/13 41/17 immune [5] 6/3 16/3 27/1 27/6 36/25 Immuno [6] 25/5 38/15 73/10 73/19 74/5 91/6 Immuno's [1] 74/11 immunodeficiency [1] 142/7 immunogenicity [2] 35/19 35/21 immunoglobulin [1] 124/25 impact [2] 46/8 144/25 imperial [1] 33/19 implementation [6]	17/16 19/18 20/13 20/22 56/9 57/11 implemented [6] 17/7 42/19 45/4 45/22 46/1 134/21 implementing [1] 63/17 implicated [1] 103/13 implication [4] 94/15 95/9 113/5 139/17 Implicit [1] 92/6 imply [1] 99/22 importance [1] 129/14 important [4] 67/12 78/19 103/4 103/23 imposed [3] 44/16 46/7 127/23 imposition [3] 100/3 100/15 110/16 imprisoned [1] 15/1 improve [2] 10/21 44/8 inactivate [6] 75/24 75/25 107/18 137/19 139/19 142/21 inactivated [9] 53/18 69/17 84/3 90/17 90/19 131/22 135/17 136/8 137/6 inactivates [1] 142/23 inactivating [4] 75/9 76/18 79/20 103/7 inactivation [24] 8/7 36/7 57/14 66/4 67/3 67/5 71/9 73/20 74/20 75/24 79/1 79/14 79/17 81/1 91/12 93/23 93/25 107/23 120/5 136/1 139/11 141/20 141/23 142/3 Inactivation/Radiation [1] 67/3 inadvertent [1] 44/4 inadvertently [1] 89/16 incidence [1] 42/18 incident [3] 10/7 10/11 124/24 incipient [1] 33/13 inclination [1] 78/1 include [4] 62/10 106/12 111/17 114/7 included [6] 25/1 26/3 26/15 68/20 90/24 138/22 includes [1] 149/12 including [12] 9/12 15/24 26/1 29/16 67/19 76/9 85/7 92/13 105/2 133/20 145/4 148/15	incomplete [1] 146/3 inconclusive [1] 146/4 inconsistent [1] 145/6 incorporated [1] 18/16 increase [2] 58/8 93/22 increased [8] 2/15 14/25 54/22 63/13 64/20 116/22 131/10 134/11 increases [2] 63/14 73/3 increasing [3] 5/1 57/21 79/4 increasingly [2] 85/3 85/4 incubation [2] 2/23 3/4 indeed [10] 17/24 69/18 75/6 95/20 95/25 100/6 139/6 142/17 148/20 149/18 indefensible [1] 81/9 indeterminate [1] 56/16 indicate [10] 3/4 9/16 14/1 28/15 57/2 69/22 88/10 123/18 140/15 142/25 indicated [9] 18/23 39/1 41/22 74/5 85/16 85/20 91/20 137/12 141/6 indicates [1] 110/7 indicating [1] 19/8 indication [3] 39/22 54/10 92/14 indicative [1] 39/8 indicator [1] 56/19 individual [5] 4/1 4/14 36/2 39/7 120/17 individually [1] 4/7 individuals [4] 28/8 54/2 61/2 102/4 industrial [1] 121/1 industry [33] 20/23 38/7 40/23 41/18 42/14 46/7 50/20 51/15 57/25 59/18 63/22 91/1 92/11 92/19 93/17 105/11 109/8 109/15 109/19 109/24 110/4 110/8 110/12 110/20 111/17 115/14 121/7 122/23 123/20 125/2 130/18 136/5 139/20 industry's [1] 78/1 industry-only [1] 121/7	industry-wide [1] 63/22 inevitably [2] 127/20 129/22 infants [1] 82/19 infect [1] 128/7 infected [6] 101/17 101/20 101/21 101/24 102/3 127/24 infection [2] 6/17 64/23 infections [4] 103/10 103/11 103/14 103/17 infectious [6] 2/23 18/18 24/12 31/5 45/7 54/11 infective [1] 27/10 infectivity [2] 36/7 142/7 infer [1] 88/21 inference [3] 94/21 94/22 114/2 inform [1] 126/23 informal [2] 33/6 111/9 information [15] 1/22 9/16 10/9 28/11 28/24 30/20 35/10 66/17 89/16 90/11 105/3 115/5 115/17 145/2 146/4 informed [6] 10/23 105/2 115/7 115/11 131/24 138/13 infusion [1] 27/6 inherent [1] 75/23 inhibitor [1] 92/14 inhibitors [3] 67/1 76/21 77/10 initial [4] 49/20 64/22 75/7 138/11 initiated [1] 39/3 initiation [1] 39/19 inmates [2] 14/15 14/22 inoculated [1] 3/3 inquiries [2] 148/22 148/24 inquiry [18] 1/3 7/10 23/18 28/17 84/10 97/2 99/19 103/1 103/18 103/20 104/8 132/3 132/8 143/11 143/23 144/11 149/8 150/2 insist [1] 21/16 instances [1] 32/8 instead [3] 22/2 34/9 44/14 instigated [1] 121/13 institute [9] 5/21 5/24 14/17 15/9 24/10
----------	--	---	---	--	---

I	134/16	129/13 129/14 129/15	Joseph [2] 24/15	143/12 146/13	Konyne [2] 60/1 97/25
institute... [4] 71/18	inventoried [1] 85/17	131/5 132/6 132/15	34/25	Justice [16] 15/19	KREV0000001 [2]
86/5 112/5 119/12	inventories [1] 98/7	132/19 138/14 144/14	Joseph Smith [1]	23/10 61/16 129/5	15/18 144/14
instruction [1] 33/5	inventory [9] 85/12	146/25 148/10	24/15	144/12 145/8 145/15	Krever [14] 15/16
insufficient [1] 118/9	86/17 86/20 87/4	It's the [1] 48/3	Journal [3] 19/7 23/4	145/17 145/22 146/7	15/19 23/10 23/18
insurance [2] 59/24	87/21 92/13 92/17	item [3] 36/20 67/6	137/23	146/21 147/3 147/6	61/15 61/16 100/18
60/3	94/13 99/15	125/10	JREE [1] 69/5	148/10 149/9 149/9	118/11 118/17 144/12
insure [1] 5/6	investigating [1] 2/11	items [1] 106/22	JREE0000006 [1]	justification [1]	145/8 145/17 146/21
Intact [1] 106/23	investigation [2] 10/8	its [20] 3/10 3/14 11/6	1/18	131/13	149/9
integrity [1] 146/19	137/23	22/10 38/21 63/9	JREE0000019 [2]	justified [6] 33/16	Krever's [2] 146/7
intend [1] 83/22	investigations [2]	66/17 67/9 69/17	14/16 71/16	59/14 76/17 131/10	147/3
intended [7] 29/16	41/15 43/2	72/14 82/17 83/12	judgment [2] 129/4	132/2 145/18	Kryobulin [1] 73/11
50/18 66/25 94/19	invited [1] 104/17	99/21 135/14 136/23	145/23	justify [1] 112/16	L
114/14 133/19 134/19	invoked [1] 139/22	141/21 142/1 144/20	July [17] 3/10 3/14	K	labelled [1] 48/1
intends [2] 52/2 94/5	involved [13] 1/5 7/7	145/1 145/2	11/7 11/12 22/5 22/9	Kalster [1] 25/5	labile [3] 66/1 75/21
intense [1] 143/7	18/21 35/13 76/3 78/5	itself [6] 52/13 54/25	37/18 62/24 63/8	keep [3] 10/23 67/12	137/17
intentional [1] 108/25	86/2 96/16 109/12	99/20 113/16 136/8	63/21 64/2 77/20 88/6	85/25	laboratory [12] 2/24
interest [4] 49/13	136/10 148/1 148/25	143/15	97/3 118/12 118/19	Kempinski [1] 10/7	24/23 27/25 28/4
109/9 115/20 115/22	150/3	IV [3] 14/24 53/21	133/15	key [2] 46/11 49/4	33/21 36/19 36/21
interested [3] 48/3	involves [1] 130/16	54/1	July 19 [2] 3/10 3/14	kill [2] 136/5 137/3	79/15 81/1 81/21
71/8 88/2	involving [1] 40/2	IVIG [1] 124/16	July 1983 [1] 11/7	killed [1] 83/18	120/5 144/5
interesting [1] 59/24	Ireland [1] 143/11	IX [9] 65/25 69/16	July 1984 [3] 37/18	kind [2] 112/12	lack [5] 63/11 80/23
interferon [1] 16/5	irresponsible [1]	69/17 69/20 70/4 70/5	63/21 64/2	130/17	92/14 94/18 107/11
interim [6] 37/19	146/2	70/14 70/17 140/16	July 1985 [3] 118/12	Kingdom [11] 21/8	Lancet [10] 79/21
37/22 37/25 38/19	Irwin [1] 16/18	J	118/19 133/15	26/4 77/16 82/4 84/24	80/20 81/3 81/14
94/1 124/10	ISG [1] 58/7	Jack [8] 85/15 85/15	June [25] 58/13 58/19	85/13 85/18 86/12	103/16 138/3 138/10
intermediate [1] 13/9	isn't [3] 50/17 61/25	85/20 86/2 86/9 126/7	59/23 62/22 69/13	87/13 88/16 104/9	138/14 141/19 142/5
internal [13] 9/3 12/2	108/8	130/25 131/24	71/24 72/5 77/18	Kingdon [9] 67/23	Lane [2] 24/22 32/15
34/16 34/17 40/9	isolated [2] 8/3 79/2	Jack Ryan [3] 126/7	77/22 78/8 84/16 92/9	77/3 81/18 81/19	lapse [1] 78/13
52/12 66/21 85/11	isolation [6] 58/3	130/25 131/24	94/4 96/4 96/7 96/10	81/23 96/18 100/17	large [3] 35/24 58/4
89/24 90/12 122/12	62/21 65/14 104/12	Janeiro [1] 78/25	96/24 97/21 97/24	117/22 118/21	71/5
125/11 138/18	140/24 144/22	January [20] 14/14	98/25 99/9 99/10	Kingdon's [1] 118/8	larger [1] 63/5
internally [2] 94/1	isolation could [1]	14/21 15/3 19/6 20/8	104/16 118/10 118/18	kit [3] 117/20 117/25	last [9] 1/8 5/21 18/6
94/3	144/22	23/4 23/19 23/24 24/1	June 1 [1] 92/9	118/24	36/23 47/13 65/10
international [7] 9/11	issue [16] 15/7 21/20	31/22 43/19 45/13	June 17 [1] 94/4	kits [2] 118/9 118/23	89/6 94/11 134/12
68/21 87/22 87/25	36/17 38/4 39/5 48/16	72/7 72/25 73/19	June 1972 [1] 69/13	know [31] 2/21 5/17	lasted [1] 148/21
92/24 94/23 127/14	92/5 95/3 108/17	81/25 96/21 137/1	June 1982 [2] 71/24	7/15 12/14 12/16	late [4] 5/3 73/3 77/22
internationally [2]	108/18 117/16 122/2	138/12 138/16	72/5	13/13 25/10 31/21	137/20
98/4 98/8	126/2 130/9 134/9	January 1983 [3] 15/3	June 1983 [1] 77/18	31/25 41/25 48/10	later [34] 8/9 11/9
interval [1] 61/9	149/6	43/19 45/13	June 1984 [5] 58/19	49/25 51/22 58/18	17/18 23/20 29/24
intervened [1] 45/19	issued [3] 2/13 11/6	January 1984 [5]	59/23 62/22 77/22	63/24 64/25 73/22	45/22 47/16 49/17
interviews [1] 53/22	33/5	23/19 23/24 31/22	78/8	85/18 86/6 88/3 88/4	51/22 54/6 55/19 59/2
into [16] 7/16 67/8	issues [7] 25/18	72/7 72/25	June 1985 [4] 84/16	88/11 90/10 114/8	63/21 72/13 73/24
71/8 71/10 85/1 85/19	32/21 39/17 105/2	January 1985 [4]	96/10 96/24 97/21	119/7 119/10 128/25	74/4 74/10 75/1 79/12
85/23 86/10 92/23	109/22 122/2 132/13	81/25 137/1 138/12	June 85 [1] 99/10	130/20 130/25 131/19	83/9 83/14 83/24
103/2 112/4 117/4	it's [66] 1/18 1/18 3/22	138/16	jurisdictions [2]	135/5	84/25 88/13 101/15
119/11 132/14 146/4	9/5 9/7 9/23 10/25	Japan [1] 9/12	119/9 119/14	knowing [1] 48/16	101/20 101/21 104/4
149/4	11/25 12/16 15/17	Japanese [2] 68/23	just [50] 5/19 8/8	knowledge [5] 1/4	133/6 134/3 138/7
intravenous [4] 60/12	18/8 28/19 34/16	93/6	14/13 15/4 18/11 26/5	25/24 30/23 75/10	138/15 141/15 145/10
60/20 62/11 124/25	40/14 43/23 47/2	Jay [1] 79/19	30/3 31/12 31/13	150/2	latter [1] 64/17
intravenously [1]	47/14 48/3 49/6 52/9	jeopardise [1] 21/23	34/13 34/21 40/15	known [14] 10/19	LAV [10] 8/3 63/1 63/4
48/8	52/12 61/15 61/24	job [1] 115/23	44/23 47/12 47/17	14/25 31/5 46/9 50/1	79/1 101/21 119/20
introduce [3] 64/12	65/17 67/12 68/4 70/1	Johanna [2] 16/9	47/18 47/23 50/4	50/2 75/24 76/5 81/10	119/22 137/16 137/19
111/22 112/1	70/23 71/11 71/19	40/19	50/19 55/9 58/11	83/8 107/18 134/2	139/12
introduced [7] 10/21	71/22 72/16 74/17	John [4] 20/10 24/24	58/22 59/12 60/5 60/6	135/1 135/18	LAV inactivation [1]
18/2 21/5 28/14 64/17	75/6 82/8 84/21 86/11	52/19 138/1	60/15 61/12 62/1 68/3	Koate [10] 24/2 24/6	79/1
102/22 129/8	86/12 87/16 89/17	joined [1] 138/1	69/6 71/22 74/1 77/7	55/10 60/1 85/13	lawyers [1] 37/7
introducing [1] 51/15	90/9 90/11 94/20	joint [1] 15/7	86/12 94/9 96/23	85/17 86/11 86/18	lay [1] 138/8
introduction [8] 21/2	97/20 101/17 102/7	Jones [3] 143/10	99/22 101/1 108/1	87/20 97/25	lead [4] 11/16 23/8
21/11 63/11 121/11	103/4 111/11 114/1	143/23 144/10	118/15 120/23 120/24	Koate HT [1] 24/2	37/4 137/24
122/9 122/10 131/15	115/9 117/10 119/2	Jones' [1] 144/1	126/15 127/21 131/12	Kong [1] 85/20	leading [2] 32/9 32/25
	121/22 127/17 128/2		133/15 136/15 142/9		

(51) institute... - leading

F:

L	78/14 104/21 118/16 121/20 licences [10] 22/21 23/25 24/4 65/15 70/16 71/20 72/21 73/2 91/25 98/9 license [3] 90/17 92/22 93/12 licensed [12] 12/20 22/20 29/14 30/22 67/17 78/11 83/15 117/21 118/5 119/5 121/2 123/8 licensing [6] 70/11 73/14 117/25 120/23 120/24 148/2 licensure [1] 93/9 lie [1] 27/8 life [1] 107/12 light [4] 7/3 63/18 145/19 145/25 like [13] 1/14 8/15 10/12 32/17 43/19 61/4 61/5 86/15 87/24 92/5 104/5 119/15 119/16 likely [9] 10/2 16/21 32/5 33/24 39/1 42/25 48/20 48/24 74/9 likes [1] 126/17 likewise [1] 126/7 limit [5] 123/15 127/6 127/9 127/10 128/17 limitation [1] 27/24 limitations [3] 93/24 130/23 138/20 limited [1] 130/13 Linda [1] 87/16 Linda Frith [1] 87/16 Lindsay [3] 143/11 143/23 144/11 line [1] 51/21 link [1] 46/16 list [5] 66/22 66/24 67/7 92/11 122/13 listed [2] 86/21 106/22 listened [2] 111/7 146/14 liter [1] 55/24 literally [1] 52/10 liters [3] 9/15 50/14 56/12 litigation [2] 124/14 141/15 litres [1] 26/19 little [9] 67/22 70/7 84/25 89/7 100/23 101/11 104/4 126/25 135/12 lived [1] 29/22 liver [3] 45/3 121/12	129/20 living [1] 16/20 load [1] 78/18 lobby [2] 126/19 130/18 location [2] 106/3 107/1 Loev [1] 140/5 log [9] 136/4 136/5 136/6 137/3 138/5 138/6 138/7 141/24 142/2 logically [1] 147/2 logs [4] 136/1 137/6 139/20 141/25 London [1] 26/24 long [10] 2/23 3/4 4/12 92/4 92/8 93/18 95/8 95/10 108/11 143/2 long-term [2] 4/12 143/2 longer [10] 28/17 63/17 73/8 77/11 82/3 83/13 84/6 91/18 97/4 97/6 look [16] 7/16 11/22 17/19 37/20 69/23 71/10 71/22 87/2 116/11 119/11 119/17 122/10 129/10 130/17 132/23 148/8 looked [17] 4/21 6/21 25/9 26/17 40/15 43/17 59/12 61/13 67/23 70/11 88/8 95/3 99/22 102/14 131/13 132/16 136/11 looking [12] 4/18 11/23 34/19 34/22 44/22 47/12 57/5 60/6 61/24 62/1 62/2 69/7 looks [2] 6/15 30/19 losing [1] 69/17 loss [1] 87/11 lot [5] 4/2 86/24 87/20 87/21 105/8 lots [11] 4/5 9/10 9/13 60/1 60/4 86/22 99/10 106/15 107/10 107/16 123/23 Louis [1] 19/3 low [12] 18/21 30/1 43/8 45/16 57/20 67/20 88/9 93/13 132/21 132/23 134/24 138/22 low-cost [2] 132/21 132/23 lower [4] 61/23 66/8 87/11 87/24 lowered [1] 36/6	Luc [1] 8/1 lunch [1] 89/15 luncheon [1] 89/12 Lung [1] 15/9 lymph [1] 61/1 lymphadenopathy [4] 28/13 33/12 53/22 60/25 lyophilisation [3] 137/5 142/21 142/22 lyophilised [1] 142/6 lyophilized [1] 135/21	M Madam [5] 145/15 145/22 147/6 148/10 149/9 Madam Justice [1] 148/10 Madam Justice Benotto [1] 145/15 Madam Justice Benotto's [2] 145/22 149/9 made [31] 12/19 14/11 16/2 20/18 26/17 26/22 28/20 32/23 33/3 35/9 38/19 42/5 46/15 48/17 59/25 62/15 65/19 71/24 73/12 74/19 80/18 86/16 93/16 96/23 104/22 107/19 115/7 115/11 118/4 132/6 147/11 main [7] 29/7 32/21 65/22 105/1 135/3 139/19 140/4 mainly [1] 89/21 maintain [2] 5/7 68/18 maintained [1] 69/18 major [4] 86/22 91/10 126/6 141/10 majority [7] 38/23 38/25 39/5 63/10 116/2 118/13 118/18 make [11] 13/3 49/9 56/1 99/16 115/18 125/12 127/12 127/19 128/21 131/1 149/8 makes [1] 84/8 making [4] 35/8 52/21 97/6 130/6 male [2] 14/24 16/12 man [1] 9/14 management [4] 41/23 51/21 92/21 115/15 manager [1] 87/17 mandatory [1] 134/20 manifested [1] 26/25 manipulate [1] 144/5	Mannucci [2] 102/15 143/19 Mannucci's [1] 81/19 manpower [1] 66/15 manufacture [5] 11/21 12/25 39/23 45/5 53/10 manufactured [7] 11/8 13/9 13/16 21/11 42/21 107/17 117/20 manufacturer [5] 10/12 33/3 107/22 115/3 133/2 manufacturer's [2] 106/3 107/1 manufacturers [13] 17/14 32/25 54/25 91/10 105/20 107/15 111/18 116/4 118/25 124/8 126/21 133/11 137/18 manufacturing [4] 78/2 97/4 113/16 148/2 manuscript [2] 140/13 140/15 many [10] 2/9 17/13 18/6 28/20 57/25 64/25 71/3 102/5 102/18 135/25 march [22] 2/14 21/4 22/18 28/10 37/16 37/19 38/1 40/11 40/12 49/10 50/4 51/2 71/25 72/5 81/25 100/8 111/13 114/3 117/12 117/18 118/16 121/3 March 1983 [5] 2/14 21/4 71/25 72/5 114/3 March 1984 [4] 37/16 40/11 49/10 51/2 March 1985 [4] 81/25 117/18 118/16 121/3 March 6 [1] 38/1 Marcus [1] 91/4 Margaret [1] 59/9 Margaret Heckler [1] 59/9 margin [1] 123/25 marginalia [1] 116/11 Marietta [1] 40/14 Marilyn [1] 40/15 marked [2] 12/16 66/21 marker [6] 39/12 42/16 56/18 76/1 128/25 134/24 market [21] 18/22 35/6 35/13 53/17 55/1 68/19 76/15 102/23 107/11 110/17 118/19	122/1 123/7 123/13 127/8 127/14 127/16 133/10 134/17 144/4 144/9 marketed [1] 67/18 marketing [3] 20/18 86/17 113/13 marketplace [1] 20/15 markets [6] 13/22 85/8 85/23 97/12 102/25 127/14 marks [2] 117/10 122/5 Maryland [1] 27/20 MASAC [1] 101/9 material [10] 29/19 33/14 36/13 36/14 42/12 81/10 86/19 87/24 116/17 133/9 materials [1] 52/22 matter [8] 10/23 95/16 103/2 105/4 110/10 119/3 129/14 148/23 matters [4] 28/20 52/21 96/8 149/10 maximum [2] 5/6 20/14 may [69] 2/12 3/3 3/4 4/5 7/3 8/11 23/22 27/8 27/9 27/13 31/6 43/12 43/16 43/21 46/16 52/7 52/18 52/23 54/12 55/18 56/1 57/13 58/17 58/25 60/10 60/23 61/5 62/14 65/24 69/22 72/13 74/8 77/10 82/18 84/15 88/7 88/19 89/3 90/3 90/9 95/23 95/25 99/6 99/7 99/24 102/10 107/5 112/25 114/2 114/13 118/14 118/16 120/11 120/14 123/8 123/18 123/19 127/22 128/22 129/3 129/4 129/5 129/8 129/10 129/16 131/4 132/19 141/19 148/8 May 1983 [1] 23/22 May 1984 [4] 52/7 52/18 60/10 60/23 May 1985 [6] 88/7 88/19 89/3 90/9 118/14 118/16 May 1986 [1] 141/19 McClelland [1] 24/24 McDougal [5] 79/11 79/13 137/24 139/14 141/5 McDougal's [1] 80/10 MDUN0000020 [1]
----------	--	---	---	---	--	---

(52) leads - MDUN0000020

F:

M	108/24 109/3 109/20 109/24 110/16 111/3 111/9 111/10 111/13 111/16 111/17 111/25 117/13 121/6 121/7 121/10 122/13 122/17 122/21 126/17 130/10 143/24 144/2 meetings [6] 24/19 62/19 90/11 91/3 101/5 121/8 members [12] 2/14 15/1 16/24 17/13 19/9 38/14 38/23 38/25 39/11 52/20 91/1 149/15 Membership [1] 38/5 memo [1] 30/4 memoranda [1] 88/8 memorandum [44] 4/20 9/3 9/6 9/9 12/17 18/7 34/10 34/17 34/18 40/10 40/14 42/1 51/12 52/18 66/13 85/11 85/14 86/9 86/10 87/5 87/8 88/13 88/17 90/12 90/13 95/4 105/7 108/20 109/25 110/7 110/19 110/24 111/11 111/12 113/18 114/17 114/23 117/12 118/3 122/11 122/12 134/12 138/19 140/2 memorandums [1] 18/6 Memorial [1] 16/19 memory [3] 119/11 129/16 132/20 men [3] 16/21 63/16 131/5 mental [4] 5/21 5/24 6/1 6/16 mention [5] 20/18 41/14 129/15 143/12 143/20 mentioned [18] 5/16 19/24 40/18 60/2 65/5 65/7 71/21 72/8 75/14 76/22 78/15 78/20 92/17 93/5 93/6 94/12 114/9 125/11 merchandise [1] 85/19 merely [2] 28/23 149/5 met [10] 17/12 17/14 20/2 27/11 37/16 38/3 57/7 59/16 75/11 122/16 method [6] 24/5 57/13 66/3 73/20 74/11	74/25 methods [4] 2/25 35/15 67/5 67/13 metropolitan [1] 39/20 Meyer [4] 90/14 91/10 93/1 94/5 Meyer's [1] 94/25 MHRA0000076 [1] 37/21 Michael [3] 17/7 37/24 108/4 microglobulin [1] 40/3 microglobulins [1] 16/1 mid [2] 59/19 103/11 mid-1980s [1] 103/11 Middlesex [1] 26/24 Middleton [3] 66/5 70/7 76/22 might [16] 15/1 31/4 44/4 55/16 61/4 62/10 69/24 72/3 88/9 89/8 94/21 95/6 96/22 110/20 117/1 128/12 Mike [5] 19/11 40/24 111/19 122/19 126/11 mild [1] 82/23 Miles [2] 72/2 73/4 Miller [2] 19/3 19/4 millilitres [1] 136/3 million [13] 2/9 9/11 50/10 50/18 50/21 50/21 57/9 60/3 68/8 68/8 86/21 92/17 94/13 mind [3] 7/13 7/15 67/12 minds [1] 7/7 mine [1] 49/7 minimum [2] 106/11 125/2 minority [2] 39/5 63/14 minute [5] 29/1 47/14 126/15 130/14 131/1 minutes [9] 25/6 25/9 25/10 25/13 26/14 26/20 32/18 96/5 135/7 MIO [1] 9/11 misunderstood [1] 99/7 misuse [1] 2/1 Mitchell [1] 103/15 mix [1] 128/10 mixed [1] 128/4 MMWR [4] 14/15 62/25 80/10 80/14 moderate [1] 82/23 modest [4] 124/9	139/11 141/22 142/12 moment [3] 5/20 47/17 74/1 monitor [1] 5/5 Montagnier [6] 8/1 8/5 8/19 63/3 78/21 119/24 month [11] 7/25 8/23 11/19 23/19 24/3 31/23 52/8 57/9 62/24 63/21 118/8 months [15] 14/14 17/11 19/13 23/3 55/3 57/11 59/10 64/20 65/11 72/1 72/7 104/14 117/23 126/19 130/19 more [32] 19/8 28/6 48/20 55/7 55/12 56/10 56/24 69/14 72/3 73/22 74/9 77/14 78/11 88/1 96/1 97/11 102/1 112/6 112/14 112/14 113/10 115/12 115/13 121/15 125/9 125/16 128/12 128/16 132/9 137/6 141/7 142/23 morning [1] 51/7 most [9] 2/25 3/1 16/8 16/23 98/16 103/11 131/22 133/22 137/3 motivating [1] 19/25 mountain [1] 148/17 mouse [2] 79/20 79/22 move [7] 20/11 27/16 31/12 43/21 51/4 68/18 89/2 moved [2] 3/11 80/1 moves [1] 69/23 moving [7] 7/18 15/6 37/11 62/18 90/3 92/23 121/10 MP [1] 10/5 Mr [15] 9/7 15/19 23/10 25/5 61/16 86/7 129/5 144/12 145/8 145/17 146/7 146/21 147/3 149/9 149/20 Mr Barrowcliffe [1] 86/7 Mr Bishop [2] 9/7 149/20 Mr J [1] 25/5 Mr Justice [2] 129/5 146/21 Mr Justice Krever [7] 15/19 23/10 61/16 144/12 145/8 145/17 149/9 Mr Justice Krever's [2] 146/7 147/3	Ms [1] 149/16 Ms Richards [1] 149/16 much [11] 5/11 33/18 34/3 55/21 109/16 115/12 116/17 130/23 135/24 140/19 149/18 multiple [1] 54/11 must [6] 4/8 36/13 36/14 46/24 53/16 112/18 my [13] 12/23 49/20 53/22 70/18 74/15 102/24 116/7 116/19 119/10 119/22 120/10 128/8 146/10 myself [2] 69/11 111/20	Nevertheless [2] 125/24 142/25 new [17] 4/25 5/9 8/1 16/11 19/7 21/12 23/4 28/13 39/25 40/16 40/20 43/6 74/24 99/14 115/23 134/17 135/13 New York [8] 8/1 28/13 39/25 40/16 43/6 74/24 99/14 135/13 newly [1] 82/20 next [18] 9/22 12/15 17/3 19/14 27/16 29/8 31/12 32/3 36/8 42/3 43/5 43/22 45/14 46/5 55/8 102/5 125/10 126/14 NHF [8] 11/14 22/5 22/10 82/25 84/6 98/12 126/6 131/8 NHF's [1] 83/20 NHS [1] 36/13 NIBSC [5] 24/11 24/18 35/18 51/1 86/5 night [1] 1/8 NIMH [1] 5/24 nine [2] 14/14 72/1 nine months [2] 14/14 72/1 no [60] 2/1 3/22 4/4 13/7 20/18 21/21 28/4 33/4 33/18 33/25 34/4 36/20 36/21 45/21 49/2 49/23 49/23 50/15 61/7 62/16 63/17 65/19 71/14 76/3 76/6 77/11 78/5 82/3 83/12 84/4 84/6 84/12 90/21 91/17 91/23 93/3 96/15 97/1 97/3 97/6 97/14 98/10 99/15 99/16 99/25 101/14 101/19 101/23 107/7 107/22 108/12 110/1 112/16 114/15 115/19 119/2 125/20 126/6 126/17 137/13 no-one [2] 91/23 126/17 nobody [1] 94/25 nodes [1] 61/1 non [77] 32/10 42/18 42/18 44/9 44/9 54/16 54/16 54/18 54/19 56/2 56/2 75/4 75/4 76/1 76/1 76/2 76/2 76/5 76/5 76/19 76/19 78/2 81/24 82/3 82/7 82/15 84/13 84/18 85/4 85/6 85/13 85/17
----------	---	---	---	--	--

(53) MDUN0000020... - non

F:

<p>N</p> <p>non... [45] 86/18 87/10 88/5 88/10 88/15 88/18 88/23 89/4 89/5 90/6 90/17 90/19 90/22 91/15 91/18 91/24 92/15 92/22 94/17 95/6 95/12 95/13 96/11 96/20 97/15 97/23 97/24 98/7 98/25 99/12 99/14 100/20 100/23 101/11 103/12 103/12 106/18 106/18 113/24 124/15 124/15 131/11 131/11 133/23 133/23</p> <p>non-A [12] 42/18 44/9 54/16 54/18 75/4 76/1 76/2 76/5 76/19 103/12 131/11 133/23</p> <p>non-approval [1] 92/15</p> <p>non-B [12] 42/18 44/9 54/16 54/19 75/4 76/1 76/2 76/5 76/19 103/12 131/11 133/23</p> <p>non-existent [1] 106/18</p> <p>non-heat [5] 92/22 98/7 98/25 99/12 99/14</p> <p>non-heat-treated [32] 78/2 81/24 82/3 82/7 82/15 84/13 84/18 85/4 85/6 85/13 85/17 86/18 87/10 88/5 88/10 88/15 88/18 88/23 89/5 90/6 90/22 94/17 95/6 95/12 95/13 96/11 96/20 97/15 97/24 100/20 100/23 106/18</p> <p>non-heated [2] 91/18 101/11</p> <p>non-paid [1] 32/10</p> <p>non-prison [1] 113/24</p> <p>non-treated [1] 91/24</p> <p>non-viral [2] 90/17 90/19</p> <p>noncommercial [1] 38/7</p> <p>none [1] 98/16</p> <p>nonparticipatory [1] 115/22</p> <p>nonprofit [1] 38/8</p> <p>nor [3] 21/15 33/13 123/10</p> <p>normal [21] 28/8 46/22 48/21 58/7 106/10 121/15 122/5</p>	<p>123/11 123/15 123/17 123/18 124/2 125/3 125/4 125/4 125/6 127/6 127/6 127/9 127/10 128/17</p> <p>not [155]</p> <p>notable [1] 50/20</p> <p>notably [1] 61/11</p> <p>note [25] 4/17 18/4 40/13 41/8 41/25 44/13 45/10 50/17 51/6 58/11 69/10 96/18 99/22 102/7 103/4 111/5 112/21 115/19 116/19 118/20 133/4 135/5 136/17 140/20 141/14</p> <p>noted [5] 25/10 35/12 36/15 89/24 140/3</p> <p>notes [1] 68/16</p> <p>nothing [3] 13/23 14/9 105/9</p> <p>notice [1] 23/15</p> <p>notwithstanding [1] 80/23</p> <p>November [10] 1/1 9/1 9/6 23/23 73/1 137/10 137/21 138/14 140/2 149/24</p> <p>November 1983 [3] 9/1 23/23 73/1</p> <p>November 1984 [1] 138/14</p> <p>November 1985 [1] 140/2</p> <p>now [36] 7/17 8/8 8/14 10/8 15/17 23/24 29/3 29/20 32/14 32/17 34/19 44/12 44/13 44/24 45/3 45/17 56/7 60/8 65/17 68/24 71/12 71/22 88/4 89/8 99/2 99/18 103/3 104/5 113/2 115/13 118/20 125/19 131/19 133/6 138/7 149/5</p> <p>NTS [1] 36/12</p> <p>nuisance [2] 147/19 148/7</p> <p>nullify [1] 124/1</p> <p>number [15] 4/8 14/19 18/8 22/25 24/13 39/11 64/10 64/20 71/5 86/23 90/25 102/11 109/7 143/10 145/12</p> <p>number is [1] 86/23</p> <p>number of [1] 64/20</p> <p>numbers [2] 61/7 68/25</p> <p>numerous [1] 36/3</p> <p>NY [2] 93/25 126/21</p>	<p>O</p> <p>o'clock [3] 89/10 149/22 149/22</p> <p>objected [1] 19/10</p> <p>obligation [3] 54/7 145/1 146/22</p> <p>obscured [1] 9/21</p> <p>observed [2] 141/25 142/23</p> <p>obstacles [1] 126/6</p> <p>obtain [2] 20/14 139/23</p> <p>obtained [7] 66/16 67/9 102/21 112/25 113/2 137/8 139/14</p> <p>obtaining [1] 117/3</p> <p>obvious [2] 10/18 107/9</p> <p>obviously [5] 115/21 115/25 132/13 138/14 141/11</p> <p>occur [2] 93/7 93/9</p> <p>occurred [1] 32/20</p> <p>occurrence [2] 14/25 27/3</p> <p>Oct [1] 57/3</p> <p>Oct 1984 [1] 57/3</p> <p>October [19] 11/2 11/5 11/15 11/19 12/2 13/19 21/19 22/11 59/13 67/24 80/6 80/11 81/18 88/16 89/20 102/15 138/1 138/10 144/1</p> <p>October 1983 [5] 11/2 11/19 13/19 21/19 22/11</p> <p>October 1984 [2] 80/6 89/20</p> <p>October 1985 [3] 138/1 138/10 144/1</p> <p>odds [1] 137/7</p> <p>off [7] 44/11 44/11 50/4 99/17 120/9 134/20 146/10</p> <p>offend [1] 126/9</p> <p>offer [4] 13/12 40/4 55/10 123/14</p> <p>offered [2] 88/11 114/19</p> <p>offering [1] 7/1</p> <p>Office [2] 15/9 28/9</p> <p>official [2] 22/10 84/9</p> <p>officially [1] 126/21</p> <p>officials [3] 24/14 28/24 75/12</p> <p>often [3] 70/12 70/23 104/2</p> <p>Ojala [17] 18/5 22/14 37/15 90/10 90/10 91/3 108/3 108/21</p>	<p>109/5 109/15 111/21 118/3 122/11 122/23 133/6 134/12 134/14</p> <p>Ojala's [1] 18/13</p> <p>Okay [1] 8/22</p> <p>omitted [1] 111/1</p> <p>one [27] 5/2 7/13 9/13 19/10 19/15 21/18 25/13 27/2 29/24 32/23 47/11 47/13 48/11 55/9 60/19 74/22 88/21 91/23 93/3 117/2 117/11 121/7 126/15 126/17 128/6 146/14 148/21</p> <p>One possible [1] 27/2</p> <p>ones [3] 21/6 61/11 65/22</p> <p>ongoing [3] 5/4 7/4 7/5</p> <p>only [35] 3/5 21/10 23/5 27/10 28/16 32/12 33/23 42/11 43/3 44/6 45/25 46/9 46/10 49/3 50/1 50/8 53/23 62/16 82/25 88/25 93/19 94/22 109/24 111/18 113/6 121/7 123/20 124/11 128/6 139/9 140/24 142/12 144/15 144/18 144/22</p> <p>onset [2] 4/10 23/7</p> <p>onwards [1] 101/23</p> <p>opaque [1] 130/14</p> <p>open [1] 32/18</p> <p>opened [2] 25/20 134/6</p> <p>operating [2] 30/17 30/21</p> <p>operation [1] 57/23</p> <p>operations [2] 1/11 68/15</p> <p>opinion [5] 39/13 82/10 117/23 144/1 148/17</p> <p>opinions [1] 39/5</p> <p>opportunity [2] 55/12 116/21</p> <p>oppose [1] 63/10</p> <p>opposed [3] 48/17 78/1 147/8</p> <p>optimal [1] 34/3</p> <p>optimistic [2] 59/8 104/15</p> <p>option [1] 28/14</p> <p>or [108] 1/25 1/25 2/2 3/4 4/4 5/13 6/23 7/5 11/3 11/9 13/5 13/10 13/20 13/21 18/6 18/18 19/10 21/15 21/17 25/13 30/13</p>	<p>30/23 31/5 31/14 31/25 34/5 34/7 36/9 36/14 37/12 37/17 38/4 39/8 40/5 43/3 43/5 44/20 48/7 48/13 48/21 50/19 52/14 53/16 53/18 58/1 59/1 59/15 67/17 68/8 69/14 71/4 74/8 77/13 77/24 78/6 79/3 82/23 82/23 83/6 84/19 86/7 88/4 88/5 91/18 94/6 95/17 95/17 95/21 97/4 97/6 97/15 99/7 100/6 101/25 106/3 106/25 107/4 107/12 107/20 108/10 108/12 108/13 110/1 112/12 113/3 113/15 114/16 118/18 123/1 124/1 124/3 126/19 128/6 129/2 129/2 130/12 130/17 130/19 130/21 130/21 131/20 135/1 135/21 136/4 136/21 137/6 142/21 149/9</p> <p>or Gallo [1] 59/1</p> <p>order [10] 6/22 75/25 110/21 118/5 118/15 120/4 121/1 144/6 144/8 148/13</p> <p>organisations [5] 38/9 64/11 95/17 109/10 109/14</p> <p>Organization [2] 82/6 83/10</p> <p>organizations [1] 39/2</p> <p>originally [1] 78/9</p> <p>Osaka [1] 122/16</p> <p>other [44] 5/11 9/13 14/11 17/24 25/11 31/4 33/18 34/9 44/22 47/12 49/9 53/18 54/25 55/13 67/7 67/25 69/19 74/19 86/17 90/25 92/23 96/6 102/25 107/3 107/4 109/16 113/4 114/10 115/16 117/11 119/9 123/9 124/1 124/3 127/14 128/5 128/21 133/10 133/11 136/19 139/5 145/12 145/19 149/15</p> <p>others [8] 5/3 20/19 41/5 48/10 48/14 94/16 122/25 141/5 otherwise [3] 45/8 112/19 129/11</p> <p>ought [1] 3/19</p> <p>our [38] 10/9 10/13</p>	<p>10/14 10/15 10/22 13/5 20/16 20/19 37/3 37/6 37/6 41/17 52/4 57/25 86/16 87/20 87/23 90/11 92/13 92/21 93/21 93/21 94/4 94/6 106/21 115/18 122/19 123/4 125/12 125/13 126/1 126/8 126/9 126/17 127/2 130/12 140/8 140/22</p> <p>ours [1] 90/9</p> <p>out [31] 5/23 6/21 14/18 25/11 26/25 29/21 32/7 34/2 35/13 42/6 42/13 48/24 52/10 53/5 56/6 58/9 59/15 65/18 71/19 73/4 76/17 81/19 83/25 97/13 99/20 105/12 111/6 121/2 129/17 141/3 141/16</p> <p>outlined [1] 27/21</p> <p>outside [3] 62/10 141/17 148/11</p> <p>over [26] 9/15 12/14 16/14 19/14 23/16 35/2 35/16 42/3 42/15 52/24 55/7 61/13 89/5 89/15 89/15 90/6 92/10 106/20 112/11 112/11 112/15 115/6 123/21 126/14 129/11 148/21</p> <p>overall [2] 48/25 58/20</p> <p>overdue [1] 92/8</p> <p>overriding [1] 93/3</p> <p>overseas [1] 85/7</p> <p>overused [1] 36/16</p> <p>overwhelming [1] 27/6</p> <p>own [5] 96/8 110/15 115/18 141/21 142/2</p> <p>owned [3] 10/15 29/11 30/14</p> <hr/> <p>P</p> <p>pack [1] 6/20</p> <p>package [1] 98/20</p> <p>page [40] 1/19 3/9 5/20 12/15 14/17 15/18 15/19 19/14 26/20 27/16 29/3 29/8 32/17 34/15 34/16 36/8 40/16 42/3 42/3 43/23 45/14 47/11 47/14 47/17 52/24 53/2 55/8 60/6 61/15 71/17 92/10 94/10 97/20 101/1 106/20</p>
---	---	---	---	---	--

P	87/6	80/22 81/17 82/21	131/6	29/13 30/21 32/11	104/10 105/1 105/11
page... [5] 114/25	paragraph 238 [2]	82/23 83/1 83/2	personally [2] 11/13	38/8 112/23 116/5	105/12 107/25 111/6
115/6 126/14 142/8	96/17 99/4	101/13 101/15 101/19	145/11	plausible [1] 3/1	112/15 114/18 122/23
144/14	paragraph 254 [1]	102/2 102/18 124/15	personnel [1] 131/7	plays [1] 103/22	124/12 126/18 132/2
page 106 [1] 71/17	108/20	140/23	perspective [1] 34/12	please [46] 3/9 9/5	132/25 133/5 133/7
page 2 [2] 42/3 97/20	paragraph 90 [1]	pause [11] 4/17 41/8	pertinent [2] 74/17	12/14 14/16 15/18	133/15 145/1 145/19
page 3 [2] 26/20	145/22	41/25 44/13 57/4 74/2	106/8	17/3 19/14 20/9 26/20	positions [1] 82/7
43/23	paragraph above [1]	99/2 112/21 133/4	Pete [2] 116/14	29/3 29/8 34/14 36/8	positive [47] 16/13
page 306 [1] 1/19	144/15	140/20 147/17	116/16	37/21 40/11 41/16	16/21 28/6 28/7 39/7
page 325 [1] 3/9	paragraph of [1]	pay [1] 30/10	Pete De Hart [1]	42/3 47/9 47/10 52/17	39/11 42/16 42/17
page 5 [3] 29/3 47/11	26/21	payment [1] 32/11	116/14	52/24 66/20 69/4	43/4 44/12 44/15
47/14	paragraph says [1]	pending [2] 92/15	Peter [6] 40/16 45/14	71/17 85/9 86/8 87/14	47/19 44/24 45/4
page 529 [1] 144/14	122/14	92/20	131/2 143/10 143/23	90/7 90/7 92/10 97/17	46/10 46/12 48/4
page 6 [1] 34/15	paragraph starting [1]	Penny [4] 108/2	144/10	97/20 98/21 100/25	48/21 50/2 50/10 53/9
page 7 [1] 101/1	27/19	122/15 124/21 126/11	Petricciani [15] 25/1	105/15 105/16 111/11	54/2 54/3 54/5 54/12
page 76 [1] 14/17	paragraphs [1]	people [16] 18/8	27/19 27/20 28/20	121/8 123/19 126/14	54/15 54/20 55/11
page 770 [1] 15/18	113/21	22/25 23/1 25/25	33/1 33/4 35/4 36/15	140/1 140/4 142/4	55/19 56/14 56/15
page 772 [1] 61/15	parallel [1] 88/15	29/10 40/13 48/2 48/6	90/24 105/14 111/7	142/8 143/5 144/13	57/19 58/6 60/13 61/3
page 9 [1] 32/17	parameters [1]	48/7 48/9 48/11 62/22	111/16 112/4 126/12	plus [2] 57/15 124/22	61/20 63/4 87/3 98/16
page in [1] 47/17	113/19	63/4 64/1 64/21 80/15	138/2	pm [5] 10/5 10/6	105/6 105/25 108/6
pages [1] 32/13	parent [3] 66/16 71/23	per [40] 16/12 16/14	Petricciani's [1] 27/17	89/11 89/13 149/23	108/9 110/6 122/5
pages 9 [1] 32/13	140/10	16/22 28/7 28/8 44/19	pharma [1] 71/1	point [27] 3/11 17/21	123/3 124/20
paid [5] 10/1 32/4	parenthesis [1]	46/14 48/6 48/7 48/8	pharmaceutical [5]	26/17 30/3 37/8 41/16	positively [1] 106/10
32/10 35/14 92/3	136/17	48/15 48/19 48/22	1/4 73/15 134/10	45/20 47/3 49/9 58/20	positives [2] 44/2
panel [3] 121/6	Paris [1] 120/3	49/4 50/1 50/10 50/14	149/13 150/3	64/5 64/13 65/2 73/4	44/8
122/20 123/2	parroted [2] 41/24	50/18 50/21 55/24	phone [1] 98/14	74/17 76/4 84/5 94/22	positivity [2] 47/1
paper [4] 27/14 27/17	51/21	57/9 60/18 60/21	phrase [1] 117/11	96/22 118/20 119/9	61/22
28/17 29/2	part [13] 9/8 34/1	60/23 61/1 61/2 61/18	PHS [1] 2/13	125/18 128/21 130/24	possession [1] 13/5
papers [3] 39/4 41/14	34/21 59/19 65/1	61/20 63/12 63/16	physical [1] 36/7	136/15 138/16 146/11	possibility [3] 10/11
70/23	86/22 103/23 104/7	68/9 68/13 68/16	physicians [2] 80/4	point 5 [1] 41/16	78/3 117/16
paragraph [35] 3/10	129/24 135/3 145/12	68/22 87/25 88/9	80/8	pointed [4] 26/25	possible [14] 3/6
5/21 5/23 17/3 18/12	148/7 148/21	111/6 121/23 121/24	pick [6] 18/12 42/4	29/21 32/7 141/3	20/14 27/2 27/5 27/12
25/11 25/17 26/21	partially [1] 53/23	127/3	42/7 43/24 64/1	points [2] 25/14 81/19	28/5 31/3 39/10 55/18
27/19 31/12 31/13	participate [1] 115/24	perceived [2] 8/25	114/25	policies [1] 35/1	86/25 88/3 91/25
32/3 40/25 52/5 58/14	particular [12] 13/21	124/13	picked [4] 8/13 8/16	policy [9] 11/17 11/20	128/2 129/11
63/6 63/25 68/4 75/16	13/22 15/13 29/19	percent [1] 54/3	75/1 143/21	12/6 12/8 13/12 21/23	possibly [3] 27/7
87/6 90/1 94/11 96/17	75/5 92/12 95/18	percentage [3] 45/2	piece [2] 7/2 89/16	22/6 52/8 52/15	48/13 94/16
99/4 101/3 101/7	95/19 123/6 123/12	46/25 47/2	Pier [1] 102/15	political [3] 35/11	post [1] 54/16
105/16 108/20 113/6	123/23 138/21	perfected [1] 143/21	pilot [7] 15/24 39/19	112/17 112/20	posted [1] 85/25
113/21 122/13 122/14	particularly [10] 1/23	performance [1]	40/2 41/15 46/9 49/24	pool [13] 26/16 26/18	postulated [1] 37/6
142/9 144/15 145/22	8/7 49/13 70/5 76/19	91/13	49/25	32/24 33/4 34/5 35/24	potent [1] 20/18
Paragraph 1 [1] 40/25	79/10 103/5 112/17	performed [1] 15/24	Pindyck [3] 16/9	36/1 99/11 107/20	potential [12] 4/11
paragraph 173 [1]	143/24 145/19	performing [1] 112/3	40/19 43/5	127/11 127/18 128/4	17/1 17/9 18/24 35/19
25/11	partners [1] 1/24	perhaps [9] 7/6 23/14	pipeline' [1] 124/10	128/7	38/4 38/14 56/19
paragraph 184 [1]	parts [3] 5/14 15/12	32/5 48/11 50/20	place [29] 1/9 3/13	pool sizes [1] 26/16	56/21 91/22 114/24
25/17	25/9	71/22 72/2 94/21	15/10 18/10 21/7	pooled [2] 3/24 13/9	115/25
paragraph 198 [1]	pass [2] 31/5 45/7	132/15	24/20 32/19 33/6 45/9	pools [12] 13/1 13/7	potentially [4] 18/18
52/5	passages [1] 34/12	period [16] 2/23 3/4	51/3 52/8 58/16 59/19	14/2 32/23 33/9 34/4	57/21 128/12 128/14
paragraph 202 [1]	passed [1] 78/15	8/4 22/2 71/25 73/13	73/19 75/11 79/10	35/25 44/1 106/12	power [1] 136/3
58/14	past [2] 105/24 112/8	76/13 85/2 87/13	79/17 80/17 89/3 90/4	121/16 128/11 128/12	practicable [1] 34/5
paragraph 203 [1]	paste [1] 124/22	102/1 112/25 118/2	96/7 104/25 108/16	population [4] 39/15	practically [1] 36/20
90/1	pasteurisation [2]	130/17 130/20 131/17	109/21 111/3 111/10	48/1 56/19 102/2	practice [2] 124/4
paragraph 205 [1]	67/15 72/18	133/14	121/18 129/1 130/11	populations [2] 53/20	132/6
63/6	pasteurised [3] 24/2	permission [3] 139/24	placed [3] 23/10 58/4	54/3	pragmatic [2] 80/21
paragraph 207 [1]	67/10 72/22	139/24 141/2	127/11	posed [1] 134/17	81/3
63/25	Pasteurized [1]	perpetually [1] 125/22	plane [1] 111/21	position [41] 5/15	pre [4] 12/22 75/9
paragraph 215 [1]	140/14	persist [1] 30/9	planning [1] 5/25	11/7 18/1 22/10 28/22	84/25 96/8
68/4	patient [4] 4/15 64/22	person [5] 11/9 48/12	plans [3] 20/19 99/16	38/21 39/4 41/14	pre-dated [1] 75/9
paragraph 219 [1]	83/9 107/21	48/12 49/12 101/23	122/19	45/12 53/19 60/9 64/5	pre-empt [1] 84/25
75/16	patients [22] 3/17 6/6	person-to-person [1]	plasma [183]	78/16 83/12 83/17	pre-empting [1] 96/8
paragraph 233 [1]	6/9 7/20 7/21 7/24	48/12	plasmapheresis [10]	83/20 84/9 92/19 95/8	pre-existing [1] 12/22
	66/25 76/22 77/11	personal [3] 8/19 22/7	10/16 21/7 29/6 29/9	95/9 95/11 99/6 99/21	precautionary [1]

(55) page... - precautionary

<p>P</p> <p>precautionary... [1] 52/3</p> <p>preceded [1] 109/24</p> <p>precedent [1] 93/18</p> <p>precisely [2] 49/7 61/4</p> <p>preclude [2] 91/19 125/14</p> <p>precludes [1] 140/7</p> <p>predict [1] 3/6</p> <p>prediction [1] 104/13</p> <p>predominantly [1] 64/7</p> <p>preferred [1] 82/19</p> <p>preliminary [5] 62/25 80/11 126/13 138/25 149/5</p> <p>preparations [2] 81/11 142/20</p> <p>prepare [1] 115/17</p> <p>prepared [11] 18/5 25/7 27/15 33/9 34/11 39/4 40/7 40/10 41/14 63/1 141/2</p> <p>prescient [1] 20/11</p> <p>prescription [1] 81/9</p> <p>presence [1] 40/4</p> <p>present [12] 2/7 20/17 24/14 24/19 24/21 33/23 76/12 86/6 91/5 102/4 111/18 115/21</p> <p>presentation [31] 1/3 25/12 25/18 27/18 28/19 52/6 58/14 63/7 64/1 65/18 65/20 67/8 68/5 75/16 77/17 87/7 90/2 99/5 104/1 104/7 108/21 111/1 123/4 132/11 132/12 133/14 135/4 148/16 148/25 149/11 150/2</p> <p>presentations [5] 32/20 74/6 80/18 149/12 149/14</p> <p>presented [6] 8/2 37/18 63/9 70/23 78/23 79/7</p> <p>presenting [3] 27/14 73/19 120/4</p> <p>presently [1] 137/17</p> <p>president [1] 132/17</p> <p>press [6] 57/1 58/25 59/3 108/23 116/1 116/7</p> <p>pressure [1] 64/18</p> <p>pressures [1] 19/24</p> <p>presumably [8] 27/4 45/6 48/1 96/24 109/9 110/14 119/5 127/14</p> <p>prevailing [1] 39/12</p>	<p>prevalence [2] 46/18 46/21</p> <p>prevalent [1] 132/9</p> <p>prevent [2] 103/9 108/13</p> <p>prevented [1] 95/11</p> <p>previous [10] 13/10 17/14 19/16 24/20 60/1 83/12 86/10 88/8 133/25 148/22</p> <p>previously [8] 12/19 13/16 33/15 44/4 74/13 82/21 105/5 137/8</p> <p>price [5] 63/14 85/16 87/24 88/1 88/9</p> <p>prices [1] 54/23</p> <p>primarily [1] 132/12</p> <p>Prince [17] 104/2 104/3 135/5 135/13 136/25 138/7 138/23 139/6 139/20 140/7 140/13 140/22 141/11 141/15 142/10 144/19 148/15</p> <p>Prince's [11] 137/7 138/11 138/21 139/1 139/17 143/6 144/18 144/21 144/25 145/7 145/14</p> <p>prior [2] 10/6 41/17</p> <p>priority [4] 66/22 66/24 67/7 74/23</p> <p>prison [32] 12/7 13/2 13/4 13/8 14/15 14/21 21/19 30/7 30/24 31/2 111/25 112/3 112/10 112/14 113/4 113/23 113/24 114/11 114/16 116/18 116/19 117/16 125/15 125/21 126/1 126/9 129/25 130/5 131/2 131/14 132/4 134/7</p> <p>prisoners [2] 13/17 112/13</p> <p>prisons [11] 11/21 12/21 30/5 30/18 30/22 31/3 112/8 112/24 114/7 114/8 117/3</p> <p>privately [3] 28/15 37/4 39/21</p> <p>probable [1] 60/24</p> <p>probably [9] 9/17 20/22 32/11 36/12 37/6 48/11 116/25 134/19 142/23</p> <p>problem [4] 45/24 93/11 94/6 123/19</p> <p>problems [4] 75/23 92/12 112/8 134/18</p>	<p>procedure [1] 142/14</p> <p>procedures [8] 4/25 5/9 29/6 36/19 36/22 58/1 124/17 137/17</p> <p>proceeding [1] 67/21</p> <p>proceedings [1] 88/22</p> <p>process [21] 13/1 66/18 74/6 83/16 89/22 91/12 91/15 92/2 93/21 107/17 107/24 120/24 120/25 135/15 135/23 136/8 138/18 139/11 139/18 142/1 142/13</p> <p>process' [3] 106/5 107/2 107/6</p> <p>processed [3] 13/10 108/8 108/10</p> <p>processes [9] 10/15 21/3 21/12 24/8 75/24 91/21 93/13 93/25 135/17</p> <p>processing [3] 35/15 38/9 142/20</p> <p>procession [1] 36/6</p> <p>procured [1] 56/12</p> <p>Procurement [1] 57/23</p> <p>prodromal [1] 40/5</p> <p>prodrome [3] 50/8 54/3 61/3</p> <p>produce [3] 91/18 91/24 109/5</p> <p>produced [9] 21/14 46/18 54/19 83/23 96/24 106/15 109/11 134/23 136/16</p> <p>producers [1] 90/15</p> <p>producing [1] 133/16</p> <p>product [90] 3/17 5/2 6/14 9/2 11/1 13/11 18/20 21/20 22/19 29/18 31/15 31/22 32/9 37/6 42/10 53/11 56/22 57/9 60/2 60/4 64/19 65/8 66/25 67/10 67/10 67/16 67/17 68/10 69/9 70/6 72/9 72/22 72/23 72/25 73/7 73/8 73/9 76/7 77/2 80/9 82/4 84/4 84/24 85/3 85/4 86/23 86/24 86/25 87/1 87/10 88/5 88/9 88/10 88/23 91/14 91/18 92/18 93/21 94/14 95/13 95/21 95/22 97/12 98/4 99/23 100/18 104/4 106/3 106/15 108/11 108/11 109/23 122/7</p>	<p>123/16 124/22 125/3 125/5 126/11 130/11 132/21 134/4 135/23 136/9 136/12 136/13 136/16 143/15 143/17 144/4 148/3</p> <p>production [3] 55/3 96/11 123/22</p> <p>productions [2] 4/13 90/17</p> <p>products [168]</p> <p>professional [2] 146/16 146/18</p> <p>Professor [3] 81/19 102/15 143/19</p> <p>Professor Mannucci [1] 143/19</p> <p>Professor Mannucci's [1] 81/19</p> <p>Profilate [3] 24/6 72/14 99/23</p> <p>Profiline [1] 99/14</p> <p>profit [1] 87/11</p> <p>profound [1] 26/25</p> <p>Program [1] 16/11</p> <p>programme [2] 58/12 58/21</p> <p>programmes [1] 39/3</p> <p>programs [1] 39/13</p> <p>progress [4] 4/25 69/13 71/8 85/25</p> <p>progressed [2] 66/15 125/18</p> <p>prohibited [1] 144/19</p> <p>project [7] 10/22 68/12 68/15 68/17 69/8 86/1 117/25</p> <p>projected [1] 68/20</p> <p>prompt [1] 109/17</p> <p>promptly [3] 12/9 12/24 145/3</p> <p>proof [2] 53/17 146/13</p> <p>Proplex [4] 96/12 99/1 99/5 99/11</p> <p>proposal [12] 19/10 19/15 92/12 106/21 107/8 108/5 110/20 128/10 130/3 130/4 131/6 134/21</p> <p>propose [2] 107/21 125/25</p> <p>proposed [6] 12/16 19/11 84/2 92/22 130/21 135/18</p> <p>proposing [1] 134/13</p> <p>proposition [2] 11/11 108/14</p> <p>pros [2] 53/4 58/9</p> <p>prosecution [2] 145/13 147/11</p> <p>prospect [1] 63/19</p> <p>prospective [1] 21/13</p>	<p>protagonists [1] 148/19</p> <p>protect [3] 52/3 127/23 144/8</p> <p>protection [3] 44/5 133/21 133/24</p> <p>protein [2] 75/20 75/21</p> <p>proteins [2] 27/7 66/1</p> <p>prove [1] 104/14</p> <p>provide [7] 19/13 19/17 39/22 44/6 54/8 65/19 79/12</p> <p>provided [11] 6/25 37/19 50/9 50/12 50/25 52/23 64/22 105/3 105/7 136/25 139/1</p> <p>providers [1] 6/10</p> <p>provides [3] 55/12 119/13 126/11</p> <p>providing [5] 6/7 66/7 97/12 104/20 147/4</p> <p>provisions [1] 125/12</p> <p>PRSE0002534 [1] 142/4</p> <p>PRSE0003071 [1] 25/8</p> <p>prudent [1] 82/3</p> <p>psychological [4] 6/3 6/5 6/17 7/12</p> <p>PTC [2] 91/11 92/14</p> <p>public [14] 2/17 2/24 4/16 19/24 52/13 63/22 91/20 92/6 96/14 100/13 108/16 108/18 109/3 141/1</p> <p>public.' [1] 144/24</p> <p>publication [7] 19/7 21/4 23/4 62/25 139/24 144/21 144/25</p> <p>publicly [2] 51/23 62/13</p> <p>publish [5] 81/13 139/21 141/2 141/13 141/18</p> <p>published [6] 61/17 79/19 80/9 137/22 138/9 138/15</p> <p>publishing [2] 140/7 144/20</p> <p>purchase [3] 12/20 13/6 81/6</p> <p>purchased [1] 98/2</p> <p>Purification [1] 142/20</p> <p>purpose [7] 5/13 38/11 38/25 62/17 75/8 113/16 135/15</p> <p>purposes [3] 28/16 107/4 126/8</p> <p>pursue [2] 116/13</p>	<p>116/25</p> <p>pushed [1] 132/22</p> <p>put [15] 11/12 13/12 21/7 23/14 47/11 73/16 108/1 110/4 110/20 121/17 127/3 129/1 130/2 134/14 134/19</p> <p>putative [1] 3/1</p> <p>putting [2] 60/16 108/14</p> <hr/> <p>Q</p> <p>qualified [1] 145/6</p> <p>quality [1] 10/18</p> <p>quantities [1] 57/7</p> <p>quantity [3] 120/21 135/16 138/22</p> <p>quarantine [2] 56/15 130/17</p> <p>quarter [1] 68/24</p> <p>Quarterly [1] 69/13</p> <p>question [10] 35/5 41/2 70/18 74/15 82/14 89/4 90/5 109/23 116/12 116/14</p> <p>questionable [1] 149/2</p> <p>questioned [2] 43/1 91/15</p> <p>questioning [1] 115/15</p> <p>questions [7] 9/18 10/3 12/13 29/16 44/10 50/6 77/8</p> <p>quickly [3] 94/6 101/8 118/6</p> <p>quietly [1] 92/5</p> <p>quite [3] 9/22 71/8 128/2</p> <p>quotation [4] 110/7 110/11 117/10 122/5</p> <p>quote [42] 12/18 23/13 31/20 32/21 42/8 42/23 43/6 43/7 45/15 45/23 46/6 50/5 56/6 68/17 76/25 77/25 81/8 83/18 83/19 88/24 97/10 101/6 108/22 110/11 113/22 115/1 118/1 118/4 118/22 119/2 131/8 132/2 133/1 137/1 137/15 139/10 139/15 141/22 144/1 144/17 145/23 146/17</p> <p>quoted [2] 23/11 43/5</p> <p>quotes [1] 116/10</p> <hr/> <p>R</p> <p>Radiation [1] 67/3</p> <p>raised [3] 47/3 109/22</p>
--	---	---	---	---	---

(56) precautionary... - raised

R	108/12 109/23 114/16 126/18 130/12 132/19 recalled [6] 9/10 21/16 21/21 22/24 99/10 134/4 recalls [4] 22/3 31/14 31/15 42/11 received [9] 2/9 7/21 23/25 28/25 30/12 70/24 72/21 98/15 149/17 receiving [2] 112/6 140/23 recent [1] 85/15 recently [2] 9/14 10/21 recipients [3] 27/3 142/19 143/3 recognise [1] 82/18 recognised [2] 25/22 33/16 recognized [1] 39/6 recollect [1] 129/16 recommend [3] 20/13 82/11 126/7 recommendation [8] 11/6 19/2 19/12 100/9 100/10 100/11 101/10 116/8 recommendations [8] 2/13 2/18 2/19 21/4 34/20 37/20 82/17 83/3 recommended [10] 4/3 17/6 18/13 18/15 36/22 39/19 40/2 41/16 41/18 83/13 recommending [2] 18/1 98/3 record [7] 37/9 40/7 45/20 75/14 100/19 140/4 144/2 recorded [5] 25/25 80/14 88/13 100/18 131/5 recording [1] 26/22 records [3] 29/15 50/23 112/11 recover [1] 96/12 recovered [1] 20/6 recruiting [1] 16/16 rectify [1] 111/2 Red [8] 8/24 11/3 19/3 23/22 40/17 45/15 91/6 147/23 reduce [8] 34/6 42/9 44/5 44/12 44/17 44/24 53/11 57/20 reduced [3] 42/18 57/24 136/2 reduces [1] 78/6 reducing [1] 86/20	reduction [8] 17/10 34/4 79/16 135/25 136/4 136/6 138/5 138/7 redundancy [1] 57/17 refer [4] 50/19 71/6 84/24 99/4 reference [25] 5/9 7/23 18/3 18/7 28/1 31/13 31/23 43/10 52/5 58/13 59/11 69/11 86/23 94/23 97/14 109/9 110/24 110/25 114/3 114/13 117/1 123/1 124/19 127/17 144/16 references [6] 5/10 63/5 63/25 71/4 77/16 148/23 referred [16] 6/19 22/14 37/12 67/8 69/8 72/16 86/10 87/6 87/8 102/16 104/2 114/2 114/9 131/1 133/5 148/20 referring [3] 117/13 131/12 132/15 refers [9] 12/3 40/12 49/21 49/24 52/22 108/22 109/8 111/13 118/3 reflected [1] 131/7 reflection [1] 3/3 refrain [1] 41/19 regard [1] 12/6 regarding [3] 4/4 9/18 87/20 Regards [1] 10/24 Regier [1] 10/25 regime [1] 70/13 regimes [1] 133/19 registration [1] 93/7 regret [1] 10/10 regular [2] 87/20 90/10 regulating [1] 31/9 regulation [1] 100/9 regulator [6] 9/25 121/17 144/17 147/4 147/9 147/13 regulators [1] 121/14 regulatory [14] 4/4 11/16 22/1 89/4 90/5 92/2 95/11 100/3 100/6 100/16 110/21 114/15 126/3 127/15 Reilly [11] 40/20 91/7 105/13 105/17 109/15 111/19 112/3 115/23 122/18 125/11 125/22 Reilly's [2] 109/23 111/6	reintroducing [1] 134/7 rejected [2] 105/3 133/9 rejection [2] 50/9 63/12 relabel [1] 85/22 relate [1] 61/21 related [5] 42/22 51/4 61/19 121/11 145/2 relating [2] 1/3 150/2 relation [1] 4/11 relations [1] 63/22 relatively [2] 18/21 134/24 relatives [1] 6/10 relaxing [1] 113/24 relevant [1] 129/22 reluctance [2] 77/4 122/25 relying [1] 143/1 remain [1] 43/25 remainder [1] 13/6 remained [3] 30/22 69/21 91/25 remaining [2] 87/9 123/7 remains [2] 13/5 123/8 remark [1] 98/16 remarkably [1] 118/2 remember [2] 120/9 146/10 remind [2] 10/14 47/21 removal [2] 67/2 107/10 remove [3] 93/3 98/25 142/21 renamed [1] 101/22 renamed HIV [1] 101/22 render [1] 128/11 rendered [2] 140/17 143/13 rendering [1] 60/8 renew [1] 12/22 repeat [1] 141/17 repeated [2] 27/6 50/22 replace [2] 16/17 96/13 replaced [2] 2/18 99/6 replacing [1] 97/15 replied [2] 33/4 93/1 report [27] 14/18 14/22 15/16 17/11 18/9 37/17 37/19 38/16 39/3 51/1 61/15 61/16 62/25 63/10 69/13 71/19 85/15 100/18 118/11 119/12	144/13 145/5 145/9 146/8 146/22 147/25 148/5 reported [12] 5/17 8/10 14/15 14/19 16/12 42/17 62/12 79/21 93/11 139/7 141/5 142/18 reportedly [2] 99/12 99/13 reporting [1] 122/12 reports [4] 42/15 53/25 60/11 81/13 represent [2] 116/2 116/21 representative [2] 17/8 25/4 representatives [9] 1/11 17/13 25/2 38/6 41/10 41/12 91/6 104/25 109/7 represented [1] 39/2 reputation [2] 10/17 146/19 request [2] 109/20 129/1 requested [3] 33/2 91/16 111/16 requesting [1] 98/6 requests [1] 88/25 require [1] 3/17 required [10] 16/17 19/5 19/5 46/8 59/18 66/14 123/9 139/23 143/4 148/12 requirement [7] 17/18 19/20 57/24 95/5 121/18 127/22 128/22 requirements [11] 4/4 18/17 57/8 100/3 100/6 100/16 121/14 124/9 127/15 133/3 133/10 research [13] 5/25 6/1 15/23 28/16 66/12 68/6 68/7 69/12 70/19 71/6 71/8 144/20 144/22 reservations [1] 17/22 residual [1] 135/24 resigned [1] 64/14 resisted [1] 64/11 resolved [1] 125/1 resource [1] 28/23 Resources [4] 40/21 91/7 105/13 116/4 respect [8] 63/23 75/4 78/16 131/14 131/17 134/16 142/16 148/15 respected [1] 139/5 respond [1] 93/19	responded [3] 12/9 92/11 131/6 response [12] 1/4 1/13 88/12 88/25 97/19 111/8 121/13 126/17 130/4 130/9 132/13 150/2 responsibility [2] 20/6 98/18 responsible [6] 8/3 31/24 52/21 133/9 146/16 146/17 responsibly [1] 148/14 rest [4] 29/12 87/4 93/16 117/9 restated [2] 11/14 22/10 restating [1] 11/6 result [6] 23/20 33/6 54/21 81/14 138/4 149/14 resulted [1] 142/2 resulting [1] 70/6 results [22] 8/11 16/10 64/22 78/23 79/6 79/20 80/10 80/11 87/3 120/4 124/20 126/24 136/25 137/7 137/11 137/22 139/14 139/17 139/21 141/4 141/18 144/5 retrospective [2] 54/14 126/22 retrovirus [2] 79/20 79/22 retroviruses [1] 79/23 return [3] 98/3 98/6 129/12 returning [4] 89/14 99/9 116/5 131/14 returns [2] 86/11 98/10 reversal [1] 133/25 reversed [1] 83/12 review [9] 38/11 92/20 92/21 93/8 93/11 94/1 94/3 102/14 126/18 reviewed [7] 15/23 18/22 52/9 92/24 93/15 94/24 125/10 revised [1] 82/17 revisiting [1] 117/16 Revlon [2] 108/4 140/10 Revlon/Armour [1] 108/4 revoke [1] 92/1 reworked [2] 92/18 94/14 RHCG [1] 140/9
----------	---	---	---	---	--

(57) raised... - RHCG

R	running [2] 15/12 110/12 Ryan [3] 126/7 130/25 131/24	82/2 84/4 99/2 101/6 109/16 110/3 130/3 133/13 146/6 148/10 saying [10] 11/13 47/24 49/10 49/12 51/16 51/17 60/10 81/3 84/12 105/8 says [20] 9/9 12/4 12/12 12/18 14/23 32/20 37/25 45/20 46/2 87/17 90/13 97/21 113/21 116/15 118/11 122/14 125/20 130/19 146/14 146/21 scale [2] 121/1 148/16 scenario [1] 84/1 scepticism [5] 43/17 59/14 59/14 76/16 79/9 scheduled [2] 19/6 20/8 science [1] 125/17 scientific [11] 3/13 33/17 35/10 80/6 96/15 108/24 112/16 112/18 118/1 140/25 144/23 scientists [2] 2/24 143/25 Scottish [1] 24/25 screen [23] 9/5 14/16 34/14 43/22 47/10 52/17 55/6 60/16 66/20 69/4 71/16 85/9 87/14 90/7 97/17 99/17 105/15 121/8 124/9 124/11 125/18 133/2 140/1 screened [6] 20/17 55/4 55/5 56/3 124/7 133/17 screening [26] 9/19 18/16 21/3 21/12 33/21 34/2 42/9 42/25 53/22 55/2 55/9 55/20 56/24 57/5 57/8 63/20 64/17 102/21 103/6 104/5 108/19 109/4 110/2 120/21 123/6 133/19 screening/selection [1] 9/19 script [1] 122/23 search [1] 2/25 Seattle [2] 124/16 124/24 second [16] 9/2 17/20 47/21 52/24 58/11 60/6 67/6 75/3 106/11 107/14 110/18 113/6 122/7 130/8 142/8 147/16	second page [1] 60/6 Secondly [1] 40/1 Secretary [6] 1/16 59/3 59/9 59/16 62/21 104/11 Secretary Heckler [1] 62/21 section [7] 26/21 32/18 34/15 67/12 73/14 89/6 101/1 section just [1] 101/1 see [30] 12/15 14/21 17/23 17/24 22/22 34/16 36/11 37/22 43/20 47/18 47/24 52/18 52/25 69/15 70/12 86/9 87/15 96/7 97/20 105/12 108/2 109/18 110/18 110/22 113/3 113/5 117/9 130/3 135/16 135/24 seeing [1] 91/2 seek [5] 65/23 75/25 93/12 110/15 111/2 seeking [2] 93/22 132/21 seem [3] 37/3 99/22 132/9 seemed [2] 37/1 68/22 seemingly [1] 4/20 seems [8] 8/14 8/18 24/16 44/13 61/21 74/22 95/3 108/5 seen [12] 7/23 11/22 18/5 22/6 37/15 63/23 65/13 74/9 75/10 78/12 132/7 134/12 sees [3] 45/21 45/24 121/10 segment [2] 43/9 46/8 segments [1] 42/14 segregated [1] 107/2 select [1] 124/11 selected [1] 134/23 selecting [1] 123/5 selection [1] 9/19 selectivity [1] 43/8 self [1] 28/12 self-exclusion [1] 28/12 sell [6] 85/6 85/19 86/25 94/19 94/19 121/19 selling [2] 85/22 97/6 send [3] 12/10 87/16 91/17 sending [1] 147/8 senior [1] 90/14 sense [1] 93/22 sensitive [1] 141/8 sensitivity [1] 149/1	sent [16] 6/21 13/22 18/8 52/19 87/6 87/15 88/7 88/20 98/1 98/5 116/14 126/21 130/10 132/17 139/21 146/24 sentence [2] 94/11 94/22 sentences [1] 36/24 separation [4] 55/11 58/2 58/3 74/12 September [22] 7/25 8/18 8/23 23/23 26/17 66/22 67/7 67/23 75/11 75/19 76/12 79/18 79/19 79/24 80/1 80/18 81/18 102/15 102/24 104/24 105/10 132/16 September 1979 [2] 66/22 67/7 September 1982 [1] 76/12 September 1983 [3] 7/25 8/23 23/23 September 1984 [6] 79/18 79/19 79/24 80/1 104/24 105/10 September 1986 [1] 102/24 sequence [1] 14/13 series [1] 83/25 seroconversion [2] 142/18 143/3 seroconversions [3] 102/12 143/10 143/19 serologic [1] 39/12 servant [1] 86/4 serve [1] 126/8 Service [5] 2/17 2/24 4/16 24/25 147/22 Services [2] 1/18 117/19 set [11] 13/21 14/18 25/11 53/5 56/6 58/9 65/18 105/12 111/5 134/18 141/16 sets [3] 52/10 71/19 83/25 setting [3] 42/6 79/15 99/20 seven [4] 48/19 56/4 84/16 117/23 seven months [1] 117/23 several [10] 6/2 9/13 15/24 19/9 50/10 50/18 92/21 106/7 133/11 148/18 severe [3] 82/20 82/21 83/2 severity [1] 93/23 sexually [1] 1/23	shall [3] 51/7 89/9 135/8 share [3] 55/1 68/19 144/8 she [11] 16/12 43/5 43/7 145/16 145/16 146/6 146/10 146/11 146/13 147/10 148/12 she's [1] 146/12 shell [1] 142/24 shipment [1] 112/9 short [8] 7/2 51/10 73/13 93/13 101/4 113/20 118/2 135/4 shortage [4] 42/12 46/1 107/13 115/13 shortages [1] 63/14 shortened [1] 78/14 shortly [2] 57/5 90/1 should [58] 3/22 10/5 10/13 10/20 11/24 19/5 20/5 21/20 28/15 32/22 33/10 34/1 35/6 36/5 36/10 36/12 37/5 37/8 38/19 39/14 39/15 39/23 41/18 42/20 45/4 45/16 45/21 50/10 54/18 54/21 57/19 72/8 80/4 81/4 82/8 82/14 82/25 83/7 89/5 89/16 90/6 93/4 94/25 96/25 103/25 105/23 106/1 106/4 107/7 107/22 111/24 114/4 116/3 121/16 128/21 138/24 142/14 146/24 shouldn't [1] 84/12 show [5] 35/25 50/9 54/14 109/3 137/2 showed [10] 30/4 30/5 31/17 46/17 46/18 46/20 63/3 69/14 78/25 119/19 showing [5] 58/15 62/2 81/1 81/14 107/23 shown [5] 29/25 54/4 98/18 107/18 109/6 shows [4] 14/19 49/20 52/7 84/1 sic [1] 54/16 side [3] 24/15 25/23 47/11 side-effect [1] 25/23 signed [1] 116/15 significance [1] 72/13 significant [3] 55/23 56/16 71/11 significantly [2] 46/20 86/20 signs [1] 33/11
----------	--	--	--	---	---

(58) Richard - signs

F:

S	9/25 11/17 12/2 13/18 14/5 14/14 15/14 16/6 18/6 23/21 31/6 40/22 43/14 43/23 44/3 46/13 46/21 47/21 47/23 48/1 48/18 48/19 50/12 51/19 52/11 52/12 53/4 56/4 58/9 60/18 60/21 60/25 61/20 62/4 62/17 63/2 64/2 64/4 64/13 64/18 65/8 66/9 67/5 67/11 69/13 69/24 70/14 71/1 72/4 72/7 72/18 72/23 73/2 73/13 76/11 77/4 78/8 79/6 79/24 80/25 82/12 83/3 83/10 84/4 85/1 88/16 88/21 89/8 92/4 93/17 95/8 95/8 95/10 97/6 99/24 100/15 101/10 101/23 104/19 105/9 108/5 108/11 109/11 109/17 110/9 110/14 111/3 112/4 113/12 114/13 115/23 116/4 116/8 117/12 118/6 118/15 120/1 120/23 120/25 121/7 121/12 121/24 122/7 123/10 123/22 128/2 128/10 129/6 129/18 130/14 133/11 134/3 135/11 135/19 136/1 136/21 136/22 137/13 138/12 141/18 141/19 143/20 145/8 147/3 148/4 149/22 so-called [1] 46/21 socio [1] 112/17 socio/political [1] 112/17 softening [1] 45/12 sold [5] 88/14 95/7 95/12 99/13 127/8 sole [1] 68/25 solicitors [1] 88/21 solution [3] 67/11 67/16 136/21 solve [1] 94/6 solved [1] 92/5 solvent [1] 74/24 some [58] 3/12 7/7 8/24 17/22 19/23 21/24 23/10 24/19 29/9 29/19 30/13 31/20 34/12 35/16 36/17 42/2 42/4 44/22 46/13 49/17 51/14 63/21 66/12 70/20 70/21 71/4 72/13 74/5 75/1 75/17 75/18	76/11 76/16 77/5 77/16 79/3 85/5 85/19 91/12 92/20 94/16 96/7 101/4 113/15 120/7 122/24 124/1 125/12 128/23 130/1 130/16 132/13 134/4 136/19 142/24 148/24 148/24 149/3 some of [2] 75/17 75/18 someone [1] 123/1 something [14] 10/11 22/14 22/17 52/12 61/24 71/10 81/17 97/19 110/17 114/20 119/16 129/14 129/16 135/6 sometimes [2] 37/12 100/11 somewhat [5] 11/12 22/7 56/10 59/8 141/12 somewhere [3] 113/13 116/20 130/22 soon [3] 88/3 93/7 93/9 sophisticated [1] 2/25 sorry [19] 15/4 31/12 34/15 34/17 42/5 43/23 45/1 46/24 47/13 55/16 83/1 90/22 99/9 101/18 108/17 111/24 115/10 122/3 128/21 sort [1] 66/2 sought [3] 73/10 85/6 105/2 Soumik [7] 1/18 7/17 15/4 25/6 47/10 60/5 69/4 source [9] 17/19 34/9 41/3 90/11 111/25 112/7 116/22 123/8 143/7 sources [7] 17/24 112/10 112/14 115/16 125/21 132/23 139/5 SP [2] 42/20 45/25 speak [3] 41/23 51/20 104/1 speaking [3] 25/20 61/9 87/23 special [5] 4/2 90/15 94/2 109/8 123/6 specific [14] 25/14 28/4 33/14 50/7 52/1 56/20 56/24 63/20 64/15 88/25 89/25 99/25 109/16 109/22 specifically [11] 6/13 31/2 33/2 70/17 84/23	93/6 108/18 114/8 131/10 134/23 146/11 specificity [3] 4/9 45/17 63/12 specifies [1] 48/10 specify [1] 13/20 specimens [1] 3/3 speculate [1] 61/8 speed [1] 73/2 spent [5] 68/6 68/9 68/12 68/14 69/1 spike [1] 135/20 spiked [2] 69/16 79/13 split [2] 47/10 134/9 spoke [3] 91/21 93/10 109/15 spread [1] 2/2 Srigley [8] 12/1 40/23 41/5 41/10 41/22 42/23 42/24 51/19 St [2] 19/3 82/1 St Thomas' [1] 82/1 stabilised [1] 69/20 stabilisers [1] 69/24 staff [1] 58/5 stage [9] 5/3 7/8 17/25 42/1 74/22 76/5 80/25 103/18 138/12 stages [1] 37/9 staggered [1] 92/22 standard [4] 77/12 136/5 139/20 146/13 standards [3] 10/18 24/10 86/5 start [3] 17/21 45/16 149/13 starting [7] 18/13 27/19 41/19 58/23 92/23 105/17 124/21 Startup [1] 55/22 state [6] 39/9 59/4 123/5 123/11 139/9 140/18 State' [1] 140/15 stated [15] 19/4 20/5 34/25 35/5 35/18 36/10 88/22 89/21 93/15 115/3 115/16 115/25 117/23 129/19 132/25 statement [21] 1/15 1/20 3/8 3/11 4/19 4/22 5/14 6/20 13/15 37/23 37/25 38/19 59/8 77/4 96/14 96/18 100/13 114/19 117/22 118/9 118/22 states [24] 7/8 7/22 14/20 24/20 26/3 29/10 29/13 29/21 30/21 36/16 37/11	62/23 64/24 81/25 84/19 84/20 89/3 98/1 101/24 102/3 104/8 104/16 112/24 125/21 stating [4] 36/4 36/21 66/13 91/17 stations [4] 29/9 29/13 30/21 112/24 statistically [1] 61/9 status [2] 111/23 112/2 statute [1] 147/16 steal [1] 22/18 step [1] 93/23 stepped [1] 148/11 steps [8] 7/2 21/5 22/1 96/9 100/1 100/15 105/23 142/20 sterilisation [2] 142/12 143/2 Steve [7] 79/11 108/3 108/3 111/20 111/20 115/21 122/15 sticks [1] 132/19 still [22] 35/5 35/8 36/3 45/1 60/22 79/8 84/14 84/18 85/5 86/21 91/24 95/7 96/23 97/8 102/11 103/12 106/2 107/14 113/2 131/9 131/19 143/4 stock [2] 85/7 94/16 stop [4] 30/5 30/18 78/2 82/14 stopped [1] 96/19 storage [1] 106/25 stored [1] 106/2 story [3] 65/22 103/19 103/23 strategies [2] 27/21 27/23 stress [3] 6/3 62/12 104/7 stressed [1] 142/15 strict [1] 64/3 strikingly [1] 61/6 strong [1] 2/22 stronger [1] 56/1 strongly [3] 11/10 78/1 80/8 struck [1] 17/9 struggling [1] 35/5 stuck [1] 45/18 studies [25] 15/25 16/2 16/7 40/2 41/15 54/14 66/7 66/10 78/23 80/25 101/13 112/12 114/24 135/14 137/11 138/12 138/17 139/4 139/7 142/17 145/14 145/19 146/1	146/9 146/23 study [28] 23/5 37/12 37/24 38/1 38/6 38/16 38/21 39/6 39/13 39/18 39/18 39/19 40/1 46/9 49/24 49/25 61/17 62/12 63/8 111/23 112/2 113/3 113/19 115/3 137/1 137/4 138/21 141/8 subcommittee [2] 1/10 77/21 subheading [1] 144/15 subject [9] 33/15 42/22 102/17 111/23 111/24 112/2 115/20 125/16 125/23 subjected [3] 79/14 102/19 133/18 submission [1] 20/16 submissions [2] 92/20 93/8 submitted [2] 1/15 140/13 subsequent [7] 32/9 38/2 45/11 84/11 101/13 124/14 136/9 subsequently [6] 2/18 32/24 53/15 88/20 106/24 137/22 subsidiary [2] 9/8 66/17 subsidise [1] 87/9 substantial [1] 116/22 substantiate [1] 16/25 success [1] 74/10 successful [1] 34/6 successfully [2] 22/13 64/11 succinctly [1] 105/8 such [34] 4/8 4/9 5/2 7/6 12/22 12/25 17/2 18/1 21/16 22/3 23/21 33/11 33/25 38/24 52/21 60/21 64/12 66/2 81/6 84/6 87/12 90/11 92/9 93/17 102/22 103/11 103/17 106/1 106/5 112/5 115/3 134/3 143/3 146/3 suddenly [1] 101/13 suffer [1] 47/2 sufficed [1] 32/11 sufficient [4] 89/21 100/2 118/23 120/21 sufficiently [2] 50/7 139/19 suggest [5] 10/4 68/25 99/5 117/2 125/9
----------	---	---	--	---	---

(59) similar - suggest

F:

S	49/4	team's [1] 8/2	38/22 38/24 39/3	79/6 83/1 83/18 89/6	91/22 92/1 96/23 98/2
suggested [8] 2/14	suspenders' [1] 57/17	technical [3] 68/15	39/13 40/2 41/3 41/9	90/1 90/8 94/8 96/17	100/1 100/15 102/4
8/2 17/8 27/8 34/20	suspension [3] 72/18	100/12 148/25	41/19 42/2 42/13	98/12 99/2 101/9	102/18 103/7 107/10
69/18 81/7 110/19	72/19 136/21	technique [2] 67/15	43/18 45/3 49/18 50/9	105/9 108/15 110/25	107/12 112/16 115/7
suggestion [6] 17/12	switch [1] 80/22	136/10	51/6 51/16 51/24	111/19 113/9 119/16	115/11 120/16 121/7
44/14 49/21 128/19	swollen [1] 60/25	techniques [2] 70/2	52/11 52/16 53/1 53/4	121/12 121/24 122/25	132/13 133/22 133/25
130/1 146/21	sympathize [1] 93/2	79/14	53/8 55/22 56/5 56/9	123/13 124/19 125/10	140/23 140/24 141/13
suggestions [3] 10/1	symptoms [4] 4/10	Tedder [5] 24/22	56/11 56/22 57/12	129/24 137/20 138/12	142/25 149/14
128/24 130/6	31/20 33/11 102/5	26/22 26/24 27/14	57/25 58/12 58/23	140/10 147/24	thesis [1] 146/7
suggestive [1] 11/10	Syndrome [1] 38/15	120/14	59/23 63/9 63/18 64/8	their [41] 8/20 20/1	they [88] 6/24 7/4
suggests [4] 43/12	system [7] 6/3 27/6	telecon [1] 12/3	64/12 64/14 64/22	21/12 21/25 28/15	13/17 16/19 17/17
44/11 45/25 68/5	29/17 39/24 141/4	telex [1] 98/4	68/24 89/18 89/19	28/25 32/6 32/12	21/5 21/10 22/22 25/7
suit [1] 39/2	141/4 141/9	tell [1] 110/8	89/24 105/19 105/22	39/22 46/21 62/15	25/14 30/10 30/11
sum [1] 59/25	systems [1] 27/2	tells [1] 97/18	110/17 110/21 112/5	73/11 73/11 73/16	30/16 36/1 36/5 36/11
summarise [4] 64/5	T	temperature [3] 72/11	115/14 117/14 117/15	75/19 76/18 77/9	36/11 36/14 39/1
68/3 108/20 133/15	T-cell [1] 16/4	73/5 93/20	118/7 118/11 118/17	80/24 83/5 84/2 86/17	39/14 51/17 51/17
summarised [1] 15/16	table [12] 14/18 46/17	temperatures [3]	119/9 120/7 120/22	93/23 95/17 95/17	51/18 61/8 62/9 63/2
summarising [1]	47/6 47/7 47/19 47/23	67/14 93/13 93/17	121/12 122/9 122/19	96/8 109/3 110/1	63/11 63/16 65/10
28/21	49/11 49/21 71/19	tempore [1] 71/15	122/22 125/19 126/4	110/15 115/2 118/25	66/2 71/20 72/20
summarized [1] 16/10	78/12 119/12 136/11	tending [1] 37/3	126/10 126/22 127/2	120/5 121/20 124/16	73/21 74/7 74/12
summarizing [1] 39/4	tabular [1] 119/16	term [3] 4/12 124/1	128/22 128/24 129/6	124/25 131/25 138/18	77/10 77/13 79/5 81/1
summary [13] 4/18	tackle [1] 78/10	143/2	129/23 129/24 131/16	139/22 144/5 144/6	81/13 84/4 84/5 92/12
17/23 20/20 21/1	tactic [4] 17/16 19/18	terms [1] 118/1	131/18 132/8 134/16	144/8 145/18	94/18 95/21 95/23
25/18 29/1 34/19	22/15 37/15	Terry [2] 24/23 140/3	134/20	them [22] 10/3 28/22	95/25 101/24 104/18
37/23 40/25 41/13	Taiwan [1] 85/20	test [60] 16/15 16/22	testing' [1] 17/17	31/9 35/25 36/11	109/4 110/3 110/3
51/1 75/17 125/2	take [44] 1/14 5/9	17/10 22/16 33/23	tests [26] 15/23 15/24	60/16 60/16 62/17	110/8 110/9 112/5
summation [1] 5/15	5/12 6/18 7/3 7/17	36/19 36/21 41/21	16/6 28/4 33/21 43/12	64/1 76/3 78/11 95/17	112/6 112/8 112/13
summed [3] 36/4	13/13 15/4 15/17 20/5	42/5 42/19 44/11	46/4 56/24 57/5 59/6	96/13 99/15 104/20	112/14 112/18 113/24
36/20 105/8	22/1 25/16 28/1 43/10	45/17 45/18 45/22	59/10 59/12 59/17	107/13 110/10 125/14	114/7 115/4 117/3
summoned [1] 124/23	45/9 48/25 49/19 52/2	45/25 46/1 46/7 49/14	63/2 63/2 63/15 64/18	139/7 146/23 146/24	118/4 119/7 120/3
Sunday [1] 10/6	59/19 61/13 61/16	50/6 52/1 55/2 55/6	104/18 109/4 110/13	149/17	120/20 121/20 124/13
sunk [1] 55/22	66/23 72/3 74/1 76/24	55/21 56/20 57/2	119/1 119/4 120/16	themselves [2] 95/11	124/15 125/20 125/22
supplied [3] 21/8	77/5 80/21 87/5 89/7	60/25 63/11 63/20	120/21 121/1 144/5	134/14	126/23 128/12 130/2
88/24 97/13	89/9 90/19 94/9 95/11	64/15 76/6 89/25	tests/day [1] 46/4	then [44] 3/8 12/12	132/1 137/12 138/1
suppliers [2] 57/25	95/14 96/22 99/17	102/21 103/6 104/5	Texas [5] 30/1 31/14	13/12 23/3 27/12	139/7 140/17 146/9
141/10	107/22 111/4 111/10	104/13 104/21 105/25	31/15 31/24 31/25	27/16 30/11 33/9	146/23 146/24 147/9
supplies [1] 5/7	102/72 111/4 111/10	106/11 109/7 109/11	text [6] 12/5 12/15	36/25 44/16 44/20	147/19 149/1 149/14
supply [6] 4/12 5/5	128/6 135/6 135/18	109/13 109/17 110/2	12/16 28/19 91/9	46/2 47/11 51/8 56/6	they'd [1] 30/10
21/10 21/23 29/12	143/5 146/5	110/5 110/5 117/20	140/4	57/16 59/22 60/25	they're [8] 25/10
33/19	taken [26] 13/17	117/25 118/5 118/9	than [33] 19/8 28/7	62/20 70/16 72/2	37/21 48/19 62/4 65/5
support [3] 6/8 6/9	14/17 24/16 24/20	118/24 119/20 120/23	32/6 46/21 48/20	72/20 72/25 76/13	69/2 128/2 144/7
133/7	33/6 33/19 40/6 41/4	120/24 121/12 123/9	48/21 54/13 54/19	77/23 79/13 80/1	they've [2] 14/18
supported [2] 140/8	51/2 64/16 68/3 70/14	129/20 141/3 141/4	55/17 56/10 60/16	80/13 84/4 85/2 89/9	143/13
146/1	71/18 75/1 81/4 89/5	141/8 148/12	61/23 73/6 73/8 87/11	107/21 108/8 113/18	thing [1] 40/13
supposed [3] 3/21	90/6 94/24 100/1	tested [12] 44/15	91/4 102/2 108/23	113/24 114/23 114/24	think [34] 3/19 7/10
3/22 130/4	105/23 107/8 110/22	56/13 57/10 58/2 58/4	109/16 121/15 123/21	117/14 119/17 122/14	9/11 10/5 11/23 14/1
sure [4] 8/16 9/22	114/15 130/11 140/24	61/19 63/4 105/6	124/2 125/3 125/6	127/11 135/21 146/24	32/13 36/12 37/8
35/18 37/5	143/6	121/24 127/4 135/1	127/5 127/19 128/12	149/19	43/21 44/23 45/16
surface [7] 54/5 55/15	takes [2] 64/2 126/2	135/24	128/16 136/23 137/3	Therapeutics [1]	47/18 49/19 55/16
55/16 58/6 58/6	taking [10] 3/12 6/14	testimony [2] 5/11	137/6 137/13 142/23	29/24	58/16 59/11 62/1
105/22 112/9	29/20 30/5 30/18	148/19	thank [16] 7/16 7/17	there [164]	69/20 70/1 70/18
surmise [1] 48/11	79/10 79/17 96/8	testing [110] 8/6 15/7	15/3 40/6 47/22 65/12	thereby [1] 57/20	71/12 72/3 94/20
surprisingly [1]	110/25 131/9	15/11 15/14 16/1 16/9	87/2 90/23 96/2	therefore [7] 30/10	99/17 100/11 100/12
141/22	talk [2] 105/9 114/23	16/11 16/18 16/25	116/19 116/24 128/15	41/9 74/10 106/21	119/12 129/4 146/25
surrogate [7] 15/7	talking [1] 37/4	17/2 17/7 17/23 18/2	143/22 146/5 148/9	119/8 121/19 141/1	147/1 147/10 148/8
15/11 15/23 16/6	target [3] 57/6 59/15	18/16 18/19 18/23	149/18	these [47] 4/24 9/1	148/10
22/12 28/1 128/24	114/24	19/4 19/19 19/19	that [876]	11/2 15/1 16/6 16/24	thinks [3] 124/17
surveillance [1] 143/2	task [9] 17/8 17/15	19/21 19/25 20/6	that's [45] 5/20 9/11	25/9 25/13 29/11	124/19 124/21
survive [1] 66/2	19/11 19/17 20/4 20/7	20/12 20/13 20/22	24/5 26/11 34/25 37/9	29/22 52/2 52/22	third [6] 9/2 18/12
suspect [1] 35/4	22/14 37/11 37/17	20/25 22/12 27/25	37/14 44/3 44/19	59/16 66/10 68/25	29/11 105/16 106/16
suspected [2] 46/11	team [5] 78/21 120/3	28/2 32/16 34/1 37/13	50/12 60/2 61/25 62/3	70/12 71/21 73/2 77/5	130/9
	139/1 139/6 149/15	37/23 38/4 38/12	66/9 67/11 72/24 78/8	77/14 83/3 84/17 91/2	thirds [1] 63/5

(60) suggested - thirds

F:

T	Thymosinal [1] 16/4 time [44] 4/10 4/11 5/6 5/16 9/15 9/17 11/17 12/11 15/11 20/21 28/25 36/22 38/20 43/20 51/6 60/9 62/13 64/13 67/17 67/20 68/1 69/2 71/12 73/9 78/12 78/15 83/10 85/8 89/7 89/20 89/22 91/13 92/20 93/19 99/21 99/24 133/16 135/5 135/11 136/5 136/24 137/13 138/11 145/24 timely [1] 145/5 times [8] 48/20 93/13 123/11 123/15 123/18 124/2 127/10 128/16 timetable [1] 94/5 to [837] Toby [2] 40/21 46/5 Toby Simon [1] 46/5 today [3] 65/19 65/23 149/11 together [3] 8/21 125/25 134/15 told [4] 37/5 46/10 49/3 140/22 tomorrow [4] 9/8 84/22 149/19 149/22 too [1] 95/7 took [20] 1/9 11/20 15/10 18/9 32/19 52/8 58/16 73/19 75/10 80/17 84/23 89/3 90/4 96/6 104/25 108/16 109/21 111/3 111/10 117/23 top [9] 15/19 43/24 53/6 66/24 94/10 111/14 119/10 120/9 146/10 topic [3] 51/5 121/11 129/12 topics [2] 75/17 127/1 total [6] 68/6 68/13 68/22 87/11 107/11 124/7 towards [3] 70/19 74/11 109/6 trace [1] 58/19 traced [3] 61/19 62/7 81/2 trade [3] 82/6 91/8 111/19 Tragic [5] 7/19 76/24 78/22 100/22 102/8 Tragically [1] 102/1 transcript [2] 143/13 143/21 transfer [1] 85/16	transfusion [11] 1/25 2/6 2/8 7/24 24/25 26/8 42/19 48/13 61/19 126/24 129/6 transfusions [6] 2/10 2/12 7/21 19/9 23/1 23/16 transmissible [1] 27/10 transmission [11] 10/19 19/8 34/6 54/16 57/21 63/13 66/9 96/16 102/17 133/21 142/17 transmit [4] 54/18 81/16 127/25 144/18 transmitted [3] 1/21 1/23 23/15 transmitting [4] 4/1 46/11 49/5 106/16 Travenol [4] 13/15 25/4 66/16 66/24 Travenol's [1] 12/6 treat [5] 20/16 57/13 92/18 94/14 125/20 treated [99] 8/7 11/1 13/23 14/10 22/19 24/1 35/17 35/20 65/15 65/16 68/1 73/11 73/17 74/9 76/15 76/15 77/6 77/12 77/13 77/19 78/2 78/4 80/4 80/9 80/23 81/24 82/3 82/7 82/11 82/13 82/15 82/18 82/25 83/5 83/15 83/16 84/13 84/18 85/2 85/4 85/6 85/8 85/13 85/17 85/23 86/18 87/1 87/10 88/5 88/5 88/10 88/14 88/15 88/18 88/23 89/5 90/6 90/20 90/21 90/22 91/15 91/24 94/17 95/6 95/6 95/12 95/13 96/1 96/11 96/13 96/20 97/15 97/24 98/7 98/25 99/13 99/14 99/24 100/20 100/23 102/11 102/13 103/8 103/8 103/13 104/3 106/18 108/12 123/24 131/23 133/17 133/23 134/4 136/15 142/16 142/19 143/9 143/17 148/3 treating [3] 75/19 91/21 93/12 treatment [57] 3/17 5/10 18/24 24/5 24/7 39/24 53/18 57/15	65/17 65/21 66/3 66/7 66/12 67/13 70/13 73/5 74/18 74/22 75/8 76/20 78/6 79/1 79/21 79/25 80/19 81/21 82/17 83/17 84/2 89/7 89/14 89/22 90/3 97/10 102/18 102/20 103/5 103/5 103/20 103/22 107/17 107/24 117/15 120/6 126/11 131/15 131/16 135/15 136/23 137/12 137/18 138/3 138/18 139/18 140/25 142/6 144/23 Trevor [2] 85/21 86/3 trial [5] 81/15 81/19 124/16 145/23 148/21 trials [5] 15/12 67/21 76/9 76/9 76/10 trip [1] 85/15 true [3] 27/8 67/15 72/18 truthful [2] 10/2 32/5 try [7] 65/19 116/8 120/9 125/25 126/12 147/17 149/4 trying [2] 119/18 130/15 Tuddenham [3] 87/15 87/18 88/12 turn [10] 12/14 29/3 32/17 34/9 47/17 52/24 65/17 104/5 119/3 142/8 turned [2] 74/11 76/17 Turning [3] 23/3 76/13 115/6 turns [1] 59/15 twice [4] 121/15 122/5 127/6 127/9 two [24] 2/11 16/1 25/13 26/1 26/3 27/9 39/17 39/20 59/2 62/4 62/6 62/19 63/5 64/9 64/15 65/10 67/5 72/21 79/3 86/22 115/8 115/12 124/15 128/6 two days [1] 59/2 two years [2] 115/8 115/12 two-thirds [1] 63/5 types [2] 35/21 140/21	73/12 78/16 86/15 87/17 88/18 95/24 102/22 120/6 136/16 UK application [1] 73/12 UK fractionators [1] 24/14 UK position [1] 78/16 UK's [1] 24/10 Ultrafiltration [1] 67/4 Ultrafiltration/Glycine [1] 67/4 unable [3] 57/25 132/5 137/2 unacceptable [1] 93/14 unanimity [1] 39/17 uncertainty [1] 145/24 uncomfortable [1] 112/15 under [7] 10/4 10/7 16/12 29/12 68/21 142/22 147/25 undermined [2] 11/12 22/7 underpinned [1] 149/3 understand [3] 49/7 70/22 119/18 understanding [7] 28/24 98/23 102/24 119/23 127/2 128/5 128/8 understood [1] 93/1 undertake [1] 135/14 undertaken [1] 75/8 undertaking [1] 113/2 undertakings [1] 21/9 underused [1] 36/18 unfortunate [1] 10/10 Unfortunately [2] 3/5 9/21 unheated [2] 97/6 97/9 uniformly [1] 91/17 unilaterally [2] 22/16 64/17 unit [5] 87/25 88/9 92/17 94/13 108/6 United [31] 7/8 7/22 14/20 21/8 24/20 26/3 26/4 29/13 29/21 30/21 36/16 37/11 62/23 64/24 77/16 81/25 82/4 84/24 85/13 85/18 86/12 87/13 88/16 89/3 98/1 101/24 102/3 104/8 104/9 104/16 112/24 United Kingdom [11] 21/8 26/4 77/16 82/4	84/24 85/13 85/18 86/12 87/13 88/16 104/9 United States [16] 7/8 7/22 24/20 26/3 29/13 29/21 30/21 36/16 37/11 64/24 89/3 98/1 102/3 104/8 104/16 112/24 units [10] 9/12 16/16 42/17 86/21 87/22 96/12 106/5 106/23 112/10 126/19 universal [1] 17/12 unless [3] 41/21 51/18 126/2 unlikely [3] 53/19 62/14 118/24 unpack [1] 126/25 unpooled [1] 126/19 unreasonable [1] 146/2 unsafe [3] 128/19 142/16 144/4 untested [2] 54/13 127/12 until [22] 8/13 13/18 21/19 30/12 37/18 51/8 52/1 53/17 58/19 59/19 64/13 65/2 80/25 82/24 88/16 89/19 100/19 118/10 118/23 123/16 124/25 149/24 untreated [3] 36/14 82/21 97/4 unwelcome [1] 122/8 up [27] 5/13 8/13 8/16 13/13 13/18 18/12 25/6 28/18 31/13 36/4 36/20 42/4 42/7 43/24 45/2 47/9 51/2 60/16 64/1 65/2 68/2 75/1 100/25 105/8 114/25 130/16 143/21 upcoming [1] 122/20 Update [1] 97/21 upon [6] 4/12 19/15 21/16 52/4 52/14 74/21 upper [1] 123/15 us [40] 5/20 9/3 15/17 20/17 24/13 25/1 26/1 28/22 28/25 29/1 29/7 32/23 35/1 35/6 37/2 37/7 56/10 64/2 67/18 75/12 85/16 92/9 96/22 97/7 97/18 104/19 112/22 118/10 118/19 118/24 121/23 121/25 122/9 124/7 125/14 127/3 133/11
----------	---	--	---	---	--

(61) thirty - us

F:

<p>U</p> <p>us... [3] 133/16 134/20 149/19</p> <p>US companies [1] 9/3</p> <p>US counterparts [1] 29/1</p> <p>US debate [1] 28/22</p> <p>USA [3] 96/20 101/15 101/20</p> <p>use [33] 12/6 12/25 30/11 31/2 35/24 36/14 38/12 41/21 48/14 53/10 54/7 57/14 76/1 76/8 77/2 78/12 81/10 82/11 82/13 82/14 82/22 83/5 90/17 95/12 95/21 102/10 102/12 119/8 122/4 123/2 123/17 130/5 132/4</p> <p>use/productions/licen se [1] 90/17</p> <p>used [50] 8/6 12/5 12/16 12/17 13/7 13/21 13/24 14/2 14/6 19/23 26/16 28/15 29/6 31/4 39/23 39/24 45/4 55/20 66/3 67/14 69/19 81/17 82/4 82/8 85/4 96/12 100/24 101/11 102/19 106/12 107/4 108/7 110/6 113/1 114/11 117/11 120/20 121/25 122/6 123/11 123/15 123/22 127/7 127/12 127/19 133/6 137/13 137/17 138/23 139/2</p> <p>usefulness [1] 16/9</p> <p>users [6] 48/8 53/21 54/1 60/12 60/20 62/11</p> <p>using [16] 2/24 11/20 41/21 63/1 76/3 83/24 93/17 95/22 107/17 109/3 113/15 120/3 126/1 126/9 133/9 135/18</p> <p>usually [1] 91/5</p> <p>utility [1] 91/15</p> <p>utilization [1] 97/6</p> <p>utilized [2] 39/25 123/8</p> <p>utilizing [1] 141/8</p> <p>V</p> <p>validity [1] 44/10</p> <p>value [4] 33/24 35/24 85/16 92/13</p> <p>Van [1] 25/5</p> <p>Van Kalster [1] 25/5</p>	<p>variables [1] 4/8</p> <p>various [5] 15/23 16/7 67/18 80/12 80/16</p> <p>vary [1] 124/8</p> <p>vast [2] 118/13 118/18</p> <p>Vaughan [1] 116/15</p> <p>versus [1] 35/24</p> <p>very [23] 4/2 9/18 13/18 35/1 35/12 35/23 37/2 49/6 60/18 60/22 61/1 65/21 67/20 88/8 98/15 106/11 107/13 107/13 109/16 112/15 135/10 149/16 149/18</p> <p>vested [1] 49/13</p> <p>via [1] 123/5</p> <p>vials [6] 9/10 83/23 86/19 86/22 86/24 87/21</p> <p>victims [3] 6/13 56/21 126/24</p> <p>view [15] 23/17 37/8 43/14 64/16 66/7 84/2 118/21 119/9 134/6 137/20 145/8 145/18 146/14 148/13 149/9</p> <p>viewed [1] 39/10</p> <p>viewpoints [1] 125/17</p> <p>views [4] 22/8 26/23 130/1 131/8</p> <p>VIII [24] 11/1 24/3 33/20 65/25 67/1 69/7 70/3 70/13 70/17 72/6 72/9 72/12 77/12 81/24 85/24 96/20 99/23 100/24 102/19 135/15 137/14 140/21 142/19 143/14</p> <p>viral [15] 8/6 66/3 67/5 74/20 78/18 79/16 81/1 90/17 90/19 91/12 91/22 107/18 120/5 141/20 141/23</p> <p>virus [36] 8/3 16/3 27/5 44/9 44/9 54/13 57/22 65/14 69/15 69/20 71/9 75/25 79/4 79/14 83/19 84/3 91/14 106/17 107/23 119/23 127/25 128/3 128/4 135/19 135/24 135/25 136/2 136/7 137/14 137/19 137/19 138/22 139/2 140/17 142/21 142/23</p> <p>virus-free [1] 140/17</p> <p>viruses [4] 3/2 27/12 76/1 131/22</p> <p>Vivian [1] 103/14</p>	<p>volume [2] 42/13 98/10</p> <p>voluntary [2] 27/23 43/10</p> <p>volunteer [6] 32/6 35/13 42/14 43/9 45/24 46/8</p> <p>volunteers [1] 32/10</p> <p>vote [2] 41/4 45/11</p> <p>voted [3] 41/5 41/13 49/15</p> <p>W</p> <p>wait [1] 117/9</p> <p>waiting [1] 64/14</p> <p>wake [1] 148/18</p> <p>Walford [1] 77/18</p> <p>want [10] 92/2 110/3 110/20 116/1 116/13 116/25 123/10 124/13 129/3 129/17</p> <p>wanted [5] 92/8 94/19 95/21 115/3 139/20</p> <p>wanting [1] 49/13</p> <p>ward [1] 134/20</p> <p>wary [1] 130/14</p> <p>was [355]</p> <p>was made [1] 147/11</p> <p>Washington [1] 124/23</p> <p>wasn't [7] 37/5 37/18 75/13 82/24 100/9 108/18 114/11</p> <p>waste [1] 45/8</p> <p>watch [1] 37/2</p> <p>water [1] 2/2</p> <p>way [11] 14/10 15/17 34/6 70/11 95/24 97/12 113/19 114/4 115/17 121/24 123/20</p> <p>we [280]</p> <p>we'll [5] 54/6 59/20 104/4 110/22 117/9</p> <p>we're [5] 17/19 34/19 47/17 48/3 64/3</p> <p>we've [18] 11/22 18/5 25/9 34/21 47/12 59/12 64/4 72/17 75/10 78/12 78/15 88/8 91/2 130/13 135/11 143/18 148/20 149/17</p> <p>Wednesday [1] 1/1</p> <p>week [5] 13/2 13/3 13/10 13/18 126/13</p> <p>weeks [3] 13/10 51/22 139/3</p> <p>weight [1] 23/10</p> <p>well [33] 7/14 9/24 14/1 16/16 25/22 39/16 51/7 61/24 67/8 67/13 74/21 78/16</p>	<p>79/2 83/3 90/25 94/9 94/20 102/16 103/23 117/6 120/14 127/22 128/23 129/3 129/13 131/11 135/8 135/10 145/12 146/19 148/6 149/7 149/18</p> <p>well-deserved [1] 146/19</p> <p>well-documented [1] 102/16</p> <p>went [5] 28/21 63/24 71/21 112/4 148/11</p> <p>were [171]</p> <p>weren't [1] 102/25</p> <p>Western [1] 110/5</p> <p>wet [1] 72/16</p> <p>what [72] 2/5 2/20 5/15 7/9 9/9 9/22 11/24 12/4 12/17 15/19 25/22 28/24 31/24 32/22 34/9 34/22 35/2 35/6 37/2 37/24 40/25 46/16 47/7 47/24 48/10 49/7 50/2 50/17 50/20 58/22 59/16 61/14 62/1 68/3 69/1 69/2 74/7 74/16 88/12 89/4 89/4 90/5 95/14 97/21 101/5 105/17 105/23 106/1 106/4 109/1 109/8 110/22 111/15 114/1 114/9 114/18 115/2 119/14 119/19 121/2 122/3 122/7 129/18 130/3 130/25 131/8 132/5 132/8 143/14 146/11 146/21 147/14</p> <p>what's [2] 37/12 104/1</p> <p>whatever [4] 46/7 95/18 126/4 146/9</p> <p>when [29] 3/6 10/2 21/20 27/11 30/4 32/23 35/3 36/11 43/1 52/8 64/13 65/8 70/11 71/19 71/20 73/18 76/14 79/6 81/10 105/23 115/2 119/7 119/14 129/23 140/17 141/4 141/24 143/20 147/6</p> <p>where [15] 8/2 23/5 45/13 46/18 64/3 73/25 75/11 84/21 85/2 94/8 103/19 105/5 127/4 127/9 135/3</p> <p>whereas [3] 62/1 134/25 143/14</p> <p>whether [27] 6/23</p>	<p>13/20 13/22 16/24 31/25 33/2 36/9 38/13 39/22 44/20 50/17 52/14 57/6 59/15 69/23 75/23 79/3 82/9 82/14 83/6 88/4 95/21 113/3 117/8 129/2 130/21 135/16</p> <p>WHF [1] 98/12</p> <p>which [150] 1/14 2/12 2/14 3/24 4/5 6/22 7/14 8/5 8/16 8/20 10/3 11/22 12/5 13/2 13/5 13/5 13/13 14/18 14/22 15/17 16/3 17/17 25/11 26/3 27/10 27/14 28/18 29/17 30/1 30/11 30/22 31/4 31/19 33/10 33/12 33/15 33/19 34/10 43/7 44/15 44/17 46/17 49/25 50/22 52/20 58/16 58/24 60/9 60/15 62/25 64/2 66/25 67/6 67/15 68/12 68/15 68/21 68/22 69/16 71/6 71/19 71/23 72/2 72/8 73/2 73/7 74/5 74/20 75/4 75/22 76/6 76/9 76/17 77/11 78/25 80/3 81/15 81/22 83/4 83/22 83/25 87/6 88/10 89/2 93/13 94/17 95/5 95/10 95/11 96/6 97/18 99/3 99/4 99/5 102/14 102/20 103/13 105/1 105/7 105/9 105/21 106/7 106/13 107/1 107/17 107/19 107/20 108/6 108/7 108/20 109/9 109/11 110/5 110/24 111/1 113/21 114/4 114/15 117/2 117/11 117/13 119/3 119/13 119/22 120/16 121/11 122/11 123/8 126/11 127/20 127/25 129/15 129/16 130/16 131/19 132/4 132/19 132/22 135/6 136/2 136/20 138/3 139/2 140/7 146/7 146/23 147/9 148/12 148/21 149/6</p> <p>while [5] 84/13 102/9 103/4 140/22 141/11</p> <p>whilst [1] 144/4</p> <p>who [44] 1/16 6/13 7/21 11/9 20/10 23/12</p>	<p>29/22 29/24 31/20 32/1 40/13 40/24 41/6 47/2 47/8 48/2 48/6 48/6 48/7 48/9 48/12 48/17 48/17 49/12 52/4 62/10 77/22 83/9 86/2 86/9 90/14 91/5 93/12 98/1 102/18 104/20 105/23 119/14 121/18 130/25 132/17 132/17 134/2 137/24</p> <p>whoever [1] 113/12</p> <p>whole [8] 1/12 19/5 19/23 23/14 39/16 40/1 51/15 128/7</p> <p>wholly [1] 10/15</p> <p>whom [4] 9/7 39/11 61/18 62/6</p> <p>whose [1] 40/14</p> <p>why [11] 31/6 58/18 59/11 65/18 92/11 99/25 112/5 115/15 124/19 127/17 129/1</p> <p>wide [2] 11/24 63/22</p> <p>wider [1] 21/20</p> <p>widespread [1] 77/2</p> <p>will [102] 2/15 3/6 4/15 5/4 6/2 6/10 7/16 7/22 8/8 9/17 10/8 10/23 11/11 12/24 13/3 13/8 15/17 20/22 20/24 22/22 24/6 31/17 34/8 37/2 38/17 39/4 41/14 49/17 51/12 51/19 53/11 53/19 55/3 55/7 56/11 56/16 56/20 56/24 57/2 57/4 57/6 58/1 58/8 58/9 65/17 65/23 68/3 71/4 71/7 73/14 84/22 85/21 86/19 86/24 87/3 89/7 94/1 94/8 103/1 103/19 103/20 104/1 104/9 106/10 111/2 119/3 123/1 123/3 123/5 123/10 123/11 123/14 123/15 123/16 123/17 123/22 123/24 123/25 124/4 124/5 124/7 124/8 124/9 124/11 125/9 125/12 125/22 125/25 126/3 126/5 126/7 126/12 126/18 126/23 127/25 128/6 129/10 129/17 129/18 130/3 130/7 147/17</p> <p>William [1] 140/3</p> <p>willing [6] 87/9 115/20 115/24 118/25 130/2 134/14</p> <p>wisdom [1] 70/24</p>
---	---	--	---	---	--

<p>W</p> <p>wish [3] 7/3 64/1 115/18</p> <p>wished [3] 116/7 121/18 141/6</p> <p>with [206]</p> <p>withdraw [3] 33/3 83/22 108/12</p> <p>withdrawal [12] 9/4 23/22 31/21 32/9 32/25 33/6 42/10 56/23 60/1 60/2 84/17 84/23</p> <p>withdrawal/recall [1] 42/10</p> <p>withdrawals [10] 9/2 18/22 35/7 35/13 53/12 64/19 65/1 65/8 65/11 84/20</p> <p>withdrawing [3] 97/15 99/12 134/1</p> <p>withdrawn [7] 21/15 33/10 37/6 53/16 84/7 84/15 102/25</p> <p>withdrew [3] 8/24 84/16 102/22</p> <p>withheld [2] 21/17 53/16</p> <p>within [16] 3/13 17/11 18/8 23/7 52/8 52/20 59/10 61/8 64/23 86/4 87/12 88/18 90/14 104/14 112/24 130/1</p> <p>without [6] 39/12 54/24 69/17 92/5 94/6 140/8</p> <p>witness [3] 77/4 117/22 118/22</p> <p>won't [14] 5/12 28/18 42/7 43/6 61/13 61/16 68/2 71/14 75/15 76/24 85/1 103/2 111/4 120/9</p> <p>wonder [1] 89/8</p> <p>Wood [3] 85/15 86/2 86/9</p> <p>word [3] 9/22 113/10 122/4</p> <p>words [1] 69/19</p> <p>work [17] 8/21 15/10 66/6 66/14 67/25 70/14 74/7 75/7 78/17 79/20 93/20 104/3 119/18 120/5 143/6 149/3 149/15</p> <p>worked [3] 74/21 74/24 120/2</p> <p>workers [1] 6/6</p> <p>working [6] 40/13 41/15 77/23 77/24 117/24 141/6</p>	<p>workshop [2] 5/25 6/8</p> <p>world [9] 23/15 77/23 77/24 78/24 82/6 83/10 93/4 94/25 98/13</p> <p>world's [1] 101/8</p> <p>worlds [1] 95/10</p> <p>worldwide [1] 10/17</p> <p>worst [1] 84/1</p> <p>worth [3] 11/23 63/17 132/15</p> <p>worthwhile [1] 43/8</p> <p>would [124] 1/14 3/25 8/6 10/3 10/24 13/10 17/15 17/17 18/17 18/19 19/20 19/24 20/8 21/10 21/23 22/18 30/9 30/12 30/16 30/24 31/7 31/8 33/19 34/5 36/3 37/7 39/1 41/20 41/21 42/22 44/8 44/12 44/15 44/17 44/17 44/18 44/24 45/8 45/8 46/7 50/7 51/23 57/16 58/11 59/6 59/10 59/17 61/8 61/14 62/10 62/15 62/16 63/15 63/17 66/2 70/12 70/16 77/11 81/7 83/17 84/2 86/15 87/8 87/19 87/24 88/17 91/17 92/4 92/17 92/19 93/7 93/7 94/13 94/22 95/13 95/16 96/12 99/22 102/5 102/9 104/13 106/13 107/2 107/3 107/11 108/8 110/5 110/8 110/14 111/22 112/1 113/24 114/21 115/2 115/4 116/7 118/25 121/23 121/25 127/7 127/7 127/11 127/12 127/13 127/20 128/11 128/17 128/18 129/18 131/25 134/22 134/23 134/25 135/6 135/16 135/23 137/19 138/4 138/7 139/2 139/4 141/13 146/1 147/1</p> <p>wouldn't [5] 8/15 45/7 51/17 51/18 61/10</p> <p>writing [3] 12/10 13/13 138/2</p> <p>written [25] 1/15 6/19 25/12 25/17 39/22 52/5 58/14 63/6 63/25 65/18 67/8 68/4 75/16 77/17 87/7 90/2 99/4 108/21 111/1 111/12</p>	<p>114/19 116/12 116/19 137/10 148/25</p> <p>wrong [1] 129/17</p> <p>wrote [13] 34/22 41/1 76/25 77/18 77/25 82/1 97/3 100/22 103/16 105/17 111/15 137/1 142/10</p> <p>Y</p> <p>year [18] 12/23 13/7 17/18 21/2 24/20 32/2 50/11 50/14 50/18 50/22 59/20 60/2 65/13 66/11 73/25 74/5 138/15 148/21</p> <p>years [13] 2/10 16/13 16/14 23/7 55/3 69/14 115/8 115/12 126/20 130/20 132/10 133/6 146/15</p> <p>yes [72] 1/6 6/18 8/12 9/24 9/25 14/4 14/8 14/12 26/7 30/8 30/15 31/1 31/10 31/10 32/13 45/1 46/23 47/4 48/5 48/23 49/6 49/9 49/15 49/16 59/5 59/8 61/7 62/3 62/3 62/8 62/9 65/4 65/7 70/1 70/10 70/22 73/21 74/3 90/22 90/22 95/2 95/15 95/16 96/2 96/2 100/10 100/14 113/8 113/11 113/11 113/14 113/17 114/6 114/12 114/22 116/25 119/6 119/21 119/25 120/2 120/8 120/13 121/4 128/1 128/14 128/15 129/21 140/12 143/17 146/25 147/3 147/5</p> <p>yesterday [14] 4/18 4/21 5/16 6/19 12/24 20/10 24/18 28/21 31/17 40/18 43/17 46/17 47/3 50/22</p> <p>yet [6] 2/21 30/19 85/23 87/1 95/5 107/1</p> <p>yield [1] 67/20</p> <p>York [10] 8/1 16/11 28/13 39/25 40/16 40/20 43/6 74/24 99/14 135/13</p> <p>you [80] 1/14 5/12 5/19 6/18 7/16 7/17 7/22 10/23 11/11 12/13 12/15 12/23 15/3 20/9 25/16 26/5 30/4 31/17 31/17 34/16 37/22 40/6 43/16 46/16 47/3</p>	<p>47/13 47/21 47/22 51/12 51/19 60/16 61/5 61/13 61/16 62/14 62/19 65/5 65/8 65/12 65/24 69/6 70/6 73/14 76/25 82/14 84/12 85/18 85/25 86/16 87/2 87/3 87/19 88/1 88/2 88/2 89/17 90/23 96/2 96/22 97/20 103/17 111/4 111/10 116/19 116/24 119/19 122/7 123/19 127/21 128/15 129/3 129/17 132/18 143/5 143/14 143/22 146/5 147/16 148/9 149/18</p> <p>you'd [1] 61/7</p> <p>you'll [3] 9/7 66/4 114/16</p> <p>you're [2] 58/15 71/1</p> <p>you've [3] 62/1 62/19 63/23</p> <p>your [5] 76/7 86/22 87/2 143/13 149/15</p> <p>Z</p> <p>Zuck [1] 23/12</p> <p>Zuck's [1] 23/17</p>		
--	--	---	--	--	--

(63) wish - Zuck's

F: